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Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the 
central nervous system (CNS) causing neurological disability in young adults. 
The neuropathological features of MS include large perivascular inflammatory 
cell infiltrates, microglia activation, antigen presentation and reactive 
astrogliosis. The CNS is protected by highly regulated blood-brain barrier (BBB) 
that is breached in MS as detected by MRI. Formation and regulation of the 
BBB involves the interactions of the interendothelial tight junction-associated 
proteins, occludin, ZO-1 and claudin. The results from this study suggest that 
the BBB is disrupted at the molecular level with alterations in ZO-1 and 
occludin expression being observed in blood vessels from MS tissue compared 
with normal control white matter. Tight junction (TJ) disruption was observed 
predominantly within vessels from active MS lesion however disruption was 
also observed within the normal appearing white matter and chronic lesions. 
The results of this study suggest that TJ disruption plays a critical in disease 
progression as TJ abnormalities were observed in conjunction with serum 
protein leakage and large inflammatory infiltrates. BBB leakage as gauged by 
MRI is reported to cease after an attack however this study shows that a low 
level of persistent serum protein leakage occurs in chronic lesions.
The recruitment of circulating leukocytes and resident glial cells to sites 
of CNS inflammation is dependant on the interaction of adhesion molecules, 
chemokines and their receptors and cytokines and their receptors. A disintegrin 
and metalloproteinase-17 (ADAM-17) is an enzyme that has been shown to 
mediate proteolytic cleavage of some of these inflammatory components. The 
results in this study have described the constitutive expression of ADAM-17 by 
the cerebral endothelial cells in human and rat CNS. ADAM-17 is also shown to 
be expressed by resident glia and inflammatory cells and is elevated in active 
MS lesions and in the spinal cords of rats during peak phase of experimental 
autoimmune encephalomyelitis suggesting a pathogenic role for ADAM-17 in 
these disease processes. In vitro studies confirmed the production of ADAM-17 
by cerebral endothelial cells and astrocytes. ADAM-17 expression is increased 
under pro-inflammatory conditions whereas its natural inhibitor TIMP3 is 
decreased. Release of TNF from GP8 cell surface is induced following 
treatment with TNF and LPS.
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Chapter 1
Introduction
1.1 Multiple sclerosis
Multiple sclerosis (MS) is described as a chronic inflammatory 
autoimmune demyelinating disease of the central nervous system (CNS). 
This description encompasses a number of aspects that are either 
generalised or based on supposition from research using animal models. MS 
was first described by a French neurologist, Jean Martin Charcot, in 1868. 
Charcot described the pathology of patients, who had intermittent episodes 
of neurological dysfunction, as having an accumulation of inflammatory cells 
in a perivascular distribution affecting both the brain and spinal cord white 
matter (Hafler, 2004). Charcot termed his findings as sclerose en plaque 
disseminees, or multiple sclerosis (Thompson and McDonald, 1996; Hafler,
2004). MS symptoms and neurological disability arise from inflammation, 
demyelination, reduction in axonal function and loss of axons within the CNS 
(DeLuca etal., 2004). These demyelinated areas of the CNS are referred to 
as lesions or plaques.
1.1.1 Epidemiology of MS
Mean age of onset occurs during early adulthood (30 years old), 
however the distribution actually shows a bimodal distribution with a peak 
age of onset at 21-25 years and a lesser peak at 41-45 years old (Thompson 
and McDonald, 1996). However childhood onset, though uncommon, has 
been reported along with a diagnosis in patients over 70 years old. As MS 
begins in early adult life it carries major consequences on careers, family and 
social life (Thompson and McDonald, 1996). MS, like many other 
autoimmune diseases is more common in females than males, in a ratio of 
3:2. Over 1 million people suffer from MS worldwide (Barcellos and 
Thomson, 2003). MS has a prevalence of approximately 85,000 cases within 
the UK with an incidence of about 2,500 new cases a year. The prevalence 
of MS is varied worldwide and has been shown to be more prevalent in 
temperate countries and areas of northern latitudes, suggesting that an 
environmental factor may have an influence on a person’s likelihood of
developing MS. Prevalence varies geographically in the UK, with the south of 
England having approximately 50 cases /100,000 of the population while the 
Shetland and Orkney Isles having 300 cases /100,000 of the population 
(Swingler and Compston, 1986). Japan, although geographically would be 
expected to have a high prevalence of MS, actually has a very low 
prevalence, indicating a genetic role in MS susceptibility. Following 
migrational studies, individuals emigrating from an area of high prevalence to 
an area with a lower prevalence before the onset of puberty adopt the 
prevalence of their new residence. People emigrating after the age of onset 
of puberty retain the prevalence risk factor of their original country (Gale and 
Martyn, 1995) further implicating the influence of environmental factors in the 
development of disease.
1.1.2 Genetics and gene association studies in MS
It is widely believed that susceptibility to MS is determined by a 
complex interaction of susceptibility genes and the environment (Wilier et al., 
2003). Genetic factors are further suggested by twin studies in which 
monozygotic twins have a higher concordance rate (30%) than dizygotic 
twins (4%) (Ebers et al., 1986; McFarland, 1993; Wilier et al., 2003; Lindsey,
2005). It has recently been suggested that twins with MS share a systemic 
condition called the MS trait, in which an environmental trigger is required to 
transform the trait into the disease (Poser, 2004).
Family studies assessing the risk of MS to twins, siblings, half siblings 
and adoptees to parents with MS have clearly shown a familial aggregation 
for the disease suggesting genetic and environmental factors in MS aetiology 
(Herrera and Ebers, 2003; Dyment etal., 2004). Half sibling studies support 
the notion that shared genetics rather than family environment is critical for 
familial aggregation of MS (Sadovnick etal., 1996). The recurrence rate of 
offspring born of conjugal parentage (both parents with MS) is significantly 
higher (30.5) in comparison to offspring from one parent with MS (2.49%) 
(Dyment et al., 2004).The recurrence rate for family members and 
concordance rates for twins indicate that the genetics of MS is complicated 
and not associated with the presence of a single disease gene or Mendelian 
trait (Barcellos and Thompson, 2003). A recent cohort study in Sardinia has
2
reported an association between MS and insulin-dependent diabetes mellitus 
(Marrosu etal., 2002). People with MS in Sardinia had a 5 times greater 
prevalence of diabetes than the general public and 3 times higher prevalence 
than their siblings (Marrosu etal., 2002).
Gene association studies in MS
Association screening or linkage disequilibrium studies are applied to 
determine genes with small or modest effect in complex traits (Risch, 2000). 
Recently large multicentre studies in America, Canada and the UK have 
carried out full genome searches for candidate genes in MS (Dyment and 
Ebers, 2004; Sotgiu etal., 2004). Based on the assumption that MS is an 
autoimmune disease, genetic studies have concentrated on the immune- 
related genes (Herrera and Ebers, 2003; Sotgiu etal., 2004). The major 
histocompatibility complex (MHC) is unambiguously associated with MS 
(Dyment et al., 2004). There are over 200 genes in the MHC that play . 
important roles in the development and maturation of the T cell repertoire 
(Dyment et al., 2004). The first genetic association with MS was reported to 
involve human leukocyte antigen (HLA) class I antigens (Jersild etal., 1972). 
More recently HLA class II antigens have been commonly and repeatedly 
reported as having associations with MS (Olerup and Hillert, 1991). In 
northern Europeans DRB1*1501, DQA1*0102 and DQB2*0602 haplotypes of 
the HLA molecule have been shown to be linked to MS susceptibility 
(Herrera and Ebers, 2003), in addition DRB1*13-DQB1*0603 was found to 
have a protective effect in Finland (Herrer and Ebers, 2003). As well as 
having a role in MS susceptibility the HLA DRB1*15 haplotype has been 
associated with an earlier age of onset (Hensiek et al., 2002).
The genetic analysis of multiple sclerosis in Europeans (GAMES) 
carried out linkage screens across 15 countries involving nearly 10,000 MS 
patient DNA samples using large panels of PCR-based microsatellites and 
pooled DNA samples (Barcellos and Thompson, 2003; Sawcer and 
Compston, 2003). GAMES revealed associations in 19q13 and 6p21 regions 
but the most promising regions highlighted by GAMES were 11q23 and 
17q11 (Barcellos and Thompson, 2003). 17q11 was also reported to have 
the highest evidence of linkage following meta-analysis of the Canadian and
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American screen samples (Dyment et al., 2004). However caution remains 
since it has been noted that following a positive genetic association in 
candidate studies, the report of a positive association is commonly followed 
by a negative report (Colhoun et al., 2003). It is suggested that 95% of initial 
positive associations are then shown to be negative (Colhoun et al., 2003).
Functional candidate gene analyses have studied genes coding for 
cytokines, chemokines, interleukins, myelin antigens, HLA and T cell 
receptors, however no functional link has consistently been demonstrated in 
MS (Kenealy etal., 2003; Herrer and Ebers, 2003; Dyment et al., 2004). 
Apolipoprotein E (apoE) is a major carrier protein that has been reported to 
be an anti-inflammatory agent and is associated with regeneration of axons 
and myelin following lesion formation (Kenealy etal., 2003; Herrer and 
Ebers, 2003). CNS and intrathecal concentrations of apoE are decreased in 
MS compared with controls (Kenealy etal., 2003; Herrer and Ebers, 2003). 
The gene encoding for apoE is located on chromosome 19 (19q13) of which 
there are 3 variants: z2, z3 and z4 (Herrer and Ebers, 2003). The z4 allele is 
associated as a risk factor in Alzheimer’s disease and also affects disease 
course in MS (Kenealy etal., 2003; Herrer and Ebers, 2003). People with MS 
carrying the z4 allele are reported to have shorter disease duration, more 
annual relapses and reach a higher expanded disability status scale (EDSS) 
score sooner (Herrer and Ebers, 2003) Although the genetic aspect of MS 
has been known for a long time, identification of strong susceptibility gene(s) 
remains unknown. The use of new high throughput technologies like gene 
microarray analysis and using single nucleotide polymorphisms (SNPs) for 
association studies should help unravel the complex genetic interactions 
involved in MS.
1.1.3 Clinical symptoms of MS
Initial onset of MS is monosymptomatic in 85% of patients. Presenting 
symptoms vary between individuals and are correlated to the location of the 
lesion(s) within the CNS. The most common clinical presentations are optic 
neuritis, sensory disturbance of the limbs, leg weakness, fatigue and ataxia. 
As MS is not the only demyelinating disease of the CNS, careful diagnosis 
and classification is vital when deciding upon the therapeutic direction (Poser
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and Brinar, 2004). People with MS each experience varying degrees of 
disability throughout the course of the disease. It is important that these 
symptoms are carefully monitored throughout the disease progression. The 
Kurtzke EDSS (Table 1.1) enables neurologists to determine the extent of 
the neurological impairment which allows them to determine how progressive 
the disease is and also to determine if treatments are of any clinical benefit 
(Kurtzke, 1983).
1.1.4 Diagnosis of MS
Although MS was first described over 130 years ago, diagnosis of MS 
remains problematic with no single conclusive laboratory based 
immunological assay available (Poser and Brinar, 2004). Over the years 
numerous diagnostic criteria have been implemented, the most recent of 
which being the McDonald criteria (McDonald etal., 2001). The McDonald 
criteria incorporate many of the original Poser criteria (Poser etal., 1983) 
with the addition of the use of magnetic resonance imaging (MRI). Poser 
suggested that MS can be diagnosed on the basis of impaired visual evoked 
potential (VEP), the presence of oligoclonal IgG bands in the cerebrospinal 
fluid (CSF) and a detailed clinical history (Poser etal., 1983). Demyelination 
of the optic nerve and the clinical presentation of optic neuritis is the most 
common initial symptom of MS making VEP very useful in the diagnosis of 
MS (Thompson and McDonald, 1996). MRI has become a very important tool 
in the diagnosis of MS and is the optimal imaging technique for MS (Figure 
1.1) however results from MRI are not necessarily MS specific (Miller etal., 
1998; Poser and Brinar, 2004).
1.1.4.1 Magnetic resonance imaging
Conventional MRI is a sensitive technique for the detection of MS 
lesions and has been adopted to support clinical evidence for the diagnosis 
of MS and is used in the management and the monitoring treatment effects 
in MS (Miller et al., 1998; McDonald etal., 2001; Moore, 2003; Zivadinov and 
Bakshi, 2004; Korteweg etal., 2005). A hyperintense lesion detected by 
conventional T2 weighted MRI is primarily related to increased water content 
and therefore does not distinguish between inflammation,
5
Table 1.1 Selected scores from the Kurtzke expanded disability status scale 
(EDSS), rating neurological impairment in MS (Kurtzke, 1983).
0 Normal neurologic exam
1.0 No disability, minimal signs in one functional system
1.5 No disability, minimal signs in more than one functional system
2.0 Minimal disability in one functional system
2.5 Minimal disability in two functional systems
6.0 Intermittent or unilateral constant assistance (cane, crutch or brace)
required to walk about 100 meters with or without resting
6.5 Constant bilateral assistance (canes, crutches or braces) required to
walk about 20 meters without resting
7.0 Unable to walk beyond 5 meters even with aid. Essentially restricted
to a wheelchair. Wheels self in standard wheelchair and transfers
alone. Active in wheelchair about 12 hours a day
7.5 Unable to take more than a few steps. Restricted to wheelchair. May
need aid to transfer. Wheels self but cannot carry on in standard
wheelchair a full day. May require a motorized wheelchair
9.0 Helpless bed patient. Can communicate and eat
9.5 Totally helpless bed patient. Unable to communicate effectively or
eat/swallow
10 Death due to multiple sclerosis
6
Figure 1.1 MRI scan from a patient with MS
A typical MRI from a person with MS displaying hyperintense T2 lesions (arrows) 
in periventricular locations. Specifically, the periventricular lesions and the more 
peripheral white matter lesions near the grey matter-white matter junction are 
typical MRI findings in MS. 
www.emedicine.com/ radio/topic461 .htm
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edema, demyelination and axonal loss (Werring et al., 2000; Zivadinov and 
Bakshi, 2004). The contrast agent gadolinium-diethylenetriaminepentaacetic 
acid (Gd-DTPA) improves the pathological specificity of MRI (Werring et al., 
2000). Areas of enhancement with Gd-DTPA MRI reflect inflammatory 
infiltrate induced blood-brain barrier (BBB) disruption and neovascularisation 
(Bruck et al., 1997; Miller et al., 1998). Magnetic transfer imaging (MTI) has 
been shown to detect changes in the normal appearing white matter 
(NAWM) at the site of future MS lesions (Moore, 2003). It has been reported 
that focal changes in MTI may exist up to one month before being detected 
by Gd-DTPA MRI (Moore, 2003). Diffusion MRI techniques enable the 
detection of subtle changes in motion (diffusion) of water molecules within 
the brain and has been reported to display changes in the NAWM up to 6-8 
months prior to Gd-DTPA MRI detection (Werring et al., 2000).
A lack of correlation between conventional MRI and MS disability 
(Kurtzke scale) has been reported however the advent of new MRI 
techniques have allowed histopathological and MRI correlates to be obtained 
(Fillipi etal., 1995; Moore, 2003; Zivadinov and Bakshi, 2004). Magnetic 
resonance spectroscopy (MRS) allows the identification of specific 
compounds within specific structures. N-acetyl aspartate (NAA), an 
axonal/neuronal specific marker, has been used to determine axonal loss 
and pathology within MS lesions. NAA has been shown to be decreased in 
chronic MS plaques correlating with axonal loss in pathologic studies (Trapp 
et al., 1998; Fu et al., 1998). MRS has also been used to detect ongoing 
demyelination. Abnormal lipid peaks in MRS are representative of myelin 
breakdown into neutral lipid during demyelination (Moore, 2003). MRI 
continues to evolve and non-conventional MRI techniques now provide a 
powerful tool to non-invasively study pathological substrates of lesions and 
NAWM (Zivadinov and Bakshi, 2004). However it is important to note that 
diagnosis of MS cannot be made solely on MRI as other neurologic diseases 
such as glioma gives similar MRI to MS lesions. Similarly a normal MRI 
cannot rule out the diagnosis of MS as approximately 5% of patients with 
confirmed MS can show normal MRI (Poser and Brinar, 2004).
1.1.4.2 Analysis of CSF in MS
The CSF of MS patients is examined to detect an increase in the y- 
globulin/albumin ratio and y-globulin oligoclonal bands on isoelectric 
focussing (Brosnan and Raine, 1996; Hickey, 2001). Presence of oligoclonal 
bands occurs in pathological conditions where B cells enter the CNS, 
following alterations of the BBB. B cells, clonally expand, differentiate into 
plasma cells and secrete antibody into the extracellular fluid of the CNS and 
is therefore detected in the serum and CSF as clonally restricted IgG bands 
(Hickey, 2001).
1.1.5 Disease course in MS
MS presents and manifests in a number of different clinical disease 
courses (Figure 1.2). The most common course of MS occurs when an 
individual experiences an episode of neurological dysfunction (relapse), 
onset of which can be rapid (overnight) or eventual (over a week), for a 
duration of 4-6 weeks then the symptoms regress to a baseline of normal 
function (remission). The remission stages can last variable durations from 
months to several years. This pattern of MS is called relapsing remitting MS 
(RRMS) and is accountable for approximately 85% of MS patients 
(Weinshenker, 1994; Hohol etal., 1995). After 15 years approximately 65% 
of RRMS patients will develop secondary progressive MS (SPMS). As the 
name suggests SPMS is secondary to RRMS and only occurs in people who 
have had RRMS. During SPMS the neurological dysfunction fails to return to 
normal and the MS patient experiences subtle but definite deterioration in 
their level of function (Weinshenker, 1994; Hohol etal., 1995). In some 
cases however people with RRMS fail to develop SPMS and continue to 
have relapses that return to the baseline of normal function, this is benign 
MS. People are generally only diagnosed with benign MS when they have 
not developed any new symptoms 10-15 years after initial attack. Primary 
progressive MS (PPMS) is different to the other forms of MS in that people 
with PPMS do not experience attacks or remissions but begin with subtle 
problems that slowly worsen over time. People with an older age of onset are 
mainly affected by PPMS which accounts for approximately 15% of the 
people with MS. PPMS is clinically associated with a lack of response to any
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Figure 1.2 Graphical representation of the different clinical courses of MS
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The majority pf people with MS (approx 80%) experience a disease with a 
relapsing and remitting course (a). After 15 years approximately 65% of 
RRMS patients will develop secondary progressive MS (b). People with PPMS 
do not experience attacks or remissions but begin with subtle problems that 
slowly worsen over time (c) 
www. ms-gateway. com/.../ whatisms/foijigisofms.jsp
form of immunotherapy (Hohol etal., 1995). Following a 25 year population 
based study, the progressive phase of PPMS and SPMS were reported to 
display remarkable similarities (Ebers, 2004).
1.2 Cellular constituents of the CNS
The CNS is composed of the cerebral endothelium and the BBB, 
neurons, oligodendrocytes, astrocytes and microglia. The cells within the 
CNS communicate via various ion channels, transporter mechanisms and 
signalling pathways helping to maintain homeostasis within the CNS.
1.2.1 Cerebral endothelia and the BBB
The BBB is a complex cellular system that plays a crucial role in 
regulating cell trafficking and maintaining homeostasis within the extracellular 
microenvironment of the CNS (Petty and Lo, 2002; Wolburg and Lippoldt, 
2002). The BBB, once regarded as a static physical barrier between the 
vascular system and the CNS, is now considered as a complex dynamic 
structure that is capable of rapid modulation (Huber etal., 2001).
The BBB is comprised of capillary endothelial cells resting on a thin 
but multilayered basal membrane which separates them from closely 
adherent pericytes, perivascular microglia and the astrocytic foot-processes 
(Prat etal., 2001; Ballabh etal., 2004) (Figure 1.3).
Perivascular astrocytes extend large cellular processes (end-feet) that 
abut and cover most of the ab-luminal surface of the cerebral capillary wall 
(Prat et al., 2001). This close contact acts as a structural support for the BBB 
and as a two way signalling pathway between the endothelium and the 
surrounding neuroenvironment (Ballabh etal., 2004). Close contact between 
the astroglia and the endothelium is deemed essential for establishing and 
maintaining an optimal barrier (Hirase et al., 1997; Prat et al., 2001). 
Astrocytes are also reported to confer a protective role on the BBB against 
hypoxia and aglycemia (Abbruscato and Davis, 1999). Although little studied, 
pericytes are also believed to have a protective role as well as roles in: 
angiogenesis, maintaining the structural integrity of the vessel and the 
formation of tight junctions (TJ) (Hori etal., 2004). It is reported that all these
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Figure 1.3 Schematic representation of the BBB
Cerebral endothelial cell
! Lumen
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Parenchyma Pericyte
The BBB is comprised of the inter-endothelial tight junctions (TJ) of the 
vascular endothelial cells. The endothelial cells are in intimate contact with 
astrocytic end feet, pericytes and the basement membrane (BM). (Adapted 
from Terasaki et al., 2003).
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cellular components of the BBB are essential for normal function and stability 
of the BBB (Ballabh et al., 2004).
The microvascular endothelium of the BBB differs from and is more 
specialised than the peripheral endothelium throughout the rest of the body 
due to;
• lack of fenestrations,
• has fewer endocytic vesicles,
• possesses a higher mitochondrial volume fraction and
• forms extensive TJs
• a high transendothelial electrical resistance (Prat et al., 2001; Petty 
and Lo, 2002; Ballabh et al., 2004)
An important characteristic of the BBB endothelial phenotype is the 
possession of a high transendothelial electrical resistance (TEER), in the 
range of 1000-5000Qcm2 in comparison to the ‘non-barrier’ placental 
endothelial cells which have an electrical resistance of 22-520cm2 (Huber et 
al., 2001; Petty and Lo, 2002). High electrical resistance in the CNS 
microvasculature is a consequence of the extreme structural specialization of 
the endothelium, in particular its minimal ‘pore’ size, this enables the cerebral 
endothelia of the BBB to regulate the passage of molecules and cells to the 
parenchyma (Romero et al., 2003).
The function of the BBB is to protect the brain microenvironment from 
the potentially damaging effects of substances in the blood, whilst ensuring a 
supply of nutrients by the action of specific transport systems (Petty and Lo,
2002). Passage across the BBB can occur either through the endothelial cell 
via the transcellular route, or between adjacent endothelial cells via the 
paracellular route (Fanning etal., 1999; Tsukita and Furuse, 1999; Dallasta 
etal., 1999; Huber et al., 2001; Petty and Lo, 2002). Only lipophilic 
substances of a molecular weight less than 450, can cross the BBB via the 
transcellular route by passive diffusion (Petty and Lo, 2002). There is 
however active transport of some large hydrophilic molecules into the brain 
via the transcellular pathway (Huber et al., 2001; Petty and Lo, 2002;). Ions 
and solutes normally diffuse down their concentration gradient between
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adjacent endothelial cells by the paracellular pathway, however at the BBB 
this pathway is blocked by cell-cell contacts at the apical region of the 
endothelial cells. These contacts are the inter-endothelial TJs of the BBB 
(Huber et a/., 2001; Petty and Lo, 2002; Ballabh et al., 2004;). Control of 
paracellular diffusion by the TJs is also known as the barrier function. TJs 
also restrict protein movement within the plane of the endothelial membrane 
(so called ‘fence’ function ), thereby ensuring that the apical and basolateral 
membrane domains remain distinct allowing active transport of nutrients 
(Tsukita and Furuse, 1999; Fanning etal., 1999).
1.2.2 Microglia
Microglia, derived from monocytes from the bone marrow, are 
ubiquitously ditributed within the CNS, where they are spaced out evenly 
throughout the brain and spinal cord and account for approximately 12% of 
the cells in the CNS (Minagar etal., 2002; Streit, 2005). In the normal 
uninjured CNS the microglial cells are referred to as resting microglia and 
morphologically are highly branched or ramified. These cells are the primary 
immune effector cells of the CNS, responding to biochemical or bioelectrical 
alterations within the microenvironment (Hickey, 2001; Minager et al., 2002;). 
Resting microglia express the macrophage phenotypic marker CD11b and 
constitutively exhibit low levels of expression of MHC Class II and the co­
stimulatory molecules CD86 and CD40 (Ponomarev et al., 2005). The 
microglia are both targets and sources of numerous cytokines and 
chemokines. Activated microglia have shortened cell processes and may 
conform to a bushy macrophage-like morphology and are capable of 
phagocytosis. Activated microglia, as observed in areas of inflammation and 
trauma can express both MHC class I and II, B7 co-stimulatory molecules, 
ICAM-1 and Fc receptors suggesting a role for these cells in antigen 
presentation (Minagar et al., 2002; Mack et al., 2003). Ex-vivo murine 
microglia have been shown to differentiate into dendritic cells in vitro 
following stimulation with granulocyte macrophage colony stimulating factor, 
thus increasing the efficacy of antigen presentation within the CNS 
(Ponomarev et al., 2005). Activated microglia release the cytokines, 
interleukin (IL)-1, IL-4, IL-6, IL-12 and tumor necrosis factor (TNF) and
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interact with Th1 and Th2 cells inducing clonal expansion and cytokine 
release (Minagar etal., 2002). Interestingly the chemokine fractalkine 
(CX3CL1) is expressed on neurons whilst its receptor CX3CR1 is expressed 
on the microglia (Nishiyori etal., 1998; Garton etal., 2001). This distinct 
separation in cellular location of CX3CL1 and CX3CR1 suggests a role for 
fractalkine in mediating neuron-microglia interactions in basal conditions and 
in disease (Streit, 2005). The microglial plasma membrane is complex with a 
large repertoire of potentially immunogenic surface antigens resulting in the 
detection of microglia by numerous antibodies detected in cells from a 
monocytic lineage (Streit, 2005). Microglia can be detected with antibodies to 
lymphocytic antigens including lymphocyte function antigen (LFA) and 
leukocyte common antigen (LCA) as well as detection of MHC. However 
within the CNS MHC expression is not limited to microglia but is also 
expressed by macrophages and endothelial cells (Streit, 2005). It has been 
reported that distinction can be made using flow cytometric analyses where 
resident microglia express CD11b/c+ CD45l0W whereas parenchymal 
macrophages have been described as being CD11b/c+ CD45hl (Ford et al., 
1995).
1.2.3 Astrocytes
Astrocytes are the major cellular components of the CNS out 
numbering neurons 10:1 (Okada et al., 2005). Astrocytes were traditionally 
considered as structural elements of the CNS as they are in close contact 
with several cellular components of the brain parenchyma (Pellerin and 
Magistretti, 2005). However astrocytes are now considered to be more 
dynamic and are reported to play an important role in the homeostasis of the 
CNS, release neurotrophic factors, contribute to neurotransmitter metabolism 
and regulate extracellular pH and K+ levels (Dong and Benveniste, 2001; 
Kettenmann and Steinhauser, 2005; Pellerin and Magistretti, 2005). 
Astrocytes are also reported to play a major role in the formation and 
regulation of the BBB (Hamm et al., 2004). Astrocytes are reported to take 
up extracellular glutamate, an excitatory neurotransmitter of the CNS 
(Pellerin and Magistretti, 2005). Astrocytes lack the capacity to deliver co­
stimulatory signals to T cells and therefore cannot function as competent
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antigen presenting cells (APC) (Dong and Benveniste, 2001). Astrocytes 
express functional IL-4 receptors and upon exposure to IL-4 they secrete the 
neurotrophins, nerve growth factor and brain derived growth factor, 
supporting axonal growth (Minagar et al., 2002; Pellerin and Magistretti, 
2005). Astrocytes can be detected in vivo and in vitro by 
immunohistochemistry using antibodies against glial fibrillary acidic protein 
(GFAP) and S-100 (Zheng et al., 2000).
1.2.4 Oligodendrocytes
Oligodendrocytes are responsible for the synthesis and maintenance 
of myelin within the CNS. Myelin membranes are extended out from the 
oligodendrocytes and wrap around axons, forming a multi-lamella myelin 
sheath, thereby increasing nerve conductance velocity (Franklin and 
Blakemore, 1997). Each oligodendrocyte, unlike their peripheral nervous 
system counterparts, Schwann cells, is able to myelinate more than one 
axon however one oligodendrocyte does not myelinate the same axon more 
than once (Jessen and Mirsky, 2005). In addition to myelinating 
oligodendrocytes, non-myelinating satellite oligodendrocytes and adult 
oligodendrocyte progenitor cells (OPCs) are also evident within the CNS 
(Scolding etal., 1998; Dawson etal., 2000). Throughout the CNS 
oligodendrocytes have been detected at different stages of maturation 
expressing distinct phenotypic markers, listed below (Armstrong et al., 1992; 
Norton, 1996; Levine etal., 2001).
Table 1.2 Phenotypic markers of oligodendrocyte maturation 
Maturation stage Phenotype
Progenitor cell NG2, A2B5+ and GD3+
Pre-oligodendrocyte 04+, A2B5+ and Gd3+
Immature oligodendrocyte GC+, A2B5' and Gd3_
Mature oligodendrocyte 04+, GC+, PLP+, MBP+ and CNP+
Phenotypic markers for oligodendrocytes include expression of chondroitin 
sulphate proteoglycans (NG2), surface gangliosides (A2B5 and GD3) and the
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myelin proteins myelin basic protein (MBP), proteolipid protein (PLP), 
galactocerebroside (GalC) and 2’, 3’-cyclic nucleotide-3-phosphohydrolase 
(CNPase).
1.3 Pathology of MS
Demyelination is regarded as the pathological hallmark of MS along 
with inflammation, through BBB breakdown. However other pathologies exist 
in the MS lesion including axonal loss, oligodendrocyte loss and astrogliosis. 
(Bjartmar et al., 2003).
The classical hallmarks of MS are demyelinated lesions, disseminated 
throughout the CNS but with an apparent predilection to the optic nerves, 
white matter tracts of the periventricular regions, the brain stem and the 
spinal cord (Hafler, 2004). Macroscopically, lesions of the autopsied brain 
are grossly visible, irregular in shape and size and can be clearly 
distinguished by the discolouration of the white matter (Figure 1.4). Recently 
formed lesions appear pink or even yellow due to the hyperemia and lipid 
breakdown and neutral fat production, whereas older more chronic lesions 
have a darker grey-tan appearance (Thompson and McDonald, 1996;
Hickey, 1999; Hafler, 2004). Developing an understanding of the 
pathogenesis of MS lesion formation is problematic as most cases are 
presented at the end stage of the disease at autopsy where the majority of 
lesions are old, chronic and inactive, and may bear no significance to the 
underlying pathogenic mechanisms involved. The CNS of a person with MS 
may contain lesions that are disseminated in time and as such at different 
stages of lesion activity.
Lesion classification with regards to activity has been reported as 
being of great importance in pathological studies investigating early lesion 
development (Lassmann, 1998). In general there are three main ages of 
lesions described based on histological appearance; active lesions, chronic 
active lesions and chronic inactive lesions (Figure 1.4) (Lassmann, 1998, 
Trapp etal., 1999):
• Active lesions are early lesions with active demyelination occurring 
throughout the lesion. Macrophages containing myelin proteins are 
evenly spread throughout the lesion. Active lesions containing
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Macroscopic appearance of discoloured periventricular white matter 
lesions (arrow) (a), (b) Clearly demarcated active lesion edge (dashed line) 
of a chronic active lesion with an abundance of HLA-DR+ foamy 
macrophages. A cmpariable demyelinated area of chronic active lesions 
stained with luxol fast blue (LFB) (c). Histologically large perivascular cuffs 
are observed within lesions and NAWM (d) that contain CD68+ 
macrophages (arrows) (e). Large vascular associated active lesion with an 
abundance of ORO lipid laden macrophages throughout the lesion (f). 
Evidence of LFB+ myelin debris within a HLA-DR+ macrophage (g). Images 
were obtained from archival MS autopsy material from the Belfast Brain 
Bank, Pathology Department, Royal Group of Hospitals Trust, Belfast, N 
Ireland.
Figure 1.4 Digital photographs of pathological hallmarks of MS
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acrophages with myelin immuno-reactive protein are considered to 
be very recent, 2-3 weeks (Trapp et al., 1999) (Figure 1.4a).
• Chronic active plaques are generally characterized by an 
enrichment of MHC class II positive lipid laden foamy macrophages 
along a clearly demarcated hypercellular border (Figure 1.4b).
• In inactive lesions the area of demyelination is hypocellular with 
very few MHC class II positive cells. Myelin is replaced by reactive 
astrocytes forming gliotic scar tissue.
• A key feature of active MS plaques is the presence of large 
perivascular cuffs, areas containing various lymphocytic 
inflammatory cells (Figure 1.4d). The majority of MS plaques are 
centred on an associated venule. The cellular constituents of the 
perivascular cuff vary throughout lesion development and are 
discussed later (Section 1.5.1.2).
1.3.1 Heterogeneity of MS lesions
Recently the idea that all MS lesions evolve using the same 
mechanism has been revised (Lucchinetti etal., 2000). MS lesions, not 
surprisingly considering the clinical differences in progression, severity and 
duration of MS, have been shown to be heterogeneous. By examining 235 
actively demyelinating lesions from both autopsy and biopsy material, four 
distinct lesion patterns have been described that may be indicative of 
different underlying pathogenic mechanisms (Lucchinetti etal., 2000; Kornek 
and Lassmann, 2003).
Lesion patterns I & II: In these lesions it is reported that the myelin 
sheath is the main target of the destructive process (Lucchinetti etal., 2000). 
Pattern I & II lesions are typically centred on small veins and venules with 
clearly demarcated borders. Demyelination in pattern I is suggested to be 
mediated by macrophage released toxins such as TNF and reactive oxygen 
species, whereas in pattern II demyelination is suggested to be specifically 
antibody and complement mediated (Lucchenitti et al., 2000; Kornek and 
Lassmann, 2003).
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Lesion pattern III: In comparison to patterns I & II, pattern III lesions 
are not associated with small veins and venules. Indeed preservation of 
myelin surrounding blood vessels within the lesion was reported. This lesion 
pattern of active demyelination displays diffuse borders that spread into the 
surrounding white matter. Another distinguishing characteristic of pattern III 
is that the oligodendrocytes appear to be the main target. Surprisingly myelin 
associated glycoprotein (MAG) appeared to be preferentially lost while other 
myelin proteins appeared to be unaffected. The loss of MAG is associated 
with oligodendrocytes undergoing apoptosis (Lucchinetti et al., 2000), similar 
to pathology observed in acute white matter in stroke (Kornek and 
Lassmann, 2003).
Lesion pattern IV: This pattern type of lesion has a clearly demarcated 
lesion border, with oligodendrocyte loss that is associated with the 
periplaque white matter. Oligodendrocytes are described as apoptotic due to 
the fragmentation of the DNA, however no morphological aspects of 
apoptosis were described. This type of lesion pattern was only identified in 
samples that were obtained from people who had suffered from PPMS 
(Korneck and Lassmann, 2003).
All lesions were reported to have inflammatory infiltrates of T cells and 
macrophages, the lesions were segregated based on distribution of myelin 
loss, plaque geography, the pattern of oligodendrocyte destruction, and the 
immunopathological evidence of immunoglobulin and activated complement 
deposits (Lucchinetti et al., 2000; Kornek and Lassmann, 2003). MS lesions 
are heterogeneous between individual MS patients however it was reported 
that each individual contained only one lesion pattern (Lucchinetti etal., 
2000). Others have reported five lesion types following multifactorial cluster 
analysis incorporating detailed immunocytochemical analysis of CD4+ CD8+
T cell and plasma cell populations, macrophage morphology as well as 
parenchymal fibrinogen staining, indicative of BBB disruption (Gay et al.,
1997). Lucchinetti’s description of lesion type is highly regarded in the 
literature however it is not accepted universally by all researchers as it fails 
to include the presence or extent of axon loss which has been described in
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MS pathology for over a century (Charcot, 1867; Evangelou et al., 2000; 
DeLuca, 2004) (Section 1.3.2).
1.3.2 Axonal pathology
Axonal loss has been observed in MS for a long time however new 
insights into the timing and functional consequences of axonal loss have 
brought axonal research to the fore again (DeLuca et al., 2004). It has been 
suggested that the cumulative loss of axons is a major determinant in the 
progression from RRMS to the SPMS, where aspects of the neurological 
dysfunction become irreversible (Trapp etal., 1998, Bjartmar etal., 2000 &
2003). MS patients are reported to contain a mean axonal loss of 68%
(range 45-84%) compared with controls. A supporting role for axonal 
degeneration in irreversible neurological disability is suggested as MS 
patients in this study had an EDSS > 7.5 (Bjartmar and Trapp, 2001).
Acute axonal damage can be determined immunohistochemically by 
the presence of amyloid precursor protein (APP) (Ferguson etal., 1997; 
Kornek et al., 2000; Kuhlmann et al., 2002). APP is a neuronal protein, 
transported by fast antegrade axonal transport and can only be detected 
when axoplasmicflow is compromised (Ferguson, etal., 1997). Following 
axonal transection the transport of APP is interrupted leading to an 
accumulation of APP in the proximal axonal ends (Ferguson etal., 1997; 
Kuhlmann et al., 2002) as such very little APP is detected in normal brains 
(Kronek etal., 2000). Transected axons appear as axonal ovoids or axonal 
bulbs that are reported to be an early event in lesion formation, with the 
highest amount of acute axonal damage associated with active 
demyelination and inflammation (Ferguson etal., 1997; Trapp etal., 1998; 
Bitsch et al., 2000b; Kornek et al., 2000). A quantitative study reported 
axonal bulbs being more abundant and larger in active lesions (11,236/mm3) 
than either the active rim (3138/mm3) or lesion centre (875/mm3) of chronic 
active lesions (Trapp et al., 1998). Axonal bulbs were also reported in the 
NAWM (17/mm3) and control white matter (1/mm3) but to a far lesser extent 
(Trapp et al., 1998). Acute axonal loss is also reported to be at its highest in 
the early stages of disease progression in RRMS and SPMS with the highest 
number of APP+ axons observed in patients with a disease duration < 1 year
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(Kuhlmann et al., 2002; Fillipi et al., 2003). A recent study confirmed the 
appearance of extensive axon loss early in disease however it suggested 
that no correlation exists between the amount of axon loss and disease 
duration (DeLuca etal., 2004). In a lesion matched immunohistopathological 
study, acute MS white matter displayed more APP+ axons than in chronic MS 
cases (Kornek et al., 2000). The amount of acute axonal loss in PPMS is 
lower than that observed in RRMS and does not change significantly over 
time (Bitsch etal., 2000b; Kuhlmann etal., 2002). Investigation of the 
periplaque white matter has demonstrated acute axonal damage associated 
with CD8+ T cells but without evidence of demyelination (Bitsch et al., 2000b; 
Kronek et al., 2000; Kuhlmann, et al., 2002). These findings suggest that 
some axonal loss may be independent of demyelination or even may 
precede demyelination (Bitsch et al., 2000; Bjartmar and Trapp, 2001; 
Kuhlmann et al., 2002). Axonal loss has been demonstrated within the 
lumbar regions of the corticospinal tracts correlating with spasticity and 
paralysis of the lower limbs in MS. Axonal loss was also reported to be 
prevalent in the small nerve fibres (< 3pm diameter) with larger nerve fibres 
preserved (Bjartmar and Trapp, 2001; DeLuca et al., 2004).
Demyelinated axons are reported to have an increased expression of 
Na+ channels leading to a high Na+ load within the axon reversing the 
Na+/Ca2+ exchanger resulting in an influx of Ca2+ into the axon which 
activates Ca2+ dependant degenerating enzymes which destroys the axon 
(Craner et al., 2004; Brand-Schieber and Werner, 2004; Bechtold and Smith, 
2005) (Figure 1.5). In a recent study the myelin associated neurite outgrowth 
inhibitor, Nogo-A and its receptor NgR, have been demonstrated in chronic 
active demyelinating lesions (Satoh et al., 2005). The presence of Nogo-A 
and NgR may prevent axonal regeneration following injury in MS (Satoh et 
al., 2005).
1.3.3 Oligodendrocyte pathology
Oligodendrocytes are susceptible to damage by a variety of immune 
effector mechanisms during an inflammatory response (Selmaj and Raine 
1988; Merrill and Scolding, 1999). Oligodendrocytes have been suggested 
as being the primary target for destruction in the demyelinating process in
22
Figure 1.5 A schematic representation of axon degeneration in MS
Action potential Posts ynapticNormalMyeSnatedAxon
MyelinDemyelination sheathAxon
Sodium
channels
ChronicallyDemyeiinatedAxon Action potential
Conduction restored by 
increase in density of 
sodium channels
Postsynaptic
V. End of 
transected 
axon
The normal myelinated axon (A) is demyelinated as a result of a direct or indirect 
immune attack (B) and nerve signals no longer transmit along the axon. Demyelinated 
axons are reported to have increased expression of Na+ channels (C) leading the 
axons to become loaded with Na+ temporarily restoring nerve conduction. Increased 
axonal Na+ triggers Ca2+ entry which activates Ca2+ dependant degenerating enzymes 
which destroy the axon (Craner et al., 2004) which becomes transected and is 
detected histologically by an accumulation of amyloid precursor protein in the proximal 
axonal ends (D).
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MS (Ozawa etal., 1994; Merrill and Scolding, 1999; Lucchinetti etal., 1999; 
Wolswijk, 2000). The presence of both p55 and p75 tumor necrosis factor 
receptors on oligodendrocytes along the leading edge of active plaques 
suggests a role for TNF induced oligodendrocyte death via apoptosis in 
lesion formation (Raine etal., 1998).
In a large quantitative study of oligodendrocytes in MS lesions, two 
distinct patterns were observed based on the presence or absence of 
oligodendrocyte recruitment in the lesion (Lucchinetti, et al., 1999) (See 
section 1.3.1).
In acute MS lesions, demyelination has been associated with a loss of 
oligodendrocytes however some mature oligodendrocytes are preserved 
(Ozawa etal., 1994). During early exacerbations of chronic MS, complete 
preservation of oligodendrocytes is observed, however in late developing 
lesions demyelination is accompanied by almost total destruction of 
oligodendrocytes (Ozawa etal., 1994). Two morphologically distinct 
populations of oligodendrocytes have been reported in MS lesions 
(Kuhlmann etal., 1999; Wolswijk, 2000). The first type of oligodendrocyte 
cell has been described as large process-bearing GalC+, MOG immature 
oligodendrocyte, suggesting that they were derived from a pool of OPCs. 
These cells were mainly associated with lesion borders and not the 
surrounding white matter. The second type described was small, round, non­
myelinating GalC+ MOG+ oligodendrocytes believed to be mature 
oligodendrocytes that have lost their myelinating processes due to continued 
episodes of demyelination (Wolswijk, 2000). The small mature rounded 
oligodendrocytes were reported to be most abundant in the centre of lesions 
where recent demyelination had taken place (Wolswijk, 2000). Loss of 
oligodendrocytes is reported to be correlated with an increased number of 
macrophages suggesting that cytotoxins released by macrophages may play 
a pathogenic role in oligodendrocyte death (Lucchinetti etal., 1999).
Recently a new type of lesion pathogenesis has been proposed 
following the study of a very early lesion (Barnett and Prineas, 2004). This 
report came from an MS patient who died within 24 hours of the onset of a 
new symptomatic and fatal brainstem lesion (Cannella and Raine, 2004). It 
has been suggested that apoptotic cell death of oligodendrocytes is the initial
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event in lesion development preceding an inflammatory response (Barnett 
and Prineas, 2004). Leukocyte infiltration was proposed to occur after myelin 
breakdown to remove the large amount of myelin debris that has resulted 
from oligodendrocyte cell death (Barnett and Prineas, 2004).
1.3.4 Remyelination
Remyelination has been described in many MS lesions either at the 
lesion edge or even extending throughout the entire lesion where it becomes 
a shadow plaque (Lassmann etal., 1997; Stangel and Hetung, 2002; Bruck 
etal., 2003). Incomplete remyelination usually occurs at the lesion edge 
where it forms a transition zone between the NAWM and the lesion centre. 
Shadow plaques appear as areas of myelin pallor within the NAWM (Bruck et 
al., 2003). The process of remyelination has been suggested to be a 
recapitulation of developmental myelination (Capello etal., 1997) however 
others have reported differences between the two processes (Stangel and 
Hartung, 2002). The hallmarks of remyelination are the shortened internodes 
and a decrease in the axon diameter: myelin thickness ratio (Adams, 1989). 
Areas of remyelination have been shown to coexist with areas of active 
demyelination (Lassmann etal., 1997).
Remyelination within MS lesions is correlated to the number of 
oligodendrocytes surviving within the lesions (Ozawa etal., 1994; Lassmann 
etal., 1997). The anti-apoptotic protein Bcl-2 has been suggested as an 
influencing factor in oligodendrocyte survival (Kuhlmann, et al., 1999). Bcl-2+ 
MOG+ oligodendrocytes have been reported to be at their most abundant in 
remyelinating lesions especially remyelinating lesions of RRMS patients 
(Kuhlmann etal., 1999). However the source and origin of the cells 
responsible for remyelination remains unclear. Remyelinating cells may be 
derived from a pool of OPC or are mature oligodendrocytes that have 
survived the demyelinating attack (Lassmann et al., 1997; Keirstead and 
Blakemore, 1999; Blakemore and Keirstead, 1999; Wolswijk, 2000).
Ultimately remyelination in MS fails (Franklin, 2002). A number of 
explanations have been proposed however none have been categorically 
proven. It has been proposed that OPC fail to migrate into lesions to 
remyelinate, however OPC have been identified within early active plaques.
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OPC appear to be of a finite supply (Blakemore and Franklin, 1997; Chang et 
al., 2002) and numbers of OPC tend to decrease with lesion progression 
(Wolswijk, 2000; Chang etal., 2002). OPC may fail to differentiate into 
myelinating mature oligodendrocytes due to possible lack of growth factor 
stimulation or actual attack by the disease process (Franklin, 2002). More 
recently it has been suggested that the myelinating properties of 
oligodendrocytes have been turned off by the Notch pathway, or that the 
axons themselves are not responsive to remyelination (Chang etal., 2002; 
Mastronardi and Moscarello, 2004). Paradoxically it has been suggested that 
the inflammatory environment may actually promote remyelination (Franklin, 
2002).
1.4 Inflammation and the BBB
During basal conditions the BBB acts as a barrier limiting the entry of 
immune cells into the parenchyma. A multistep model for leukocyte 
transmigration has been proposed that involves the sequential interaction of 
selectins, chemokines and integrins in a process that involves tethering 
rolling, adhesion and transmigration (Springer, 1990, 1994, Butcher, 1991). 
Circulating lymphocytes are tethered (captured) where they transiently 
adhere to the vascular bed where they then roll along the vessel wall until 
they can become attached to the endothelium by interactions of selectins (L- 
selectin, E-selectin and P-selectin) (Figure 1.6). T cells upregulate their cell 
surface expression of (32 integrin lymphocyte function associated antigen-1 
(LFA-1) and a1 integrin very late activation antigen (VLA-4) when activated 
(Vora etal., 1997; Ransohoff, 1999; Laschinger etal., 2002; Kohm and 
Miller, 2003). Chemokines activate and mediate the directional migration of T 
cells along their concentration gradient. The attachment of these cells is then 
further strengthened by interactions of their integrins and the endothelial 
adhesion molecules, which are upregulated upon activation of the cerebral 
endothelium by chemokines and cytokines (Johnston and Butcher, 2002). 
VCAM-1 is the major ligand for VLA-4, whereas intercellular adhesion 
molecule-1 and -2 (ICAM-1 and ICAM-2) are the major endothelial ligands for 
LFA-1 (Bo etal., 1996; Ransohoff, 1999; Kohm and Miller, 2003;
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Figure 1.6 Schematic representation of the mechanisms involved in cellular
infiltration across the BBB
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Schematic representation of the stages (a) and adhesion molecules (b) 
involved in the transmigration of inflammatory cells across the BBB in MS. 
Activated endothelial cells and lymphocytes upregulate their expression of 
adhesion molecules and ligands allowing the firm attachment to the 
endothelial wall. Activated lymphocytes enter the brain parenchyma 
following a chemotactic gradient to the areas of inflammation.
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Eikelenboom et al., 2005). Cells migrate between or through the endothelial 
cell layer and matrix metalloproteinases (MMPs) degrade the basement 
membrane and extracellular matrix allowing cells to enter the brain following 
chemokine gradients (Ransohoff, 1999; Avolio etal., 2003). Recently another 
stage has been added in the transmigration of monocytes into the brain. 
Following the attachment of monocytes to the vascular endothelium, they 
then move from the site of firm adhesion to the nearest junction in order to 
begin diapedesis, a process called locomotion (Schenkel etal., 2004; Ancuta 
et al., 2004).
Endothelial adhesion molecules are now believed to play a more 
important in transendothelial migration than just cellular adhesion 
(Greenwood etal., 2002, Lyck etal., 2003, Turowski etal., 2005). ICAM-1 
has a very short cytoplamsic tail, approximately 28 amino acids in humans, 
however it is capable of elicitating intracellular signals that are vital for 
transendothelial migration (Greenwood et al., 2002, Turowski etal., 2005). In 
vitro studies have illustrated that the extracellular domain of ICAM-1 is 
sufficient to support T cell attachment whereas transendothelial migration 
was strictly dependant of the cytoplasmic tail (Lyck et al., 2003). Intracellular 
ICAM-1 signalling is triggered by multimerization leading to signalling 
cascades that result in cytoskeletal rearrangement that facilitates 
transmigration (Greenwood etal., 2002). ICAM-1 molecules can interact 
directly with components of the actin and microtubule cytoskeleton, namely 
a-actinin and p-tubulin (Carpen etal., 1992). ICAM-1 also interacts with the 
actin cytoskeleton through the ERM proteins ezrin, radixin and moesin 
(Turowski etal., 2005). Consequently ICAM-1 cross linking lead to 
cytoskeletal rearrangement in the formation of actin stress fibres and the 
phosphorylation of the cytoskeletal-associated proteins focal adhesion 
kinase (FAK), paxillin and p130Cas (Etienne etal., 1998). In vitro data has 
demonstrated that src activity and the phosphoryaltion of cortactin increases 
significantly, as a result of Ca2+ signalling through a protein kinase- 
dependant pathway, following ICAM-1 cross-linking o rT  cell adhesion 
(Eteinne-Manneville etal., 2000). ICAM-1 cross linking and T cell adhesion 
has lead to reported increases in endothelial Rho proteins and activation of 
Rho GTPases (Adamson et al., 1999). Inhibition of Rho proteins have
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prevented the cytoskeletal changes in endothelial cultures and attenuated 
the clinical signs of EAE suggesting a central role for Rho proteins in ICAM-1 
dependant transendothelial migration (Walters et al., 2002, Adamson et al.,
1999).
Immunohistochemical studies of endothelial cell associated adhesion 
molecules have shown an increase in ICAM-1, VCAM-1 and E-selectin on 
the cell surface of the vascular endothelial cells in MS lesions compared to 
NAWM and control sample white matter (Sobel et al., 1990; Washington et 
al., 1994; Bo etal., 1996; Dobbie etal., 1999; Etienne-Manneville etal.,
2000). This up-regulation of adhesion molecules is suggested to be a result 
of TNF actions as In vitro models of the BBB report an upregulation in ICAM- 
1, VCAM-1 and E-selectin following TNF stimulation (Wong and Dorovini-Zis, 
1992 & 1995). MS lesions contain a large number of VLA-4+ and LFA-1+ 
lymphocytes (Bo etal., 1996).
Cleaved adhesion molecules in their soluble form are believed to act 
as inhibitors of adhesion with respect to the membrane bound form, by a 
competitive mechanism (Avolio etal., 2003). Soluble ICAM-1 is reported to 
block lymphocyte attachment to cerebral endothelial cells. Serum levels of 
soluble VCAM-1 in people with relapsing-remitting MS are increased with a 
decrease in MRI activity, suggesting a role for endothelial VCAM-1 in 
disease progression (Calabresi etal., 1997; Rieckmann etal., 1998; Avolio 
et al., 2003). A member of the a disintegrin and metalloproteinase (ADAM) 
family, ADAM-17, may also influence lymphocytic infiltration as it has been 
shown to be the mediator of the cleavage and shedding of adhesion 
molecules L-selectin, and VCAM-1 (Borland etal., 1999; Garton etal., 2003).
During inflammatory conditions such as stroke, human 
immunodeficiency virus-1 encephalitis and MS, disruption of the BBB 
integrity occurs associated with infiltration of activated monocytes, 
lymphocytes or neutrophils (Kwon and Prineas, 1994; Perry etal., 1997; 
Boven et al., 2000). Increased leukocyte migration has been reported to 
induce BBB breakdown and loss of the tight-junction associated proteins ZO- 
1 and occludin of the cerebral endothelial cells in an in vivo rat model (Bolton 
et al., 1998). Other researchers however report that ZO-1 and occludin
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remain associated with the endothelial cell borders and are not degraded 
following neutrophil adhesion and migration in vitro (Burns etai., 2000).
During human immune deficiency virus-1 encephalitis (HIVE), HIV-1 
infected monocytes infiltrate the parenchyma and are associated with a 
breakdown in BBB and alterations in the tight junction associated proteins 
occludin and ZO-1 (Dallasta etal., 1999). Loss of ZO-1 and occludin 
expression are claimed to be associated with evidence of serum protein 
leakage in HIVE (Dallasta etal., 1999). TJ disruption is also reported in HIV- 
1 associated dementia and simian immunodeficiency virus encephalitis, with 
ZO-1 alterations related to monocyte infiltration and CD68+ perivascular 
macrophages (Boven etal., 2000; Luabeya etal., 2000).
TNF may exert an influence on TJ by reorganisation of the associated 
actin cytoskeleton (Wolburg and Lippoldt, 2002) resulting in the formation of 
intracytoplasmic aggregates of F-actin (Walsh et al., 2000). Transendothelial 
permeability is increased across the cerebral microvasculature of Wistar- 
Furth rats and brain endothelial monolayers in vitro following stimulation with 
TNF (Blum etal., 1997, Prat etal., 2001; Mayhan, 2002).
Immunocytochemical studies have demonstrated BBB breakdown and 
dysfunction in HIVE, human cerebral malaria and experimental neutrophil 
induced BBB breakdown (Bolton etal., 1998; Dallasta etal., 1999; Brown et 
al., 1999; Luabeya etal., 2000; Boven etal., 2000). The structural basis for 
these BBB permeability changes were shown to lie at the level of the TJ 
(Luabeya et al., 2000).
1.4.1. BBB in Multiple Sclerosis and other CNS disorders
Breakdown of the BBB has been suggested as an invariable and 
perhaps obligatory event in new lesion development in relapsing-remitting 
MS or secondary progressive MS (Lai et al., 1996). A phase of gross but 
focal dysfunction of the BBB has consistently been demonstrated in vivo 
using Gd-GTPA MRI (Kermode etal., 1990 a&b; McDonald, 1994; Paty and 
Moore, 1998) suggesting BBB breakdown precedes clinical signs and is a 
prominent event in the pathogenesis of MS (Claudio et al., 1995). 
Furthermore BBB leakage has been recorded in many old chronic plaques
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(Kwon and Prineas, 1994), even persisting in the absence of active 
inflammation, at levels which are not detected by routine MRI (Claudio et al., 
1995; Paty and Moore, 1998). BBB breakdown in people with relapsing- 
remitting MS is a common phenomenon usually associated with more 
aggressive disease and a younger age of onset (Stone et al., 1995). TNF, 
present in perivascular cuffs in MS (Woodroofe and Cuzner, 1993), is also 
postulated to be responsible for the redistribution of VE-cadherin and JAM, 
and for the formation of intercellular gaps between cells (Walsh et al., 2000)
1.5 Immunology of MS
Based on observations from the experimental model of MS, 
experimental autoimmune encephalomyelitis (EAE), which are described 
further in Chapter 4, MS has been described as a T cell mediated disease. T 
cells transmigrate across the BBB where they interact with macrophages 
resulting in myelin destruction, which in turn leads to a perpetuating cycle of 
damaging inflammatory responses (Hohlfeld etal., 1995; Bar-Or etal.,
1999). Currently however MS pathogenesis is believed to involve a synergy 
between the immune responses of B-cells, monocytes, microglia and 
macrophages along with T cells (Archelos et al., 2000).
1.5.1 Immune response in MS
1.5.1.1 T cells
Activated T cells secrete various cytokines depending on the required 
response (Figure 1.7). CD4+ T helper cells (Th1) are associated with pro- 
inflammatory cytokines TNF, IFNy, lymphotoxin (LT) IL-12 and IL-1p 
resulting in a Th1 response that enhances APC activation, which in MS 
results in the destruction and removal of myelin. Secretion of anti­
inflammatory cytokines IL-4, IL-10 and IL-13 induces a Th2 response. It has 
been suggested that the disease processes in lesion formation is controlled 
by both Th1 and Th2 cells (Kleine et al., 2003). A large group of Th1 and 
Th2-type receptors (IL-12R, IL-18R, and IFNyR, IL-4R, IL-10R and IL-6R) 
have recently been described to be ubiquitously and constitutively expressed 
by oligodendrocytes in MS lesions and normal control white matter (Cannella 
and Raine, 2004). Expression of the corresponding cytokine ligands by the
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Figure 1.7 Molecular interactions involved in APC activation of T celts
microglia is proposed to represent a novel innate immune network within the 
CNS between the oligodendrocytes and microglia (Cannella and Raine,
2004). The role of pro-inflammatory cytokines in EAE, has lead to the belief 
that MS is a Th1 mediated disease and elevated levels of TNF and LT have 
been detected in MS (Selmaj and Raine, 1988; Hofman etal., 1989). The 
role of cytokines in MS is complex, indeed subpathological levels of TNF 
have been suggested as being protective (Raivich and Banati, 2004) and it is 
believed that both Th1 and Th2 responses coexist. Presence of both Th1 
and Th2-type cytokine receptors suggests that no pathway predominates but 
any outcome results from a shift in the local cytokine balance (Cannella and 
Raine, 2004).
T cells have been identified in peripheral blood from MS patients that 
are reactive to epitopes from myelin basic protein (MBP), proteolipid protein 
(PLP), and MOG (Ota etal., 1990; Stinissen etal., 1998; Bar-Or etal., 1999; 
Lindert et al., 1999; Iglesias et al., 2001). The same myelin reactive T cells 
are also know to be part of the regular repertoire in normal control subjects, 
however certain epitopes are reported to be immunodominant in MS patients 
only (Ota, etal., 1990; Lunemann etal., 2004). T cell epitope spreading has 
been reported in MS, whereby an initial response against a defined epitope 
diversifies with time to be directed to other epitopes on the same molecule 
(intramolecular) or different molecules (intermolecular) (Vanderlugt et al.,
1998). Spreading of responses to different epitopes of PLP has been 
reported in patients with demyelinating syndromes who eventually developed 
MS (Tuohy et al., 1997). MBP reactive T cells from MS patients are reported 
to be in a higher state of activation than those from control. T cells are 
activated upon presentation of antigen associated with MHC class II by 
APCs (Figure 1.7).
Microglia and macrophages have been shown to be MHC class II 
positive within MS lesions suggesting a role in antigen presentation (Hayes 
et al., 1987) however dendritic cells (DC), known as the professional APC, 
are the most potent APC. DCs have been shown to be present in the 
perivascular infiltrate in active MS lesions (Plumb et al., 2003). The presence 
of DCs within the perivascular cuffs of MS lesions may allow the stimulation 
of naive T cells infiltrating the inflamed brain (Plumb et al., 2003). Several
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groups have examined the phenotype of T cells within perivascular cuffs.
The predominant T cell within the perivascular infiltrate has been reported as 
being CD4+ T cells (Compston et al., 1991) however others have reported 
CD8+ T cells (Esiri et al., 1989; Gay et al., 1997) as the predominant cell, 
whilst others have reported an equal distribution of CD4+ and CD8+T cells 
within the perivascular cuffs (Woodroofe etal., 1986). Effective antigen 
presentation also requires the expression of costimulatory or accessory 
molecules on the surface of the APC binding to their receptor counterparts 
on the T cell (Windhagen et al., 1995) (Figure 1.7). All CD4+ and CD8+ T 
cells express CD28 constitutively, interactions of CD28 with the costimulatory 
molecules, CD80 (B7.1) or CD86 (B7.2), induce differentiation of naive T 
cells into either Th1 (CD80-CD28) or Th2 (CD86-CD28) cells. CD80 
expression has been demonstrated in active MS lesions to be associated 
with inflammatory macrophages and lymphocytes (Windhagen etal., 1995). 
CD86 expression was observed in areas of MS lesion and stroke infarct 
within the same brain suggesting that costimulation with CD86 results in 
induced scar tissue with fibrosis and not demyelination (Windhagen et al., 
1995).
To prevent an autoimmune attack, the CNS regulates autoreactive T 
cells by inducing T cell apoptosis (Pender and Rist, 2001). T cell apoptosis is 
mediated through the Fas pathway and the death receptor pathways such as 
TNF receptor pathway (Brunner et al., 1995). Apoptotic T cells are removed 
via phagocytosis by the CNS glial cells (Nguyen and Pender, 1998; Pender 
and Rist, 2001).
1.5.1.2B cells
Physiologically B cells function as effector cells through their 
differentiation into plasma cells and secretion of antibodies, release of 
cytokines and mutual T cell activation. Normal individuals have non- 
pathological autoantibodies, although their function is unclear (Archelos et 
al., 2000). Memory B cells can become activated by a T cell-independent 
mechanism in the presence of IL-2, IL-4, IL-10 and TNF (Hodgkin and 
Basten, 1995), all of which have been identified within MS lesions. An 
increase in BBB permeability allows activated B and T cells to enter the CNS
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where they have been detected in the perivascular cuff along with plasma 
cells and macrophages in the Virchow-Robin space (Prineas and Wright, 
1978; Esiri, 1977; Esiri and Gay, 1990;). Myelin specific autoantibody may 
bind to the myelin sheath leading to macrophage-dependent demyelination 
(Van der Goes etal., 1999). Autoantibodies against MOG have been 
reported within acute MS lesions (Genain etal., 1999). Antibody-mediated 
demyelination involves the activation of complement (Weerth et al., 2003; 
Lassmann, 1998). Deposition of complement activation products have been 
shown in MOG induced EAE and a subset of MS patients (Storch et al.,
1998; Lassmann, 1998). The presence of oligoclonal bands in the CSF of 
MS patients provides supportive evidence of clonal B cells producing IgG 
(Hickey, 2001).
Molecular mimicry has been proposed as a possible mechanism 
involving T cells and B cells in the pathogenesis of MS (Bar-Or etal., 1999; 
Archelos et al., 2000). Many bacterial and viral proteins share partial 
sequence similarity to MBP in their genome (Wucherpfennig and Strominger, 
1995). Hepatitis B virus and MBP contain sequence similarity and this 
sequence was encephalitic in rabbits (Wucherpfennig and Strominger, 1995, 
Wucherpfennig, 2001a). Vaccination with Hepatitis B vaccine has also been 
reported to activate previously existing MS and the appearance of CNS 
demyelination, consistent with MS (Faure, 2005).Two other micro-organisms, 
human herpes virus 6 and Chlamydia pneumoniae have been reported to be 
associated with molecular mimicry in MS (Swanborg et al., 2003). MS 
patients with high EDSS scores were reported to have Chlamydia 
pneumoniae detected within their CSF (Sriram et al., 1998). Treatment with 
antibiotics was reported to coincide with neurological improvement however 
other investigators have disputed the role of Chlamydia pneumoniae in MS 
(Swanborg etal., 2003). HHV-6 has been demonstrated to be expressed 
within MS plaques and in the CSF of people with RRMS (Soldan etal., 1997; 
Swanborg et al., 2003).
1.5.1.3 Microglia
The activation of microglia and secretion of inflammatory cytokines 
are important events in the pathogenesis of MS lesion formation (Woodroofe
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etal., 1986; Brosnan and Raine, 1996). Microglia have homeostatic and 
reparative responsibilities and respond rapidly to physiological and stress 
stimuli (Aloisi, 2001). A small population of monocytes are reported to be 
able to migrate into the brain parenchyma where they differentiate into 
microglia (Stroll and Jander, 1999, Priller etal., 2001). The presence of dying 
cells and cellular debris transforms ramified and highly branched resting 
microglia into rounded phagocytic macrophages (Aloisi, 2001, Raivich and 
Banati, 2004). In MS, activated microglia and macrophages are associated 
with the upregulation of molecules involved in antigen presentation, myelin 
and tissue breakdown, and the production of reactive oxygen species (Jack 
etal., 2005, Raivich and Banati, 2004). Microglia also secrete cytokines, 
chemokines, growth factors and components of the complement cascade 
(Raivich and Banati, 2004). Microglia have been reported to express 
increased levels of the costimulatory molecules B7.1 and CD40 in MS 
lesions, suggesting a role in T cell antigen presentation (De Simone et al., 
1995; Jack et al., 2005). Activated microglia have been shown to express IL- 
1, TNF, IFNy, MCSF, GMCSF and IL-12, which have been shown to have 
disease promoting activities. Monocytes can develop into either DC or 
phagocytic macrophages depending on their migration pattern through the 
endothelium (Randolph etal., 1998). Monocytes can switch between these 
two differentiation pathways until a late stage of commitment (Palucka etal., 
1998). The entry of monocytes into the brain to establish a population of 
perivascular microglia is well recognised (Hickey and Kimura, 1988; Stoll and 
Jander, 1999).
It has been proposed that presence of the numerous CNS signalling 
receptors on microglia indictates that they are regulated by neuronal signals 
(Philips and Lampson, 2000). Neurotrophins have been shown to decrease 
microglial expression of MHC class II and costimulatory molecules in vitro 
(Neumann etal., 1998). Microglia and neurons act cooperatively to 
downregulate brain inflammation by inducing the anti-inflammatory cytokines 
IL-13 and IL-4. Following their release migroglia undergo apoptosis (Shin et 
al., 2004; Park et al., 2005).
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1.5.1.4 Astrocytes
As a component of the BBB the astrocyte is likely to be the first glial 
cell to encounter and react to inflammation in MS (Ayers et al., 2004). 
Reactive gliosis and glial scar formation are pathological characteristics of 
the MS lesion and are characterised by an increased intensity of staining for 
GFAP, corresponding to the increased density of astroglial processes 
relative to normal parenchyma (Holley et al., 2003; Ayers et al., 2004). 
Astrocytes have been shown to proliferate in response to TNF stimulation 
(Selmaj etal., 1990; 1991c) and have been demonstrated to express TNF 
and LT at sites of lesions in MS and EAE (Hofman et al., 1989; Plant et al.,
2004). Activated astrocytes express vascular cell adhesion molecule-1 
(VCAM-1) In vitro and within the spinal cord of mice with EAE (Hurwitz et al., 
1992; Gimenez etal., 2004). This expression of VCAM-1 is suggested to 
facilitate the migration of T cells into the CNS with subsequent pathological 
consequences (Gimenez et al., 2004).
1.5.2 Cytokines in MS
Cytokines are small secreted proteins that are critical components of 
the immune inflammatory process and enable communication between cells 
(Imitola et al., 2005). A single cytokine can be expressed by more than one 
cell type and communicate via cytokine receptors. The Janus kinase and 
signal transducer/transcription-activating (Jak/STAT) family play an important 
role in the signalling of many cytokine receptors (Imitola et al., 2005). 
Cytokines have been reported to play an important role in the pathogenesis 
of MS and EAE (Brosnan et al., 1995; Laman et al., 1998; Yang et al., 2002). 
TNF has long been associated with the pathogenesis of multiple sclerosis as 
described further in section 1.5.2.1.1. IL-12 is critical for the differentiation of 
Th1 cells and is reported to play an important role in MS (Miller et al., 2004). 
Increased IL-12 mRNA expression was demonstrated within acute MS 
plaques (Windhagen etal., 1985). In MS patients, IL-12 expression by 
peripheral blood mononuclear cells is associated with increased EDSS and 
disease activity as measured by MRI (Makhlouf et al., 2001). IL-12 has the 
ability to induce IFNy production by Th1 cells (Miller et al., 2004). IFNy is 
typically produced by Th1 cells and is a marker for a Th1 response and was
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shown to be expressed by perivascular cuffs in MS lesions and is secreted 
by T cells from people with RRMS and SPMS (Woodroofe and Cuzner, 1993; 
Balashov et al., 2000). Administration of IFNy to people with MS increased 
their relapse rate (Panitch et al., 1987).
IL-10 is a key endogenous inhibitor of pro-inflammatory Th1 cytokines 
produced primarily by Th2 cells (Miller et al., 2004; Imitola et al., 2005) and 
expressed by astrocytes in MS lesions (Brosnan etal., 1995; Hulshof etal., 
2002; Cannella and Raine, 2004). Decreased levels of IL-10 mRNA were 
detected in peripheral blood mononuclear cells from patients with RRMS and 
SPMS (Karp et al., 2001). Serum levels of IL-10 protein are reported to be 
decreased in samples from RRMS, however levels were reported to increase 
in correlation with the resolution of Gd-DTPA MRI lesions (van Boxel-Dezaire 
et al., 1999). Another Th2 cytokine associated with MS is IL-4, which is 
expressed by microglia and foamy macrophages in acute and chronic active 
MS lesions (Brosnan etal., 1995; Hulshof et al., 2002; Cannella and Raine,
2004).
1.5.2.1 Tumor necrosis factor family
TNF has been associated with inflammation and cell injury, with the 
TNF/TNFR family also being involved in such diverse processes as host 
defence, apoptosis, inflammation, autoimmunity and organogenesis (Wallach 
etal., 1999; Young and Eliopoulos, 2004). TNF is associated with the 
pathogenesis of a number of different human inflammatory diseases 
including rheumatoid arthritis, Crohn’s disease, diabetes and MS. TNF binds 
to two membrane bound receptors, TNFR1 (p55) and TNFR2 (p75), the 
combination of each receptor ligand complex inducing different T cell 
responses and pathological outcomes (Akassoglou et al., 1998 & 2003; 
Kassiotis and Kollias, 2001). Different expression patterns of TNFR have 
been observed within the CNS. TNFR expression has been reported to be 
associated with glia, neurons, and vascular endothelium, which may be 
critical in determining whether TNF will activate, induce proliferation or 
cytotoxicity in these cells and ultimately determine whether the outcome is 
pathogenic (Akassoglou et al., 2003). TNFR p55 and p75 are also present in 
soluble forms, which have been shown to influence TNF activity in vitro and
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in vivo (Jureicz et al., 1999). TNF has long been associated with the 
pathogenesis of multiple sclerosis (Brosnan etal., 1988; Selmaj and Raine, 
1988; Hofman etal., 1989; Merrill etal., 1989; Selmaj etal., 1990; 1991a&b).
1.5.2.1.1 In vivo evidence for TNF involvement in MS
Increased TNF levels in the cerebrospinal fluid (CSF) and serum 
samples of MS patients have been reported to be associated with the 
pathogenesis of the disease (Maimone etal., 1991; Drulovic etal., 1997), 
however the significance in relation to disease activity is unresolved as 
contradictory reports have also been made (Franciotta etal., 1989). TNF was 
detectable within the CSF of MS patients and not within samples from non­
inflammatory neurological disorders (Maimone et al., 1991; Drulovic et al.,
1997). TNF was only associated with the CSF of patients with active MS, 
with the TNF CSF concentrations being directly correlated with the degree of 
patient’s disability (Drulovic et al., 1997). However another study involving 
approximately 120 samples, 50 of which were MS, reported no significant 
differences in CSF TNF levels between MS and control samples, suggesting 
that TNF was not involved in the maintenance of the disease, however the 
possibility of TNF being involved in the initiation of the disease process was 
not ruled out (Franciotta et al., 1989). Increased shedding of TNFR p75 was 
found in MS patients in comparison to healthy volunteers, together with 
decreased p55 shedding, measured in serum (Jurewicz etal., 1999). In 
another study however, no differences were observed in p55 and p75 in 
serum samples of MS and control patients (Martino etal., 1997).
1.5.2.1.2 Autopsy tissue evidence for TNF involvement in MS
Immunohistochemical studies have identified the presence of TNF
within MS autopsy material (Hofman etal., 1989; Woodroofe and Cuzner, 
1993; Brosnan etal., 1995; Cannella and Raine, 1995; Bitsch etal., 2000a). 
TNF immunreactivity has been identified as being associated with astrocytes, 
macrophages (Hofman etal., 1988; Selmaj et al., 1991a) and microglial cells 
(Cannella and Raine, 1995). TNF immunoreactivity has not been reported in 
other neurological diseases such as Alzheimer’s and Parkinson’s disease, 
however it has been demonstrated, albeit to a lesser extent than in MS, in
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subacute sclerosing panencephalomyelitis (SSPE) and 
adrenoleukodystrophy (ALD) (Selmaj etal., 1991a). Careful classification of 
MS lesion autopsy and MS biopsy material allowed interpretation of TNF 
involvement in lesion formation (Selmaj etal., 1991a; Bitsch etal., 2000a). 
Very little TNF was detected in chronic inactive plaques, whereas TNF+ cells 
were observed in all areas of active lesions (Selmaj et al., 1991a). Further 
evidence for a role for TNF in MS lesion formation is offered by the presence 
of both p55 and p75 TNFRs on oligodendrocytes along the leading edge of 
active plaques (Raine et al., 1998). Presence of TNFR on peri-plaque 
oligodendrocytes correlated with reported oligodendrocyte pathology in MS 
lesions (Ozawa etal., 1994).
1.5.2.1.3 In vitro evidence for TNF involvement in MS
In vitro studies have investigated the effects of TNF on 
oligodendroglial, astroglial and endothelial cells. TNF mediated the death of 
oligodendrocytes in vitro (Selmaj and Raine, 1988; Selmaj et al., 1991b; 
Andrews et al., 1998; Buntix et al., 2004a&b). Some researchers found that 
TNF induced oligodendrocyte necrosis (Selmaj and Raine, 1988) whereas 
others reported oligodendrocytes undergoing TNF mediated apoptosis 
(Buntinx et al., 2004a&b). Further debate lies with the efficacy of TNF to 
induce oligodendroglial cell death, as it has been reported that TNF can act 
directly on oligodendrocytes (Selmaj et al., 1991 b) however others report that 
TNF potentiates the toxicity of IFNy (Andrews et al., 1998) another cytokine 
that has been shown to play a role in the pathogenesis of MS (Raine, 1995). 
TNF had less of an effect on cells of oligodendrocyte lineage, the more 
differentiated the cells were (Andrews et al., 1998). However in vivo studies 
have shown increases in TNF mRNA correlated with a decrease in mature 
MOG+ oligodendrocytes, whereas there was no such correlation between 
TNF mRNA and PLP+ oligodendrocyte precursor cells (Bitsch etal., 2000). 
TNF does not affect oligodendrocyte proliferation (Selmaj et al., 1990)
TNF induces astrocyte cell proliferation (Selmaj etal., 1990; 1991c; 
Merrill, 1991) and reactivity (Tzeng et al., 1999). This proliferative response 
to TNF may contribute to the reactive gliosis that is a pathological hallmark of 
MS.
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TNF effects on the cerebral endothelial cells of the microvasculature 
are vital in the disruption of the BBB. In vitro studies on endothelial cell 
cultures suggest that the reported up-regulation of vascular adhesion 
molecules in MS is mediated by TNF (Wong and Dorovini-Zis, 1992; 1995; 
Cannella and Raine, 1995; Dobbie etal., 1999; Freyer et al., 1999).
Further evidence for a pathogenic role of TNF in MS is provided in 
studies that investigated treatment of MS patients with IFN-p. Treatment with 
IFN-P shows a decrease in adhesion molecule expression at the BBB with an 
increased level of soluble VCAM-1 within the serum. Loss of adhesion 
molecules at the BBB correlated with improved symptoms and a decrease in 
the number of enhancing lesions on MRI (Calabresi etal., 1997; Rieckmann 
et al., 1998). It has been suggested therefore that the TNF-induced increase 
in adhesion molecules at the BBB correlates with worsening of disease 
(Calabresi etal., 1997; Rieckmann etal., 1998). The formation of soluble 
adhesion molecules within the serum is suggested to have originated from 
the proteolytic cleavage of the membrane bound parent molecule by ADAM- 
17 (Avolio et al., 2003).
1.5.3 Chemokines in MS
Chemokines are chemoattractant cytokines that belong to a super 
family of small secreted proteins (8-14 kDa) that were originally associated 
with regulating leukocyte trafficking. To date there are over 40 members of 
the chemokine family (Cartier etal., 2005). The chemokine family is divided 
into four subgroups based upon the number and spacing of their conserved 
cysteine residues in their sequences. The chemokine families are C, CC, 
CXC, and CX3C, where X represents the number of amino acids between 
the first 2 cysteines (Murphy et al., 2000; Bajetto et al., 2001; Cartier et al., 
2005). Chemokines have been implicated in numerous functions including 
cell adhesion, cytokine secretion, cell proliferation, cell activation and 
apoptosis (Cartier et al., 2005). Chemokines exert their biological effect 
through chemokine receptors. Chemokine receptors belong to the 
superfamily of seven-transmembrane domain receptors that signal through 
heterotrimeric GTP-binding proteins (Bajetto et al., 2001). One chemokine 
can activate more than one receptor and conversely one receptor can be
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activated by more than one chemokine (Bajetto et al., 2001, Cartier et al.,
2005). However unique chemokine-chemokine receptor relationships do 
occur, e.g. CX3CL1-CX3CR1, CCL20-CCR6 and CXCL12-CXCR4 (Bajetto 
et al., 2001; Cartier et al., 2005).
CX3CL1 (fractalkine) and CXCL12 (SDF-1a) are the only chemokines 
to be constitutively expressed within the CNS, however 8 chemokine 
receptors have been reported to be constitutively expressed (Rottmann et 
al., 1997; van der Meer etal., 2000; Xia etal., 2000; Goldberg etal., 2001). 
Chemokines and their receptors have been reported to be elevated in MS 
especially in the perivascular cuff, in lesion formation and disease 
progression (Simpson et al., 2000; Zhang etal., 2000; Ying et al., 2000; 
Trebst et al., 2001 & 2003; Mahad et al., 2002; 2003 & 2004; Kivisakk et al., 
2004;). Three members of the monocyte chemoattractant protein family -1, -2 
and -3 (CCL2, CCL7 and CCL8) have been associated with hypertrophic 
astrocytes and inflammatory cells within acute and chronic MS lesions 
(McManus etal., 1998; Van der Voorn etal., 1999). As could have been 
predicted their corresponding receptors (CCR1-3 and CCR5) have been 
described to be associated with foamy macrophages and activated microglia 
in chronic active lesions (Simpson et al., 2000a; Trebst et al., 2001).
RANTES (CCL5) has been proposed to be involved in the recruitment of T 
cells into the CNS, and has been shown to be associated with perivascular T 
cells along the edge of active plaques and upregulated within the CSF from 
people with MS compared with controls (Sorensen et al., 1999; Ying et al.,
2000). Other chemokines suggested to have a pathogenic role in MS are the 
macrophage inflammatory proteins (MIP-1a/CCL3 and MIP-1(3/CCL4), 
interferon gamma inducible protein-10 (IP-10/CXCL10) and monokine 
induced by gamma-interferon (MIG/CXCL9) (Sorensen etal., 1999; Simpson 
et al., 2000b; Zhang et al., 2000). Recently CCR7 and CCR8, receptors for 
CCL21, CCL19, CCL17, CCL1 and CCL4 have been reported to be 
upregulated in active MS lesions (Kivisaak etal., 2004) and are associated 
with phagocytic macrophages (Trebst et al., 2003).
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1.6 Matrix metalloproteinases
The MMP family is a group of Zn-dependent proteolytic enzymes that 
are involved in the remodelling of the extracellular matrix (ECM) in a variety 
of physiological and pathological processes (Yong etal., 1998; Rosenberg, 
2002; Mandal etal., 2003). Based upon their main substrates, the MMP 
family is divided into collagenases, gelatinases, stromelysins and membrane 
type MMPs (MT-MMP) and are members of the matrixin subgroup of the 
metzincin family. MMPs are synthesized as zymogens with an inhibitory N- 
terminal pro-peptide sequence with a cysteine residue that chelates the 
enzymatic Zn+ion in the active site (Leppert etal., 2001). Conformational 
changes resulting in a cysteine switch followed by an autocatalytic cleavage 
of the pro-peptide activates MMPs (Yong etal., 1998; Leppert etal., 2001; 
Rosenberg, 2002). MMPs play a pathogenic and detrimental role in a range 
of CNS diseases including, bacterial meningitis, cerebral ischemia, tumor 
invasion and metastasis, Alzheimer’s disease and MS (Yong etal., 1998; 
Romanic et al., 1998; Leib et al., 2001; Leppert et al., 2001; Shapiro et al 
2003; Meli etal., 2004).
As MMPs can degrade all of the protein constituents of the ECM their 
activity is tightly regulated (Yong et al., 1998; Leppert etal., 2001). MMP 
activity is regulated at four levels; gene expression, pro-enzyme activation, 
enzyme secretion and inhibition by specific tissue inhibitors of 
metalloproteinases (TIMPs) (Leppert et al., 2001; Visse and Nagase, 2003). 
TIMPs, of which there are four (TIMP1, 2, 3, 4), are specific endogenous 
inhibitors of MMPs and form non-covalent bonds with MMPs in a 1:1 
stoichiometry inhibiting the pro- and active forms of MMPs (Leppert et al., 
2001; Visse and Negase, 2003).
1.6.1 MMPs and multiple sclerosis
MMPs have been suggested to play a number of roles in the 
pathogenesis of MS, including facilitating transmigration of immune cells 
across the BBB and through the ECM as well as the attack and breakdown 
of the myelin sheath (Maeda and Sobel, 1996; Cuzner etal., 1996; Cossins 
etal., 1997; Chandler etal., 1997; Lepert etal., 1998; Lichtinghagen etal.,
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1999; Lee etal., 1999; Kieseier etal., 1999; Kouwenhoven etal., 2001; 
Lindberg etal., 2001; Rosenberg, 2002).
1.6.1.1 In vivo evidence for MMP involvement in MS
Increased MMP9 levels have been reported in CSF samples from 
people with MS in comparison to controls (Gijbels et al., 1992; Leppert et al.,
1998). Studies on peripheral blood monocytes (PBMC) have demonstrated 
increased mRNA levels for MMP1, 3, 7 and 9 as well as TIMP1 in patients 
with MS compared with OND and normal controls (Lee etal., 1999; 
Lichtinghagen etal., 1999; Kouwenhoven etal., 2001). However no 
significant differences were observed in the number of TIMP1 and TIMP2 
mRNA expressing PBMC in serum samples from active MS in comparison 
with stable disease and normal controls (Lee etal., 1999; Lichtinghagen et 
al., 1999). In another study however, the numbers of TIMP1 mRNA 
expressing monocytes were elevated in serum samples from patients with 
MS (Kouwnhoven et al., 2001). Further evidence for the involvement of 
MMPs in MS comes from the reduction in the abnormally high level of MMP9 
activity in the CSF of MS patients following methylprednisolone therapy 
(Rosenberg etal., 1996).
1.6.1.2 Autopsy tissue evidence for MMP involvement in MS 
Immunohistochemical studies have revealed that macrophages in
active lesions and to a lesser extent in chronic lesions, express MMP1, 2, 3 
and 9 (Maeda and Sobel, 1996; Cuzner etal., 1996; Lindberg etal., 2001). 
MMP7 and MMP9 expression is increased in areas of NAWM in comparison 
to controls and is associated with the endothelium of the microvasculature 
(Lindberg etal., 2001). All TIMPs are reported to be constitutively expressed 
in control brains (Lindberg etal., 2001).
1.6.1.3 In vitro evidence for MMP involvement in MS
It has been suggested that one of the major producers of MMPs are 
monocytes and macrophages (Kouwenhoven etal., 2001). Lymphocyte 
migration across a barrier in vitro, representing the basal lamina, has been 
shown to be mediated by MMP9 and it is believed that MMPs expressed by
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monocytes mediate their transmigration across the BBB into the brain 
parenchyma by ECM remodelling and disruption of the barrier (Leppert etal., 
1995).
1.7. ADAM family proteins
The ADAMs are related to the family of MMPs and MT-MMPs which 
comprise the matrixin subfamily of the metzincins (Killar et al., 1999).The 
ADAM family of proteins, include the adamalysin subfamily of the metzincins 
along with the snake venom metalloproteases (SVMP) (Killar etal., 1999). 
Adamalysins are similar to the matrixins in their metalloproteinase domain, 
but differ by the presence of a unique integrin receptor-binding disintegrin 
domain. The ADAM family are a large group of type I integral membrane 
proteins of which to date there are 40 family members reported (Seals and 
Courtneidge, 2003).
1.7.1 Domain structure o f the ADAM family
Members of the ADAM family are structurally similar and 
phylogenically well conserved and are comprised of: prodomain; 
metalloproteinase domain; disintegrin domain; cysteine-rich domain; and 
EGF-like domain; transmembrane domain and a cytoplasmic tail (Yamamoto 
etal., 1999) (Figure 1.8). The presence of the transmembrane and 
cytoplasmic domains in ADAMs but not SVMP proteins indicates that all the 
ADAMs exist as membrane bound forms whereas all the SVMPs are 
secreted (Killar et al., 1999).
The prodomain
The prodomain consists of about 200 amino acid residues that are 
separated from the metalloproteinase domain by one or more furin cleavage 
sites. Primarily the prodomain keeps the metalloproteinase site of the 
ADAMs inactive, through a cysteine switch mechanism (Van Wart and 
Birkedal-Hansen, 1990). Furin, orfurin-like proprotein convertases, cleave 
the prodomain from the rest of the protein, releasing it and switching the zinc 
coordination to the metalloproteinase domain making it available for catalytic 
activity (Killar et al., 1999, Seals and Courtneidge, 2003). A further function
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of the prodomain is to chaperone the proper folding of the protein (Milla et 
a l, 1999; Leonard e ta l, 2005). Constructs of ADAM 10 and ADAM 17 
devoid of a prodomain are reported to be enzymatically inactive in vivo (Milla 
etal., 1999; Anders etal., 2001).
The metalloproteinase domain
The metalloproteinase or catalytic domain consists of approximately 
200 amino acid residues that contain three conserved histidine residues 
(HEXGHXXGXXHD) that coordinate the catalytic Zn2+ in the active site (Killar 
et al., 1999; Seals and Courtneidge 2003).
The disintegrin domain
The disintegrin domain was named after its presence within the 
SVMPs where it is involved in binding to platelet integrin receptors, 
preventing platelet aggregation at wound sites (Seals and Courneidge,
2003). Structurally there is little known about the disintegrin domain of the 
ADAM proteins (Seals and Courneidge, 2003) or whether or not all ADAM 
proteins can bind to integrins (Moss etal., 2001). The disintegrin domain in 
ADAMs consists of approximately 90 amino acid residues, with 15 cysteines, 
including a 14 residue ‘disintegrin loop’ with 3 cysteines, one each at the 
start, middle and end of the loop (Moss etal., 2001).
The cysteine rich and EGF domains
Little is known about the structure and function of the cysteine rich 
and EGF domains. These domains are comprised of approximately 160 and 
40 amino acids with each also containing 14 and 6 cysteine residues 
respectively. It has been suggested that these domains are involved with 
substrate recognition and specificity, complementing the binding capacity of 
the disintegin domain (Moss et al., 2001, Seal and Courtneidge, 2003). The 
cysteine rich domain of human ADAM 12 has been shown to interact with 
syndecan in tumor cells in vitro (Iba et al., 1999), whereas the cysteine-rich 
domain of ADAM 13 has been reported to bind to both fibronectin and (31- 
containing integrins (Gaultier et al., 2002).
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The transmembrane domain
All ADAM proteins are anchored to cell membranes via the 
transmembrane domain near the C-terminus. Several ADAM proteins 
however also have an alternatively spliced form that diverges before the 
transmembrane domain, thus leading to the production of a soluble secreted 
form (Moss et al., 2001). The ADAM family members with a thrombospondin 
motif (ADAMTS) lack a transmembrane domain and are therefore all 
secreted.
The cytoplasmic domain
The cytoplasmic tail of ADAM proteins is highly variable in both length 
and sequence (Seals and Courtneidge, 2003). The cytoplasmic tail contains 
SH3 binding domains and potential phosphorylation sites suggesting a 
signalling function (Killar etal., 1999). Cell culture studies have 
demonstrated the importance of interaction of the cytoplasmic tail of ADAM-9 
with protein kinase C, thereby upregulating its cleavage of pro-heparin 
binding epidermal growth factor (HB-EGF) (Moss et al., 2001). Recent 
studies have implicated ADAM-17 as a physiological HB-EGF convertase 
(Hinkle et al., 2004).
1.7.2. ADAM proteins in biology
ADAM proteins have the potential to mediate a variety of functions 
including proteolysis, adhesion, fusion, and signalling (Killar et al., 1999). 
Expression of ADAM mRNAs is wide and differentiated suggesting that these 
are multipotential proteins (Karkkainen etal., 2000). ADAMs 1-3 play a 
pivotal role in the fertilisation of the ovum by a sperm (Evans 2001). ADAMs - 
9, -12, and -19 are suggested to play a role in myogenesis and 
osteogenesis, whereas ADAM-13 is proposed to be involved with neural 
crest migration in Xenopus (Killer et al., 1999; Seals and Courneidge, 2003). 
Adhesion protein-mediated communication between cells and between cells 
and the extracellular matrix (ECM), together with the proteolytic processing 
and remodelling of cellular and extracellular proteins are essential for the 
structure and function of the CNS (Karkkainnen et al., 2000). In 
neurogenesis, ADAM-10 has been shown to mediate cell fate decisions by
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activation of the Notch signalling pathway (Pan and Rubin, 1997) initiating 
lateral inhibition (Killar etal., 1999).
A number of ADAM proteins have been found to be involved with 
immune responses and as a result are suggested to have pathogenic roles in 
numerous inflammatory conditions. ADAM-8 is suggested to play a role in 
the degradation of vascular basement membranes and has been 
demonstrated to be expressed on monocytes and macrophages and is 
upregulated upon cellular activation (Yoshiyama etal., 1997; Yamamoto et 
a!., 1999; Killar et al., 1999). Immunohistochemical studies have 
demonstrated ADAM-15 expression by macrophages associated with the 
endothelium in atherosclerosis (Herren etal., 1997) suggesting a possible 
pathogenic role.
ADAM-10 was the first member of the ADAM family to be described 
as having proteolytic activity (Howard etal., 1996). ADAM-10 has close 
homology with ADAM-17 (Described in detail in Chapter 3) however it is 
more closely related to Kuzbanian, its Drosophila homologue (Killar et al., 
1999, Moss et al., 2001). ADAM-10 mRNA has been demonstrated to be 
expressed in hematopoietic cells and chondrocytes (Dallas etal., 1999) and 
within the adult CNS (Karkkainnen et al., 2000; Kieseier et al., 2003). ADAM- 
10 is reported to cleave myelin basic protein and type IV collagen in vitro 
(Howard et al., 1996). Further in vitro studies have also demonstrated 
ADAM-10 to be capable of cleaving TNF however it is not the main 
physiological convertase (Lun etal., 1997; Killar etal., 1999). One of the 
pathological hallmarks of Alzheimer’s disease is the presence of large 
extracellular amyloid plaques within the brain. The pathological formation of 
amyloid plaques requires the cleavage of amyloid precursor protein (APP) by 
both p-secretase (BACE) and y-secretase (presenilin-1) (Numan and Small, 
2000; Skovronsky et al., 2001; Asai et al., 2003; Koj'ro and Fahrenholz,
2005). ADAM-9 and ADAM-10 are a-secretases of APP and may process 
APP down a non-amyloidogenic pathway, acting as a protective factor in 
Alzheimer’s disease (Allinson etal., 2003; Kojro and Fahrenholz, 2005).
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1.8 Experimental autoimmune encephalomyelitis an experimental model of 
MS
EAE can be induced in animals by active immunization with CNS 
components in adjuvant, by the passive transfer of myelin-specific activated T 
cells into the blood stream or by viral infection (Lipton et al., 1979; van Noort, 
1996; Begolka et al., 1998). Depending on the animal strain and type of 
immunization and induction, either an acute, monophasic or chronic relapsing 
EAE disease course can be induced (van Noort, 1996; Rausch et al., 2003). 
Acute EAE manifests as an inflammatory disease where evidence of 
demyelination is minimal. Demyelination is a pathological feature of chronic 
EAE however, where multiple phases of tissue inflammation are followed by 
persistent damage to the myelin sheath (Rausch et al., 2003). Demyelination 
is also a pathological hallmark of Theiler’s murine encephalomyelitis virus 
induced EAE (Lipton etal., 1979). Susceptibility to EAE induction varies 
between strains of different species due to differences in the MHC genes of 
different strains of animals (Rausch et al., 2003; Behi et al., 2005). Clinical 
progression of EAE is characterised by weight loss and hind limb weakness 
that can progress to bilateral hind limb paralysis. In most species, the disease 
recovers spontaneously (Badovinac etal., 1998). In rat and marmoset, 
demyelination is strictly antibody dependant whereas in mice demyelination 
can be mediated by a TNF dependant mechanism (Iglesias et al., 2001).
1.8.1 Autoantigens in EAE
EAE was originally termed experimental allergic encephalomyelitis as 
it was believed that the inflammation observed was an allergic response to 
exogenous neuronal tissue however more recent evidence has suggested an 
autoimmune response to a self antigen as the pathogenic mechanism. As 
myelin is a primary target in demyelination the protein constituents of myelin 
were regarded as encephalitogenic. Myelin basic protein (MBP), is the major 
protein constituent of myelin and was long believed to be “the” 
encephalitogenic protein of the CNS in EAE. Moreover other myelin proteins 
have been deemed encephalitogenic including PLP, MAG, MOG and myelin 
oligodendrocyte basic protein (MOBP) (Leber et al., 1986; Sobel etal., 1986;
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Linington and Lassmann, 1987 Weerth etal., 1999; Kaye etal., 2000; Von 
Budingen et al., 2001).
1.8.2 MOG as an autoantigen in EAE
MOG is now regarded as having one of the strongest 
encephalitogenic properties of all the myelin proteins (Von Budingen et al., 
2001, Brok etal., 2001; Iglesias etal., 2001). MOG, formally known as M2 
protein (Linington et al., 1984), is expressed and incorporated into the 
outermost lamellae of the myelin sheath, making it an ideal target for 
antibody mediated demyelination (Iglesias etal., 2001; Brok et al., 2001). 
MOG is developmental^ regulated and is deemed a marker for mature 
oligodendrocytes and is the only myelin protein not to be expressed outside 
the CNS (Von Budingen et al., 2001). MOG is unique in that it is the only 
myelin autoantigen that is able to induce both an encephalitogenic T cell 
response and a demyelinating response in EAE. In the absence of a specific 
antibody response, MOG induces a purely inflammatory pathology that can 
be altered to an inflammatory response with demyelination following 
intravenous injection of MOG-specific monoclonal antibody (Iglesias et al.,
2001). MOG by itself has been able to induce EAE in inbred mice, rats and 
nonhuman primates (Von Budingen etal., 2001).
1.9 Pathology of EAE
The classic pathology of a myelin autoantigen induced EAE is of an 
acute monophasic T cell inflammatory process. However different 
autoantigens, in different species and strains can induce varying pathologies, 
which are useful in investigating the different underlying mechanisms 
involved in MS. Acute EAE displays an intense inflammatory response with 
large perivascular cuffs composed of T cells and ED-1+ activated 
macrophages with a distinct reduction or lack of demyelination (Pender,
1988, Ahmed etal., 2001, Rausch etal., 2003). In chronic relapsing models 
of EAE (CREAE) inflammatory demyelination and axonalopathy are 
prominent, especially within the spinal cord (Lublin, 1985; Baker etal., 1990; 
Kornek etal., 2000; Ahmed etal., 2001; Brok et al., 2001). In IL-12-induced 
serial relapses, levels of inflammatory cuffs were recorded to be highest
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during the first relapse and were subsequently reduced during following 
relapses (Ahmed etal., 2001). Levels of CD4+T cells and ED1 + 
macrophages were also at their highest during the first relapse and returned 
to normal levels, compared with acute EAE, during subsequent relapses 
(Ahmed et al., 2001). High levels of axons with an accumulation of p-APP 
were seen in lesions with active inflammatory activity in a CREAE model in 
marmosets and rats (Kornek, et al., 2000; Brok et al., 2001). In a non-human 
primate model of EAE, animals killed during the chronic, relapsing remitting 
phase displayed sharply defined areas of demyelination with minimal 
mononuclear cell infiltration and extensive astrogliosis comparative to 
chronic MS plaques (Genain and Hauser, 1997; Laman etal., 1998).
1.9.1 Pathological comparisons to MS
Overall the pathologies reported in different EAE models correlates with 
those observed within MS. However each induced EAE model has a specific 
disease course and known pathology, whereas the pathology of MS is 
heterogeneous (Lucchinetti etal., 2000). Four patterns of MS lesion have 
been proposed however only two of these can be replicated in experimental 
models (Lucchinetti et al., 2000; Brok et al., 2001; Kornek and Lassmann,
2003). T cell mediated and T cell plus antibody mediated lesion formation are 
observed in MS and EAE, however lesions which are a result of 
oligodendrocyte loss from direct microbial infection or cytotoxicity have not 
been demonstrated in an experimental model (Brok etal., 2001). Lesions 
within MS are disseminated throughout the brain and spinal cord, whereas in 
Lewis rats with EAE the affected area is mainly the spinal cord (Villarroya et 
al., 1996), however in marmosets with EAE, periventricular demyelinated 
lesions have been reported (Laman etal., 1998). Lesions in marmoset EAE 
tissue constantly display vesicular myelin disruption that is also evident in 
acute MS lesions (Raine et al., 1999).
1.9.2 Cellular and immune responses in EAE
1.9.2.1 Cytokines
EAE is a T cell mediated autoimmune disease that involves a complex 
cascade of pro-inflammatory chemokines and cytokines leading to a
.)
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breakdown in the BBB. Pro- and anti-inflammatory cytokines coexist in EAE 
during active disease in concordance with findings in MS (Cannella and 
Raine 1995; Laman etal., 1998), suggesting that a balance of relative 
expression of disease inducing pro-inflammatory cytokines and the 
down modulatory anti-inflammatory cytokines determines the level of clinical 
signs (Laman etal., 1998; Yang etal., 2002).
1.9.2.1.1 TNF and IFNy in EAE
TNF activity has been demonstrated to be elevated in serum samples 
from Lewis rats with EAE, with peak levels corresponding to peak disease 
symptoms (Villarroya et al., 1996). In situ hybridization for TNF mRNA shows 
expression levels that parallel clinical signs, indicating a possible deleterious 
role for TNF in EAE (Issazadeh etal., 1995b; Villarroya etal., 1996; Begolka 
etal., 1998; Glablinski etal., 2003). However TNF and LT double knockout 
mice were still susceptible to EAE (Frei etal., 1997). In another study both 
p55 TNFR and p75 TNFR knockout mice were reported to still develop MOG 
induced EAE suggesting that other cytokines may also play a pathogenic 
role in EAE induction (Kassiotis etal., 1999; Schiffenbauer etal., 2000). IFNy 
mRNA expression in spinal cord correlates with clinical signs in EAE 
(Issazadeh etal., 1995a; Glabinski etal., 2003). Furthermore intraventricular 
injection of IFNy induced further relapses in rats with EAE (Tanuma et al.,
1999).
1.9.2.1.2IL-1 in EAE
IL-1 receptor (IL-1R) knockout mice failed to develop MOG induced 
EAE (Schiffenbauer etal., 2000). IL-1 positive astroglial like cells have been 
reported in the parenchyma of EAE animals (Laman et al., 1998). Treatment 
of EAE with soluble IL-1 R and IL-1 R antagonist reduced the clinical severity 
of the disease implicating IL-1 in playing a major pathogenic role in EAE 
(Martin and Near, 1995; Badovinac etal., 1998). Presence of IL-1 R 
antagonist during in vitro priming of T-cells reduced the efficacy of inducing 
EAE by adoptive transfer (Badovinac etal., 1998). These results suggest 
that IL-1 R and by inference IL-1 are essential for the development of EAE 
(Schiffenbauer et al., 2000).
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1.9.2.1.3 IL-12 in EAE
Endogenous production of IL-12 is essential for Th1 cell generation 
and also promotes IFNy production byT cells (Issazadeh etal., 1995b). 
Administration of IL-12 to Lewis rats, following recovery from acute EAE 
induces a further paralytic relapse with associated demyelination and axonal 
loss (Ahmed et al., 2001). Only limited expression of IL-12 however was 
observed in marmosets with acute EAE (Laman etal., 1998).
1.9.2.1.4IL-4 and IL-10 in EAE
IL-4 and IL-10 are Th2 cytokines that are reported to be associated 
with remission and recovery from acute EAE (Racke etal., 1994; Begolka et 
al., 1998; Yang et al., 2002) and ameliorate the disease when administered 
in vivo (Racke et al., 1994; Rott et al., 1994). However another report 
suggests that IL-4 expression levels do not correlate with disease activity 
and that it is only detected at a very low level (Issazadeh et al., 1995a). 
Increased levels of IL-10 were reported to occur after initial onset of disease 
recovery, suggesting that IL-10 rather than initiating disease recovery 
actually acts by keeping the animal free from relapses by suppressing 
cytokine synthesis by Th1 cells (Issazadeh etal., 1995b).
1.9.2.2 Chemokines
Several chemokines have been proposed as being involved in the 
pathogenesis of EAE (Ransohoff etal., 1993; Godiska etal., 1995; Karpus, 
2001; Jee etal., 2002; Glabinski etal., 2003; Klein, 2004). During acute 
EAE, MCP-1, IP-10, RANTES, MIP-1a and MIP-1(3 are upregulated at the 
beginning of the active stage of the disease (Godiska et al., 1995; Jee etal., 
2002). In CREAE, MCP-1, IP-10, RANTES, MIP-1a and T-cell activation 
gene 3 (TCA-3) are increased during relapses of the disease (Ransohoff et 
al., 1993; Jee etal., 2002; Glabinski et al., 2003) suggesting a pathological 
involvement for these chemokines. CNS chemokine mRNA expression 
correlated with histological signs of inflammation, as expression was not 
detected in the absence of leukocyte infiltration (Godiska et al., 1995). 
Functional studies have shown that antibodies to MIP-1a and MCP-1 
ameliorate EAE and MCP-1 deficient mice display reduced macrophage
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recruitment to inflammatory areas and have a significantly milder form of 
EAE (Karpus etal., 1995; Kennedy etal., 1998; Huang etal., 2001). CC 
chemokine receptor 2 (CCR2), the main receptor for MCP-1, was 
significantly upregulated throughout the course of CREAE (Jee et al., 2002) 
moreover mice deficient in CCR2 do not develop EAE (Fife et al., 2000). 
Although the same chemokines are repeatedly reported in various EAE 
studies, chemokine expression patterns differ in different mouse strains and 
EAE models (Karpus and Ransohoff, 1998). In EAE, fractalkine expression 
is reported to be upregulated on microglia and blood vessels (Pan et al., 
1997; Jiang et al., 1998), however others report no change in fractalkine 
mRNA expression levels (Schwaebel etal., 1998).
1.9.2.3 Adhesion molecules
ICAM-1 and VCAM-1 are upregulated during the course of EAE 
development reaching a maximum at peak clinical disability (Selmaj, 2000; 
Laschinger and Englehardt, 2000; Scott et al., 2004). E-selectin is an 
adhesion molecule that is associated with activated endothelia in response to 
inflammatory cytokines including TNF and IL-1 (3 and is proposed to play a 
role in the rolling stage of leukocyte recruitment (Wagnerova et al., 2002). 
Increased levels of soluble E-selectin have been reported in MS, 
corresponding to disease activity (Dore-Duffy et al., 1995), however little is 
known about E-selectin expression in EAE. L-selectin is mainly expressed on 
the cell surface of leukocytes and like E-selectin is believed to be involved in 
the rolling phase of leukocyte transmigration (Archelos etal., 1998). L- 
selectin positive cells have been demonstrated in the brain and spinal cord 
during active EAE (Allen etal., 1994; Dopp etal., 1994) (Figure 1.6). 
Administration of an antibody to L-selectin has been reported to effectively 
suppress clinical signs, and mononuclear infiltration in an MBP-induced EAE 
model (Archelos etal., 1998). VLA-4 is the surface receptor for VCAM-1 and 
its expression is required for T-cell migration into the brain parenchyma 
(Baron etal., 1993; Laschinger and Englehardt, 2000) (Figure 1.6). 
Monoclonal antibodies and synthetic antagonists of VLA-4 have been 
demonstrated to inhibit the initiation of EAE (Brocke et at., 1999; Cannella, et 
al., 2003). VCAM-1 and ICAM-1 are mostly associated with the endothelial
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cells of the microvasculature but are also expressed by astrocytes and cells 
of microglial lineage (Selmaj, 2000). Treatment with a soluble p55 TNFR 
significantly reduced VCAM-1 expression in EAE to level comparable to that 
of non-immunised animals (Selmaj, 2000).
1.10 The aims of this thesis
The overall aim of this thesis is to further elucidate the 
immunopathological events ongoing in the CNS in MS (Figure 1.9) in 
particular the integrity of the interendothelial tight junction proteins of the 
cerebral blood vessels and to characterise the expression of ADAM-17 and 
TIMP3 within MS autopsy tissue, and to assess their role in MS 
pathogenesis. Specifically to determine:
• The expression of the TJ associated proteins, occludin and ZO-1, in 
MS at different stages of lesion development and in control white 
matter using immunofluorescence and confocal microscopy.
• Expression of ADAM-17 and TIMP3 within MS and control white 
matter at the protein level by immunofluorescence and western 
blotting and at the mRNA level by RT-PCR.
• Expression of ADAM-17 and TIMP3 over the disease course of EAE, 
an experimental model of MS, at the protein level by 
immunofluorescence and western blotting and at the mRNA level by 
RT-PCR and real-time PCR.
• Regulation of ADAM-17 and TIMP3 under pro-inflammatory conditions 
using rat cerebral endothelial cell cultures and analysis at the protein 
level by immunofluorescence and western blotting.
• Functional activity of ADAM-17 in rat cerebral endothelial cells under 
pro-inflammatory conditions by measuring soluble TNF using ELISA 
techniques.
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Chapter 2
Endothelial tight junction-associated proteins of the blood- 
brain barrier in multiple sclerosis
2.1 Introduction
The existence of a BBB was discovered towards the end of the 19th 
century through the studies of Ehrlich (1885) (De Vries et al., 1997). Ehrlich 
reported that the brain tissue remained clear following an intravascular 
injection of a vital dye. However Goldmann (1909) reported that human brain 
tissue stained when trypan blue was injected directly into the ventricular 
system, leading to the suggestion of a barrier at the site of the cerebral 
microvasculature (De Vries etal., 1997).
2.1.1 Molecular composition o f the BBB tight junction
TJ complexes of the BBB are located at the most apical location of the 
plasma membrane of adjacent endothelial cells (Wittchen etal., 1999).
Unlike the case in epithelial junctional complexes however, the adherens 
component (vascular cadherin) of the endothelial BBB TJ complex is not 
separate from the TJ components sensu stricta, but is intercalated 
throughout the whole junctional area (Schulze and Firth, 1993). The TJ 
complex is composed of interactions between transmembrane, cytoplasmic 
and cytoskeletal proteins (Figure 2.1 adapted from Petty and Lo, 2002).
2.1.1.1 Transmembrane Proteins
Formation of the inter-endothelial TJ involves the integrated function 
of three types of transmembrane proteins from adjacent cells; occludin, 
claudin and junctional adhesion molecule (JAM) (Figure 2.1).
Occludin was identified as the first integral transmembrane protein of 
the TJ (Furuse etal., 1993; Ando-Akatuska etal., 1996). Occludin is a 60-65 
kDa phosphoprotein that is composed of four transmembrane domains, three 
cytoplasmic domains and two extracellular loops. The cytoplasmic domains 
include a short NH2-terminal, a long COOH-terminal and a short intracellular 
turn (Fanning etal., 1999; Tsukita and Furuse, 1999; Ballabh etal., 2004). 
The two extracellular loops, which bind with occludin loops on neighbouring 
cells to form the TJ paracellular barrier (Ballabh et al., 2004), contain a high 
percentage of tyrosine and glycine residues (-65%) although the significance 
of this is unclear (Fanning etal., 1999). Occludin is not the only
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Figure 2.1 Schematic representation of the molecular components of the TJ at the BBB
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occludens cytoplasmic proteins that bind to the transmembrane proteins and the actin cytoskeleton. (Figure adapted from 
Petty and Lo., 2002)
transmembrane protein of the TJ however and does not appear to be 
essential for establishing a TJ (Tsukita and Furuse, 1999; Wolburg and 
Lippoldt, 2002). Thus, transgenic occludin-deficient mice were able to form 
morphologically normal TJs, which showed no reduction in transendothelial 
resistance (TER) in comparison to wild-type (Saitou et al., 2000). Other 
experimental data suggests that mature cells require occludin to regulate and 
seal rather than to establish the TJ (Wolburg and Lippoldt, 2002).
The second integral transmembrane protein or family of proteins of 
the TJ is the claudin family (From the Latin claudere meaning to close). 
Claudin-1 and -2 were first described in 1998 and now the family has 
expanded to consist of at least 24 members following sequence tagged 
database searches (Furuse et al 1998; Morita et al., 1999a; Ballabh et al.,
2004). Claudins are 22 kDa phosphoproteins that contain four 
transmembrane domains with COOH- and NH2- cytoplasmic terminals. 
Despite the topographical similarities, claudins contain no sequence 
similarity to occludin (Furuse et al., 1998). Claudins form dimers which bind 
homotypically and heterotypically to claudins from adjacent cells (Huber et 
al., 2001; Ballabh etal., 2004) to form the primary seal oftheTJ. Claudins 
are differentially expressed throughout the body, depending on the functional 
requirements of the tissue.
There is contradictory evidence as to which claudins are expressed in 
the CNS (Morita et al., 1999). The latest evidence suggests that BBB 
endothelium expresses claudin-5 and claudin-3 and possibly also claudin-12 
(Kraus e ta l 2004). Previous reports of the expression of claudin-1 in BBB 
endothelium may have been due to the cross reaction of a claudin-1 antibody 
with the claudin-3 molecule (Wolburg etal., 2003; Kraus etal., 2004; Hamm 
et al.,2004). Outside the vessels but within the CNS parenchyma, claudin-11, 
also known as oligodendrocyte specific protein (OSP), has been identified as 
a major component of CNS myelin (Fanning etal., 1999; Ballabh etal.,
2004). The importance of claudins as major structural components of the TJ 
is demonstrated by the finding that claudin-1 and claudin-2 can induce TJs in 
fibroblast cells initially lacking TJs (Tsukita and Furuse, 1999). The 
significance of the large number and variety of claudins is hinted at by the 
fact thatTJ strands containing claudin-1 are believed to form tighter junctions
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than those containing claudin-2 (Tsukita and Furuse, 1999). Claudins have 
been shown to be important determinants in TJ regulation of paracellular 
ionic charge selectivity transcellular conductance (Van Itallie et al., 2003). 
The direction of charge selectivity conferred by individual claudins may be 
due to the electrostatic effects of the charged amino acids in their first 
extracellular loops (Van Itallie etal., 2003).
The third transmembrane protein is the recently identified junction 
adhesion molecule (JAM) (Martin-Padura etal., 1998)family. JAM family 
proteins are members of the immunoglobulin superfamily that have one 
transmembrane domain that binds homotypically to JAM of adjacent cells 
and also to monocytes to aid transmigration (Fanning et al., 1999; Wolberg 
and Lippoldt, 2002). JAM-1 is expressed in both endothelial and epithelial 
cells whereas JAM-2 and -3 are expressed in most vascular endothelial cells 
(Wolberg and Lippoldt, 2002). These molecules are involved in the 
organisation of TJs, with JAM-1 responsible for promoting occludin 
localisation at the TJ (Dejana et al., 2000).
2.1.1.2 Cytoplasmic sub-membranous plaque-associated proteins o f the TJ
The first peripheral TJ protein to be identified was zonula occludens 
(ZO-1) (Stevenson etal., 1986) which is a 220 kDa peripheral membrane 
protein from the membrane-associated guanylate kinase (MAGUK) family.
To date three MAGUK family members have been associated with TJs, ZO- 
1, -2, and -3 (Itoh et al., 1999 a&b). The ZO proteins contain three defined 
core regions that are essential for their interaction with the rest of the TJ 
structure. They contain three PDZ, one GUK and one SH3 domain (Furuse 
etal., 1994; Itoh etal., 1999; Wittchen etal., 1999; Wolburg and Lippoldt, 
2002). The PDZ domains have been reported to bind ZO proteins to claudin 
(Itoh etal., 1999b) whereas the GUK domain binds to occludin (Furuse et al., 
1994) thus playing a role in organisation of the TJ at the plasma membrane 
(Ballabh et al., 2004). ZO-1 also forms independent complexes with ZO-2 
and ZO-3 via their second PDZ domain however ZO-2 and ZO-3 do not bind 
together (Wittchen et al., 1999) (Figure 2.1). Following immunoprecipitation 
experiments, the ZO proteins were also shown to bind to the primary 
cytoskeletal protein, actin (Blumetal., 1997; Wittchen etal., 1999; Itoh etal.,
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1999b; Fanning et al., 1999) providing a structural support as well as a 
possible dynamic linking role between membrane proteins and the 
cytoskeleton (Fanning etal., 1999; Ballabh etal., 2004).
Other less well characterized components of the TJ include Cingulin a 
cytoplasmic TJ associated protein that does not have a PDZ domain but 
forms bonds with the ZO proteins and myosin from the cytoskeleton, 
suggesting a structural role at the TJ (Petty and Lo, 2002). Another 
component 7H6 is a 155 kDa phosphoprotein that is found at TJs that are 
impermeable to ions and macromolecules (Huber et al., 2001, Petty and Lo,
2002).
2.1.1.3 The adherens junction
The TJ complex includes intercalated adherens junction (AJ) 
components that are composed of vascular cadherin (v-cadherin) that binds 
homotypically to extracellular domains of neighbouring v-cadherin. V- 
cadherin is also connected indirectly to the cytoskeleton through catenin that 
binds to actin (Ballabh et al 2004). AJs also interact with TJs through the 
binding of catenin to ZO-1 (Petty and Lo, 2002).
2.1.2 Regulation of tight-junctions
The selectively permeable BBB is rapidly responsive to physiological 
and pathological stimuli and plays a key role in maintaining the distinctive 
CNS metabolic and immunoregulatory homeostasis (Huber et al., 2001). As 
a result, TJ function is strictly regulated, the microenvironment of cerebral 
capillaries is highly complex with interactions and signals originating from 
numerous exogenous and endogenous sources (Huber et al., 2001; Wolburg 
and Lippoldt, 2002). In vitro models have been utilised in an attempt to 
unravel the complexities governing TJ structure and function. Recent in vitro 
studies have investigated the role of astrocytes in regulating TJs (Prat et al.,
2001). Evidence has been provided which suggests that humoral factors 
released from astrocytes, as assessed by the effect of astrocyte conditioned 
media on BBB characteristics of animal and human brain endothelial cells in 
culture, are sufficient to establish a functional barrier (Wolburg et al., 1994;
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Prat et al., 2001). It was previously reported however that cellular contact 
between cerebral endothelia and astrocytes is required for an efficient barrier 
(Tao-Cheng etal., 1987). The glial cell line-derived neurotrophicfactor 
(GDNF) appears to be one of several factors necessary for the induction of 
the BBB (Wolburg and Lippoldt, 2002).
Although occludin does not appear to be necessary for the formation 
of the TJ (Tsukita and Furuse, 1999), it does have important regulatory 
properties (Petty and Lo, 2002). Following TJ disruption, phosphorylation of 
the TJ associated proteins occludin and ZO-1 correlates with the recovery of 
the permeability barrier (Petty and Lo, 2002).
Cerebral endothelial cells are sensitive to cAMP levels, with increased 
levels associated with increased transendothelial resistance (Wolburg and 
Lippoldt, 2002; Petty and Lo, 2002). In vitro studies have suggested that G- 
proteins play a role in maintaining the barrier integrity (Wolburg and Lippoldt,
2002). Activation of heterotrimeric G-proteins leads to activation of 
secondary messengers, cAMP and Ca2+ (Wolburg and Lippoldt, 2002). 
Precipitation assays have been used to demonstrate the co-localisation of 
Ga subunits with ZO-1 (Petty and Lo, 2002; Wolburg and Lippoldt, 2002), 
and with the TJ region in rat cerebral endothelial cells in vivo (Wolburg and 
Lippoldt, 2002).
The primary cytoskeletal protein actin, which binds to ZO, occludin 
and claudin proteins, plays a major role in the regulation of TJ function. 
Circumferential contraction of the perijunctional actin ring increases 
paracellular permeability of the TJ (Fanning etal., 1999; Wittchen etal., 
1999). Actin disrupting substances, such as cytochalasin D as well as 
cytokines disrupts the TJ structure and function of endothelial cells in vitro 
(Huber et al., 2001).
2.1.3 Aim of study
In view of the MRl and pathological findings on the BBB in MS, this 
study set out to assess TJ integrity histopathologically by establishing a 
reproducible protocol for the investigation of the expression of the TJ 
associated proteins, ZO-1 and occludin, at the microscopic level. 
Immunofluorescent techniques were applied and a confocal scanning laser
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microscope was used to enable the visualisation of the entire TJ by scanning 
through the vessel. Formalin fixed paraffin embedded (FFPE) and snap- 
frozen control tissue were used to establish which tissue would allow optimal 
immunostaining of the endothelial TJs.
Snap-frozen (SF) autopsy MS tissue was used and classified according 
to macrophage/microglial activation and evidence of recent myelin 
breakdown, as described previously (van der Valk and de Groot, 2000). A 
semi-quantitative analysis of ZO-1 expression was applied to establish if any 
differences in TJ integrity exists between study groups. TJ integrity was also 
investigated in relation to pathological features of MS, namely leukocyte 
infiltration, cellular activation and BBB leakage. The major aims addressed 
were:
(i) To establish which autopsy material would allow optimal 
immunostaining of TJs for the study
(ii) To determine whether there is TJ disruption in MS which is 
detectable microscopically at the level of its constituent proteins
(iii) To determine whether such disruption predominates at a particular 
stage or stages of lesion development
(iv) To determine whether TJ disruption correlates with BBB leakage
(v) To determine whether TJ disruption, like BBB leakage is persistent
The major objective was to establish whether alterations in TJs are involved 
in the pathogenesis of the MS lesion and if so to develop an understanding 
of the destructive and reparative phases of the process.
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2.2 Materials and Methods
All tissues were obtained from the files of the Belfast Brain Bank, 
Northern Ireland Regional Neuropathology Service, Royal Group of Hospitals 
Trust, Belfast, Northern Ireland.
A retrospective case selection was carried out on the basis of a 
confirmed clinical and neuropathological diagnosis of MS and availability of 
suitable snap-frozen tissue samples containing active or chronic lesions or 
normal appearing white matter (NAWM). NAWM blocks were selected at the 
time of initial block preparation from white matter areas which were at least 
1cm from macroscopically identified plaque tissue. Tissue was received fresh 
from autopsy (<24 hours death-autopsy intervals for 13 out of 14 MS cases 
see Table 2.1). Two of the MS cases had a neuropathologically confirmed 
clinical diagnosis of acute MS and the other 12 cases had a confirmed 
diagnosis of secondary progressive MS. Individual tissue blocks were 
orientated on a cork block, SF in isopentane (cooled in liquid nitrogen) and 
immediately stored in air-tight containers at -70°C until required. These MS 
cases included 6  females, mean age 49.5 years (range 22-69) and 8  males 
with a mean age of 48.75 years (range 18-66). The tissue used had a mean 
time from death to freezing of 14.7 hours (range 1.5-29 hours). 32 SF control 
white matter blocks were also available and were obtained from 2  normal 
(road traffic accident) and 6  other neurological disease (OND) controls (1 
head injury, 3 sub-acute sclerosing panencephalitis (SSPE), 1 metastatic 
carcinoma, 1 transverse myelitis). Informed consent for research for all brain 
tissues and local ethical committee approval for the conduct of this study was 
obtained. All tissue blocks were anonymised prior to use.
2.2.1 Selection of tissue for TJ study
Samples from formalin fixed paraffin embedded (FFPE) and snap- 
frozen control tissue were prepared to determine optimal staining protocols 
for the immunocytochemical detection of occludin and ZO-1 at the cerebral 
vascular inter-endothelial tight-junctions.
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2.2.1.1 Formalin-fixed paraffin-embedded tissue
6|jm microtome paraffin sections of normal brain were dewaxed 
through two 5 minute changes of xylene then rehydrated through three 
changes of 640P (degrees over proof) and placed under running water. 
Sections were then pre-treated with one of the following methods to establish 
optimal levels of antigen retrieval.
2.2.1.1.1 Microwave antigen retrieval
Sections were immersed in citrate microwave buffer (see appendix) 
and microwaved for 20 minutes at maximum power (McQuaid et al., 1995). 
Sections were allowed to cool in running water then incubated in rabbit 
polyclonal antibodies to either occludin (1:200, Zymed) or ZO-1 (1:400, 
Zymed) overnight at 4°C. Following two five minute washes in Tris buffered 
saline (TBS, see appendix) antibodies were detected by incubating sections 
in Alexa 488 conjugated goat anti-rabbit IgG (1:500, Molecular Probes) for 1 
hour at 37°C. Cell nuclei were counterstained by incubating sections in 
propidium iodide (Sigma, 2pg/ml) for 30 seconds. Sections were mounted 
with coverslips in the non-fading mountant citifluor (see appendix). All 
dilutions were carried out in TBS.
2.2.1.1.2 Proteinase K
Following dewaxing and rehydration, sections were incubated in 
proteinase-K (Sigma, 0.5mg/ml in phosphate buffered saline (PBS)) for 5 or 
10 minutes at RT. Sections were then washed in TBS and primary antibodies 
applied and detected as described above (2.2.1.1.1).
2.2.1.2 Snap frozen tissue
12pm cryostat sections were either fixed in methanol, 10% formalin, 
4% paraformaldehyde (see appendix), 740P or ice-cold acetone for 10 
minutes. Following fixation all sections were washed in PBS (see appendix) 
with the exception of ice-cold acetone fixed sections that were allowed to air 
dry for at least 15 minutes prior to the next step. Sections were then 
incubated in antibodies to occludin (1:200) or ZO-1 (1:400) overnight at 4°C, 
washed in PBS then incubated in Alexa 488 conjugated goat anti-rabbit IgG
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for 1 hour at 37°C. Sections were counter stained and mounted as above 
(2.2.1.1.1). All dilutions were carried out in PBS.
2.2.2 Tissue characterisation
All MS and control snap-frozen blocks underwent preliminary 
screening to determine the pathological state of individual blocks. Cryostat 
sections (12pm) were cut onto glass slides (Superfrost) and routinely stained 
with haematoxylin and eosin (H&E) and oil red O (ORO, see appendix) to 
identify and grade lesion activity. ORO positive blocks were classified as 
active plaque. Plaque-containing blocks that were ORO-negative were 
classified as chronic inactive, while blocks derived from macroscopically 
normal white matter that was devoid of ORO and plaques were classified as 
NAWM.
2.2.2.1 Single label immunofluorescence staining
Principle of method
Immunohistochemistry (IHC) and immunofluorescence combines 
anatomical, immunological and biochemical principles to identify specific 
tissue components by specific antigen/antibody reactions. The concept of 
IHC has been evident since the 1930s, however the first report was not until 
1942 when Albert Coons used fluorescent labelled antibodies to detect 
antigens in tissue sections (Coons, 1942).The principle of IHC is based on 
the identification of the antigen of interest by binding an antibody specific to 
that antigen, then visualising the antigen/antibody complex by fluorescent 
dyes, enzymes or radioactive elements linked to a secondary antibody 
directed against the primary antibody (Figure 2.2). IHC or 
immunofluorescence (fluorescent label) can be applied to a wide variety of 
tissues or cell cultures.
Method
Cryostat sections (12pm) were cut onto aminopropyltriethoxsilane 
(APES) coated slides (Starfrost) and fixed in ice-cold acetone for 10 minutes
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Figure 2.2 Schematic representation of different antibody detection methods
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at room temperature (RT). Indirect immunofluorescence was carried out to 
examine cerebral vascular endothelium, basement membrane, inter- 
endothelial tight junction integrity and the extent of macrophage/microglial 
activation, using the following antibodies and dilutions (in PBS): mouse 
monoclonal antibodies to laminin (1:1000, Sigma) and HLA-DR (1:100, 
Novocastra,) and rabbit polyclonal antibodies to occludin (1:200, Zymed) and 
ZO-1 (1:400, Zymed). A biotinylated Ulex europaeous agglutinin (UEA)
(1:500, Vector laboratories) was used as a marker for vascular endothelial 
cells. Assessment of serum protein leakage was visualised using a FITC 
conjugated antibody to fibrinogen (1:100, Dako). Primary antibodies, 
biotinylated UEA and fibrinogen-FITC were incubated on sections overnight 
at 4°C and detected by incubating in Alexa 488-conjugated rabbit anti-mouse 
or goat anti-rabbit IgGs (1:500, Molecular Probes) or Z-Avidin FITC (1:50, 
Zymed; for UEA) for 1 hour at 37°C. Cell nuclei were counter-stained with 
propidium iodide for 30 seconds then washed in PBS and mounted with 
coverslips using citifluor.
2.2.2.2 Dual Label Immunofluorescence staining
In selected samples, sequential dual labelling immunofluorescence 
was used to illustrate the relationship between TJ abnormalities (ZO-1 or 
occludin) and HLA-DR activation (HLA-DR), lymphocytic infiltration 
(leucocyte common antigen (LCA, 1:50, Dako), blood brain barrier disruption 
(fibrinogen-FITC) and basement membrane integrity (laminin). Acetone fixed 
sections were incubated in the polyclonal primary antibody overnight at 4°C. 
After washing in PBS, the sections were incubated in Alexa 568 conjugated 
goat anti-rabbit IgG (1:500, Molecular Probes) for one hour at 37°C, washed 
in PBS and then incubated in the monoclonal primary antibody for one hour 
at 37°C. Detection of the monoclonal antibodies was carried out by 
incubating in Alexa 488 conjugated rabbit anti-mouse IgG, excluding 
fibrinogen-FITC as it has a direct fluorescent conjugate, for 1 hour at 37°C. 
Sections were then washed in PBS and mounted with coverslips in citifluor.
For all single and dual labelling negative control sections, the primary 
or secondary antibody (dual) was omitted from the protocol.
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2.2.3 Imaging
2.2.3.1 Con focal Scanning Laser Microscopy
Principles of method
The confocal laser scanning microscope (CSLM) is a microscope that; 
scans, uses a laser and produces a confocal image (Figure 2.3). The CSLM 
is an advancement on the conventional epi-fluorescent microscope that is 
now commonly being employed in biological research to detect specimens 
labelled with fluorophores (Amos and White, 2003). The CSLM uses a laser 
as a light source which unlike the light source of the epi-fluorescent 
microscope (mixed wavelengths) provides a discrete wavelength band and 
has a very high intensity. The main difference between the two microscopes 
is, in the confocal microscope, the presence of small apertures called 
pinholes which regulate the detection of emitted light. In focus, light 
converges to a point on the imaging plane whereas out of focus light 
converges either above or below the imaging plane. A pinhole at the imaging 
plane prevents the out of focus light being detected allowing an image 
composed of only in focus light resulting in greater resolution (Figure 2.3). 
CSLM cannot “see” out of focus objects (Murray, 1992). A specimen viewed 
by CSLM is irradiated in a point to point fashion therefore to obtain 
information about an entire specimen the laser must be guided across the 
specimen or the specimen moved relative to the laser beam along the x-y 
axis, this process is called scanning. CSLM also allows the processing of 
information taken from optical slices along the z-axis (optical sectioning), 
which is beneficial in biological research where a lot of the specimens are 
thick tissue samples. The CSLM obtains an in focus optical slice from 
different focal planes through predefined limits of the section forming a z- 
stack. Z-stacks can be reassembled to create three-dimensional constructs 
which provides information about the spatial structure and localisation of the 
antigen of interest within the specimen. Another advantage of the CSLM is 
the ability to scan the image with different laser wavelengths to detect 
several different wavelengths of emitted light. This enables the co­
localisation of two or three different labels simultaneously.
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Figure 2.3 Schematic representation of the detection principles in CSLM
Laser
Confocal
Pinholes
PMT
Detector
Objective
 - -  Net In Focal Plane
------------- In Focal Plane
   Not In Focal Plane
A laser source excites the fluorophore attached to the antigen of interest, 
resulting in an emitted light. Using a series of pinholes ensures that only emitted 
light from the focal plane are detected by the photomultiplier tubes (PMT). 
Removal of the out-of-focus light by the pinholes produces an image of greater 
resolution than conventional microscopes.
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Emitted signals from the specimen are detected by photon multiplier tubes 
(PMT) which converts the photon into an electron which forms an analogue 
current which is then digitized by an analogue-digital converter and sent to 
the digital image processor of the associated CSLM computer. The computer 
software then allows a variety of processing techniques including co­
localisation studies.
To summarise the CSLM system includes a point light source for 
illumination, a point light focus within the specimen and a pinhole at the 
image detecting plane. When these three points are optically conjugated 
together and aligned accurately to each other in the light path of image 
formation, this is confocal.
Although the CSLM is designed to produce high quality in focus high 
resolution images there are limitations in obtaining optimal images. The 
smaller the pinhole the greater the resolution obtained however the smaller 
pinhole also results in diminished illumination intensity resulting in diminished 
emitted signals. There is also a limit to how long fluorophores can be excited 
by the laser. Excessive excitation of the fluorophore by the laser can result in 
saturation of emission where illumination does not result in more emission 
which is called photo-bleaching. Normal CSLM scans are carried out to 
obtain images at 512x512 (pixels scanned per second) and a quick scan 
speed for higher resolution images, 1024x1024, or higher require a slower 
scan speed which can result in photo-bleaching of the fluorophore.
Method
Immunofluorescent images were acquired using a Leica TCS/NT 
confocal scanning laser microscope equipped with a krypton/argon laser as 
the source for the ion beam. Selection of the FITC/TRITC filter selects a 
predefined set of parameters for data acquisition. Alexa 488 and FITC 
labelled antibodies were visualised by excitation at 488nm with a 506-538 
band-pass emission filter. Alexa 568 labelled antibodies were imaged by 
excitation at 568nm with a 564-594 band-pass emission filter. Acquiring 16 
optical sections in the Z-plane and running the series-scanning mode from 
the deepest focus point to the highest focus point, allowed a projected image 
and data set to be generated from which composite projected images were
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saved as tif files in Adobe 5.0 at 300 dpi (dots-per-inch) without further digital 
manipulation.
2.2.3.2 Data Collection
Only recognizable vessels whose profile was contained within the field 
of view of the x40 objective lens were imaged. The images of 30-50 cerebral 
blood vessels were collected from each block for an analysis of TJ integrity, 
from all MS and control cases. In performing the dual labelled ZO-1 and 
fibrinogen study, data sets for approximately 20 cerebral blood vessels from 
each selected block were obtained.
2.2.3.3 Data Analysis
Initial examination ofTJ expression (ZO-1 oroccludin), resulted in a 
crude analysis of the TJ associated proteins either being described as 
normal (continuous, linear expression), as observed from the staining in 
normal control brains and previous literature reports, or abnormal (definitive 
evidence of TJ disruption). Stored images used to assess TJ integrity were 
redisplayed and the diameter of each vessel was measured on screen, using 
the quantification software in TCS-NT. The incidence ofTJ abnormality was 
plotted for ‘all vessels’ and individually for vessels in each of the four size 
classes (diameter < 10pm; >10-30pm; >30-50pm; and >50pm).
When assessing the relationship between TJ abnormalities and the 
degree of serum protein leakage, a three point grading system was applied 
for each variable (Table 2.2). TJ abnormality was graded from 0-2 based on 
an estimated percentage. A grade of 0 was assigned to normal TJ 
expression, grade 1 if up to 25% of the vessel appeared abnormal, grade 2 if 
>25% of the vessel appeared abnormal. Similarly, fibrinogen leakage was 
graded as 0 when there was no evidence of leakage, 1 for moderate leakage 
and 2 when there was severe, widespread leakage. All assessment of 
grading was carried out blinded by at least 2 independent observers. For all 
analyses where the observers result disagreed, a consensus was reached 
following joint re-examination.
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Table 2.2 TJ and fibrinogen scoring grades
0
1
2
Fibrinogen score
0
1
2
— . . r  i . . .Extent o f abnormality
No disruption
Up to 25% of the vessel displays TJ abnormality 
£ 26 % of the vessel displays TJ abnormality
No leakage 
Moderate leakage 
Severe leakage
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2.2.3.4 Statistical analysis
The incidence ofTJ abnormality in the five tissue categories examined 
was compared using the non-parametric Kruskal-Wallis test for group 
differences. A p-value below 0.05 was considered as significant. Where 
significance was observed, Dunn’s test was carried out to determine the 
significance and direction of significance, using the recommended 
experimental error rate, a = 0.15 (Daniel, 1978). All analyses were performed 
on the SPSS statistical package (version 11.0, SPSS Inc, Chicago, IL, USA).
2.2.3.5 Digital Photography
All routine histological images were acquired using a Leitz Dialux 20 
light microscope equipped with a Nikon CoolPix 950 digital camera. Images 
were transferred to Adobe 5.0 and saved as JPEGs at 300dpi.
2.3 Resuits
2.3.1 Optimisation of immunostaining protocols for TJ study
Consideration of which type of tissue samples should be used and 
optimal fixation and immunostaining protocols were assessed in preliminary 
experiments. Sections of formalin fixed paraffin embedded (FFPE) and snap 
frozen tissues from a normal control case were used for ZO-1 and occludin 
immunostaining optimisation. Sections of FFPE tissue underwent pre­
treatments (microwave retrieval, Proteinase K), but yielded very low levels, if 
any, of ZO-1 staining (Figure 2.4). Comparison of fixatives on snap frozen 
tissue using methanol, 10% formalin, 4% paraformaldehyde, 99% IMS or ice- 
cold acetone were undertaken. All fixatives allowed ZO-1 expression to be 
detected although in the methanol, 99% IMS and formalin fixed sections, ZO- 
1 expression was fragmented and weak in comparison to the normal intense, 
linear, continuous expression of ZO-1 in the acetone and paraformaldehyde 
fixed tissue (Figure 2.4). Ice-cold acetone fixation permitted effective dual 
labelling experiments with ZO-1 and occludin so was therefore used for all TJ 
studies on snap frozen tissue.
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Figure 2.4 ZO-1 detection using different tissues and fixatives
Indirect immunofluorescence detection of ZO-1 (Green) in FFPE (a) and SF tissue 
(b-d). (a) Proteinase K pre-treated FFPE tissue devoid of ZO-1 expression, (b) 
99% IMS fixed SF tissue with fragmented, weak ZO-1 expression, (c) 4% 
paraformaldehyde fixed SF tissue and (d) ice-cold acetone fixed SF tissue 
expressing linear, intense and continuous ZO-1 expression. Cell nuclei in all 
sections were counterstained with propidium iodide. Mag x400.
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2.3.2 Characterisation of SF tissue
SF blocks from 21 MS autopsy cases from the Belfast Brain Bank, 
Neuropathology Department, Royal Group of Hospitals Trust, Belfast, were 
screened by H&E, ORO and HLA-DR to characterise the pathological state 
of individual blocks and the viability of blocks for use in this study:
• ORO-positive blocks were characterised as containing active 
plaque,
• ORO negative blocks with plaques present were characterised 
as chronic inactive plaque,
• ORO-negative blocks without plaque and greater than 1 cm 
from macroscopically visible plaque were characterised as 
NAWM.
From the initial screening process, 32 blocks from 8 MS cases 
contained active plaque, 18 blocks from 7 cases were classified as chronic 
inactive plaque and 16 blocks from 6 cases were classified as NAWM (Table 
2.1). 32 blocks from 8 control cases (2 normal and 6 OND) were also 
obtained from the Belfast Brain Bank.
To assess the extent of recent myelin breakdown and cellular 
activation within the active blocks a 3 point grading system was applied to 
the ORO and HLA-DR staining (Figure 2.5, Table 2.3). Of the 32 active 
blocks, 12 displayed scattered isolated ORO-positive cells (Grade 1), while 
12 had in addition, one or more foci or clusters of ORO-positive cells (Grade 
2). In 8 blocks however, ORO-positive cells were abundant throughout the 
entire section (Grade 3) (Table 2.3).
All of the 18 chronic inactive blocks, 5 of the active and 5 blocks from 
the NAWM displayed anti-HLA-DR staining of scattered, isolated HLA-DR+ 
microglia (Grade 1). 15 of the active and 7 of the NAWM blocks displayed 
HLA-DR immunostaining that was diffuse and widespread (Grade 2), which 
involved either parenchymal process bearing cells or cells in the distribution 
of small perivascular infiltrates. An abundance of large HLA-DR positive cells 
corresponding to foamy macrophages, observed on H&E staining, were 
detected in both parenchymal and perivascular distributions in 12 of the 
active and 4 of the NAWM blocks (Grade 3) (Table 2.3).
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Table 2.3 Description and distribution of scoring for cellular activation within
the MS tissue samples studied.
ORO 1 Sparse +ve cells 12 0 0
2 Diffuse small foci +ve cells 12 0 0
3 Abundance of +ve cells throughout 8 0 0
HLA-DR 1 Sparse single microglia +ve 3* 18 5
2 Foci of +ve micoglia and foamy 
macrophages
15 0 7
3 Abundance of +ve cells throughout 12 0 4
* 2 active blocks displayed no HLA-DR immunoreactivity
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2.3.3 Indirect Immunofluorescence
All of the selected MS and control blocks used in this study were 
stained by indirect immunofluorescence for endothelial (UEA) basement 
membrane (Laminin) and TJ associated proteins (ZO-1, Occludin).
Consistent uniform staining for the endothelial marker and the basement 
membrane protein laminin indicated that blood vessel integrity remained 
intact throughout all categories of MS and control tissues.
2.3.3.1 Tight junction expression in normal and OND controls 
Immunofluorescent staining of normal and OND control CNS tissues
with either antibodies to occludin or ZO-1 resulted in a continuous, linear 
staining pattern of strong intensity, in a very high percentage of blood 
vessels (95.54% and 90.52% respectively). In the transverse view, TJ 
staining revealed short, radial or near-radial, continuous fluorescent band 
(Figure 2.6a). Within longitudinally sectioned blood vessels the TJ protein 
staining was predominantly axial and linear with occasional 
anastomoses/bifurcations (Figure 2.6e). There was no consistent numerical 
or spatial relationship between the numbers of fluorescent TJ bands seen 
and the number or disposition of nuclei as revealed by the propidium iodide 
counterstain.
2.3.3.2 Tight Junction expression in MS
In comparison to the continuous, intense linear expression and regular 
deposition of ZO-1 and occludin observed in normal control brain, 
abnormalities in ZO-1 and occludin expression were observed in MS brains. 
TJ abnormality was heterogeneous, observed as three types (Figure 2.6):
• interruption or beading
• absence
• separation or opening
The abnormality was focal, never affecting all junctions within a single 
transected vessel. As no differences in the expression levels or distribution of 
ZO-1 and occludin were observed in control or MS tissues the former was 
therefore used in the quantitative studies on the basis of ‘sharper’
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Confocal microscopic images from snap-frozen, cryostat sections stained with ZO-1 
(Green) / propidium iodide, (a) Continuous, linear and intense appearance of the 
interendothelial TJ protein ZO-1 as viewed in a transverse section of a cerebral 
blood vessel from normal control brain, (b-d) Variations in abnormal appearing TJ 
protein expression in transverse sections of cerebral blood vessels in MS tissue 
sections, (b) beaded and discontinuous (c) disrupted and absent. On rare occasions 
TJ proteins were observed as displaying an open junction. Inset d1 displays the 
apparent gross separation of two neighbouring TJs in a BV from an active plaque, 
(e) Normal expression ofTJ in longitudinally sectioned blood vessel in MS tissue. 
Beaded and discontinuous (f) and disrupted and absent (g) abnormal expression of 
TJ in longitudinally sectioned blood vessels in MS tissue, (h) Comparative staining 
for occludin and a representative of a negative control (i) following omission of the 
primary antibody. Scale bars = 25pm (a, b, c, e, f, g), 50pm (d, h, i).
Figure 2.6 Norma! and abnormal TJ protein expression
immunofluoresence signal. Both ZO-1 and occludin abnormalities were 
observed in the presence of intact endothelium and basement membrane as 
detected by dual immunofluorescence for ZO-1 and UEA/laminin (Figure 
2.7).
2.3.3.3 Extent o f abnormal ZO-1 expression in MS
30-50 blood vessels from each control and MS block (dependent on 
block size) were assessed for TJ abnormality. 3.9% and 8% of the normal 
and OND (285 and 411 blood vessels respectively) displayed abnormalities 
in ZO-1 expression. Of the 32 blocks containing active plaques 42.5% of the 
622 blood vessels examined displayed definitive ZO-1 abnormalities. 22.76% 
of the 672 blood vessels examined from the chronic inactive MS blocks 
contained abnormal expression of ZO-1, whilst 13.09% of the 904 blood 
vessels from MS NAWM, contained abnormal ZO-1 expression (Figure 2.8a). 
Statistical analysis of the incidence ofTJ abnormality in the five tissue 
categories was very highly significant (p<0.0005) using Kruskal-Wallis test, 
indicating that there were differences in the group of means (Figure 2.8a). 
The subsequent application of Dunn’s test (a=0.15) revealed that the 
incidence ofTJ abnormality in the active plaques (42.5%) was significantly 
higher than in normal control (4.46%) OND controls (9.48%), or NAWM 
(13.09%) and that TJ abnormality in the inactive plaques (22.76%) was 
significantly greater than in the normal controls. The differences in TJ 
abnormality incidence between normal controls and either OND or NAWM 
did not reach statistical significance.
2.3.3.4 TJ abnormalities and vessel size
Using the quantitative software of the Leica CSLM TJ abnormality was 
assessed against blood vessel diameter. A spectrum of blood vessel sizes 
was recorded, with the following groups established:
Blood vessels with a diameter of:
< 10pm were capillaries
11-30pm small-intermediate vessels
31-50pm large-intermediate vessels
> 51 pm were classed as large vessels
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Figure 2.7 Assessing blood vessel integrity with TJ proteins
CSLM dual immunofiuorescent images showing maintained blood vessel 
integrity (Green) as detected by anti-laminin antibody (a) and UEA (c) in the 
presence of Grade 3 abnormal ZO-1 (Red) (b) and Grade 1 abnormal ZO- 
1(Red) (d). Mag x400
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Figure 2.8a Extent of TJ disruption in all tissue categories
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No. of Cases examined: 2  6 6 8 7
Extent of disrupted blood vessels across all the tissue groups examined. A 
significant increase (*) occurs in the number of disrupted blood vessels in the 
active and inactive MS tissue group when compared to normal and OND controls, 
following Kruskal-Wallis non-parametric test (*).
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Figure 2.8b Extent of TJ disruption in all tissue categories from each case
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Scatter plot of individual case means for TJ disruption from all of the 
tissue study groups.
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The majority of the vessels examined (88%) were either capillaries or 
small-intermediate vessels. TJ abnormalities were recorded in all sizes of 
blood vessel not just confined to this microvasculature. Variation of incidence 
of TJ abnormality between tissue groups was maintained irrespective of 
vessel size (Figure 2.9).
2.3.4. Correlation ofTJ abnormalities with other aspects o f MS pathology 
To determine whether TJ abnormalities occurred in the presence of 
other MS pathologies dual label immunofluorescence for ZO-1 and occludin 
was carried out with antibodies to detect macrophage/microglial activation, 
lymphocytic infiltration and serum protein leakage. The extent ofTJ 
abnormality in blocks containing recent myelin breakdown products, as 
determined by ORO, was also compared.
2.3.4.1 TJ abnormality and evidence of recent myelin breakdown 
In the active MS block series it was possible to correlate TJ 
expression to the grade of ORO. 12 active blocks (ORO-grade 1) had 39.6% 
of blood vessels displaying clear ZO-1 abnormality. 12 active blocks (ORO- 
grade 2) had 40.7% with ZO-1 abnormality. 9 active blocks (ORO-grade 3) 
displayed 44.6% ZO-1 abnormality. A trend for increased ZO-1 abnormality 
with extent of disease activity is evident although without statistical 
significance (Figure 2.10).
2.3A.2 TJ abnormality and macrophage/microglial activation
The MHO class II marker HLA-DR detects macrophages and 
microglial cells in an activated state and has hence been applied as another 
indicator of lesion activity. Following the trend observed with ORO, areas of 
higher microglial activation in active plaques had a (marginally) higher 
frequency of ZO-1 abnormality (Figure 2.10). 45.5% of the blood vessels in 
highly activated (grade 3) areas displayed abnormal TJ expression, 
compared with 41.3% in grade 2 areas and 33% in grade 1 areas. Dual 
labelling provided clear evidence for abnormality coincident with high HLA- 
DR immunoreactivity on numerous foamy macrophages that were evident in
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Figure 2.9 Comparison of TJ abnormality with blood vessel sizes
a. All vessels
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Comparison of the incidence of tight junction abnormality between MS and 
control tissues in all vessels (a) and in vessels of different sizes (b-e). Normal and 
neurological controls are grouped in this analysis. Numbers in parentheses 
indicates the number of individual blood vessels examined.
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Figure 2.10 TJ abnormality and cellular activation within active MS lesions
Cellular Activation
% of blood 40 
vessels 
disrupted 35
Activation grade
Bar graph illustrating relationship between blood vessel disruption and level 
of cellular activation in active MS plaques as measured by both HLA-DR and 
ORO. Although not statistically significant, a definite trend exists in that 
increased blood vessel disruption occurs with increased cellular activition (3).
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perivascular locations and throughout the parenchyma of active plaques 
(Figure 2.11a).
2.3.4.3 TJ abnormality and lymphocytic infiltration
Lymphocytic infiltration as observed in perivascular cuffs is a hallmark 
of MS pathology. Lymphocytic infiltration as detected by 
immunofluorescence for LCA was observed in many of the MS sections.
Dual label immunofluorescence provided clear evidence for ZO-1 
abnormality in vessels displaying high concentration of infiltrating 
lymphocytes within perivascular cuffs (Figure 2.11b)
2.3.4.4. TJ abnormality and serum protein leakage
None of the control blocks examined forTJ proteins displayed 
extravascular staining for fibrinogen indicating intact BBB. However, 
fibrinogen leakage was observed in all MS cases to varying extents. In a 
small proportion of the MS blocks, marked alterations in the intensity and 
pattern ofTJ staining co-incident with moderate to severe perivascular 
extravasation of fibrinogen and fibrillary immunoreactivity was seen. Dual 
label immunofluorescence provided clear evidence for ZO-1 abnormality in 
vessels displaying all levels of fibrinogen leakage (Figure 2.12). 
Immunostaining for fibrinogen was of a fibrillary nature indicative of astrocytic 
uptake during the disease course, suggesting pre-mortem leakage (Brown et 
al., 1999). Dual label for fibrinogen and GFAP commonly revealed an 
association between extravasted fibrinogen and the processes of astrocytes 
(Figure 2.12d-f).
In the semi-quantitative dual-labelling study three grades were used 
for each variable. Thus TJ abnormalities were graded on the following scale:
• 0= no clear abnormality
• 1= up to 25% of the vessel wall shows abnormalities in TJ 
protein expression
• 2= more than 25% of the vessel wall contains abnormal TJs 
(Figure 2.3.13 a-c)
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Figure 2.11 TJ abnormality associated with inflammatory cells
TJ abnormalities in active MS lesions, (a) Foamy macrophages in the 
perivascular cuff and surrounding parenchyma of a blood vessel expressing 
abnormal occludin (arrows). HLA-Dr (Green) / Occludin (Red), (b) A 
lymphocytic inflitrate associated with a collapsed vessel which reveals 
abnormal expression of occludin. LCA (Green) / Occludin (Red). Mag x400.
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Figure 2.12 Serum protein leakage and TJ disruption
Immunolabelling analysis of the characteristics of fibrinogen leakage and tight 
junction abnormality in MS lesions. A fibrillary (pre-mortem) pattern of serum protein 
leakage (Green) is shown in vessels (a) from NAWM, (b) from an inactive/chronic 
lesion, and (c) from an active lesion, nuclei are counterstained with propidium iodide. 
The relationship between extravascular fibrinogen and astrocyte processes is 
revealed in the same lesion by dual labelling (d, fibrinogen (FITC; green) and e, 
GFAP (Alexa 568; Red) f, composite image). The arrows in (e) indicate fibrinogen- 
positive processes which are also stained for GFAP.
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Figure 2.13 TJ abnormality and fibrinogen leakage
* * ^
C
TJ (green) integrity was graded as; 0= no abnormality (a), 1= 1-25% abnormal 
TJ (b), 2= more than 25% TJ abnormality (c). Fibrinogen (green d-f) in a blood 
vessel with no abnormalities (d, d1). Fibrinogen leakage co-localizes with 
abnormal tight junctions (ZO-1, red, arrows) in an active lesion (e, e1) and an 
inactive lesion (f, f1).
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Similarly, fibrinogen leakage was graded:
• 0= no leakage
• 1= moderate leakage
• 2= widespread, severe leakage
Anti-fibrinogen antibody labelled leakage was observed in blocks from 
all 3 categories of MS tissue but not in any blocks from the control cases 
(Figure 2.14). In many of the MS blocks, a fibrillary pattern of extravascular 
staining was present, indicative of pre-mortem leakage. Most commonly 
fibrinogen leakage had a distinct perivascular distribution but on rare 
occasions was observed more widely throughout the parenchyma. The 
relationship between TJ protein abnormalities and fibrinogen leakage was 
assessed at the level of the individual blood vessel, with each vessel being 
graded both for TJ abnormality and fibrinogen leakage.
292 blood vessels were analysed from 19 active MS lesions, 243 
vessels from 14 areas of NAWM and 291 vessels from 17 chronic inactive 
MS lesions. Overall there was a trend that with increasing severity of TJ 
abnormality there was an increase in severity in fibrinogen leakage, which 
was most evident in the active MS cases. In 26% of the vessels in active 
lesions with severe TJ abnormality (grade 3) extensive perivascular and 
parenchymal fibrinogen leakage was observed. In chronic inactive lesions 
and areas of NAWM, where fibrinogen leakage was not as prominent, the 
severest fibrinogen leakage was associated with vessels displaying the most 
TJ abnormality (Figure 2.14).
2.3.5 Influence of Death-autopsy interval on TJ abnormalities and serum 
protein leakage
As mentioned previously utmost care was taken in selecting tissue 
samples with a death-autopsy interval (DAI) < 24 hours, however the DAI 
varied within this group from 1.5-24 hours. The incidence of TJ abnormality 
and serum protein leakage was examined against DAI to determine whether 
post-mortem autolysis had an effect on BBB breakdown and leakage. 
However it was found that there was no correlation between either presence
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Figure 2.14 Association of TJ disruption with serum protein leakage in white
matter from MS tissue including NAWM, active and inactive lesions
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Analysis of the relationship between the severity of fibrinogen leakage and the 
extent of TJ abnormality in individual MS blood vessel segments of known TJ 
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Figure 2.15 Association of death-Autopsy interval with TJ disruption and
serum protein leakage in active and inactive MS lesions and NAWM
a. DAI and TJ disruption
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Scatter plots to determine whether death-autopsy interval (DAI) has an 
influence on the parameters measured in the study, (a) TJ disruption and (b) 
serum protein leakage. No correlation appears to exist in either plot.
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and extent of TJ abnormality with varying DAI times or with the extent of 
serum protein leakage (Figure 2.15).
2.4 Discussion
The results presented here provide evidence for a spectrum of TJ 
disruption in MS CNS tissue. A semi-quantitative analysis of TJ disruption in 
active and chronic inactive lesions compared with the NAWM of MS and the 
white matter of normal control and OND samples was also undertaken. 
Utilising archival snap frozen autopsy material, the timing of the disease 
process was established based on evidence of recent myelin breakdown and 
extent of cellular activation determined by ORO staining and HLA-DR 
immunoreactivity respectively, parameters used by other authors to assess 
lesion activity (Sanders etal., 1993; van der Valk and de Groot, 2000). 
Confocal scanning laser microscopy and immuno-labelling described here 
provides a reliable method for detecting and visualising the inter-endothelial 
TJ of the BBB. Using this method the TJ associated proteins ZO-1 and 
occludin were detected in cerebral vessels of normal control white matter 
tissue as intense continuous linear bands that extended in a radial 
(transversely sectioned vessels) or longitudinal (longitudinally sectioned 
vessels) direction. Alterations in ZO-1 and occludin appearance were 
observed in cerebral vessels of MS tissue. A spectrum of TJ disruption was 
observed in MS tissue ranging from either, loss of TJ expression, interruption 
or beading of expression and even a parting or opening of the TJ.
Quantification of TJ disruption revealed an increased incidence in 
active MS lesions (42%), however “activity” does not appear to be a 
prerequisite for TJ disruption, as abnormal TJ expression was recorded in 
chronic inactive MS lesions (22%) and the NAWM (13%) at a frequency 
greater than those observed in the white matter of normal controls and OND. 
Upon examination of individual case-means there is an overlap in the 
incidence of TJ disruption between the active MS lesions (range 30-60%) 
and the more variable but lower mean values for abnormalities found in 
chronic inactive lesions (range 8-44%).This overlap may reflect the
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heterogeneity of older lesions and the heterogeneity of MS pathogenesis 
(Lucchinetti et al., 2000; Wingerchuk et al., 2001). Analysis of normal control 
white matter revealed a low level (4%) incidence of TJ disruption, which is in 
keeping with the view that a small degree of barrier opening may occur as a 
well regulated process under normal physiological conditions (Abbott, 2002). 
This opening is believed to be transient and strictly controlled by the 
interactions of the TJ and the cytoskeleton (Abbott, 2002). TJ abnormality is 
observed here at an increased incidence (13%) in MS NAWM in comparison 
to the normal white matter of normal control tissue (4%). It has long been 
considered that the NAWM in MS is not “normal” and indeed forms the basis 
from which early plaque formation develops (Allen and McKeown, 1979; 
Filippi etal., 1998; Goodkin etal., 1998). This supports the view that an 
alteration in the BBB, and hence inflammation, is an early event in the 
pathogenesis of a new lesion in MS (Kermode etal., 1990a).
The use of ZO-1 as the tight junction marker in this study is consistent with 
that of other groups (Bolton etal., 1998; Dallasta etal., 1999; Boven etal., 
2000; Kuruganti etal., 2002). Its known function is to act as an essential link 
between the transmembrane TJ proteins and the cytoskeleton. ZO-1 and 
occludin have however been reported to be expressed in astrocytes and 
non-endothellial cells (Howarth et al., 1992) but the focus of this study was 
on the endothelial TJ and as such the protocols were optimised to 
demonstrate the proteins in this context. Occludin has been successfully 
utilised as an integral membrane protein marker for TJ in a number of 
pathological studies (Bolton etal., 1998; Dallasta etal., 1999; Luabeya etal.,
2000). In comparing immunostained serial sections of control tissue for ZO-1 
and occludin, no detectable differences in the expression levels and 
distribution were observed, however ZO-1 did produce a sharper 
immunfluorescent signal, and hence was used for the quantitative aspect of 
this study. Recognition of a major new transmembrane component of the TJ 
has emerged with claudin-1, -3, -5 and possibly claudin-12 associated with 
the TJ of the BBB (Morita et al., 1999; Liebner et al., 2000; Kraus et al., 
2004). Claudin expression was not investigated in this study due to poor 
quality of immunostaining on the available snap-frozen tissue sections with
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the commercial antibodies currently available for these proteins. Three 
claudin-5 antibodies (two monoclonal and one polyclonal) were tested on 
sections of control white matter however the reaction product proved weak 
and inconsistent. However, using fresh human tissues which were immersion 
fixed in 2% paraformaldehyde plus 0.2% glutaraldehyde before vibratome 
sectioning Virgintino et al., 2004, were able to obtain high resolution 
immunostaining with anti-claudin-5 antibodies. Recently in an 
immunostaining study examining CD45 and the TJ associated proteins, 
occludin and claudin-1, -3 and -5 in SJL/N mice affected with EAE, and their 
healthy littermates, showed selective loss of only claudin-3 in blood vessels 
associated with large CD45+ perivascular cuffs (Wolburg et al., 2003). 
Contrary to what is observed in MS lesions here it was reported that occludin 
immunostaining in inflammation associated blood vessels was 
indistinguishable from those observed in healthy brains (Wolburg et al., 
2003). Provision of a wide range of MS and controls blocks prepared in this 
manner or more suitable anti-claudin antibodies for snap-frozen tissues may 
provide different, more reliable or more comprehensive data in the range of 
human disorders examined with antibodies to ZO-1 and occludin in the 
future.
Investigation of blood vessel integrity was important to ensure TJ 
alterations were not due to blood vessel distortion during sample processing 
therefore additional markers were tested in conjunction with ZO-1 and 
occludin. The lectin Ulex europaeus agglutinin (UEA) stains the endothelium 
of the microvasculature intensely (Prat et al., 2001) whilst laminin was used 
as an additional marker for the capillary basement membrane, allowing 
identification of disrupted TJ proteins in the presence of a normal intact 
basement membrane. The use of fibrinogen as a marker for BBB serum 
protein leakage has been used in previous human and animal model autopsy 
tissue studies (Kwon and Prineas, 1994; Claudio etal., 1995; Gay et al.,
1997; Dallasta etal., 1999; Brown etal., 1999; Luabeya etal., 2000). Pre- 
mortem leakage is determined by the fibrillary nature of fibrinogen following 
uptake by perivascular astrocytes (Gay et al., 1997; Brown et al., 1999). 
Fibrinogen was observed within the cell bodies and elongated processes of
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astrocytes. Thus fibrinogen staining was used to assess the association 
between TJ disruption and BBB leakage.
It has been reported that the BBB is permanently damaged in many 
old chronic plaques, at a level undetectable by Gd-DTPA-MRI (Kwon and 
Prineas, 1994; Claudio et al., 1995). This observation is further confirmed 
here with the presence of leaking blood vessels in chronic inactive lesions. It 
is tempting to suggest that such persistent leakage through disrupted 
junctions with constant destabilization of homeostasis in the parenchymal 
microenvironment could contribute to the overall inefficiency of remyelination 
in chronic plaques. Targeted therapy, directed at repair of TJ disruption in 
these areas may promote a much greater efficiency of remyelination. The 
highest degree of BBB leakage was observed in the active lesions with the 
most severe leakage occurring with the most severe TJ disruption, 
suggesting a possible causal link. Not all blood vessels with disrupted TJs 
displayed evidence of leakage this could be due to either, a lack of sensitivity 
in the detection protocol or the existence of a threshold of disruption of the 
TJ which is required to be reached before fibrinogen, a large serum protein 
(340 kD), is released and can be detected in the surrounding perivascular 
astrocytes.
Blood vessels of all sizes displayed the same pattern of TJ disruption 
between groups of blocks in different phases of disease. This demonstration 
that all blood vessels are involved in the breakdown of the BBB and that the 
greatest number of abnormal TJs coincided with the highest levels of 
microglial activation, may point to the nature of the causal mechanisms. Had 
the TJ disruption been as a result of local effects arising from 
transendothelial migration of inflammatory cells, post-capillary venules and 
veins would have been expected to bear the brunt of the TJ disruption 
(Boven et al., 2000). The involvement of all vessels and the correlation with 
perivascular HLA-DR+ foamy macrophages and activated microglia suggests 
that TJ disruption may be as a result of the pathophysiological actions of 
cytokines, MMPs and other mediators of inflammation present in MS lesions. 
Proinflammatory cytokines, TNF and IFN-y, have been shown to disrupt TJ
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function and cause reorganisation of the actin cytoskeleton and redistribution 
of the ZO-1 and occludin (Blum etal., 1997; Walsh etal., 2000; Prat etal., 
2001; Mayhan, 2002; Kuruganti et al., 2002). Treatment of HUVEC cultures 
with IFNpib inhibits IFNy induced occludin disruption (Minagar et al., 2003). 
Transendothelial resistance, the barrier function of the TJ, is reported to be 
reduced by 50% upon treatment with TNF and IFNy, with a striking 
fragmentation of ZO-1 appearance (Blum etal., 1997). Treatment with IFNp 
was able to alter ZO-1 distribution with the staining observed along the 
endothelial cell borders (Kuruganti etal., 2002). MMPs have been implicated 
in disruption of the BBB in MS (Cossins etal., 1997; Walsh etal., 2000) while 
another member of the MMP family, TNFa-converting enzyme (TACE, or 
ADAM-17) has been shown to cleave TNF from its membrane bound form 
into a soluble form (Black et al., 1997; Moss et al., 1997; Black, 2002;) 
allowing TNF to diffuse within the CNS parenchyma to trigger further 
inflammatory responses (Probert and Akassoglou, 2001).
In conjunction with BBB breakdown and serum protein leakage, 
disruption in ZO-1 and occludin was also associated with an accumulation of 
perivascular HLA-DR+ foamy macrophages and LCA+ perivascular 
lymphocytes. HLA-DR+ macrophages have previously been reported to be 
associated with blood vessels with damaged walls in acute MS lesions (Gay 
and Esiri, 1991). Similar loss in immunoreactivity of the TJ associated 
proteins, ZO-1 and occludin, with an accumulation of perivascular HIV-1 
infected macrophages and serum protein leakage has been reported in HIVE 
(Dallasta et al., 1999). The loss of ZO-1 has also been associated with 
monocyte infiltration and CD68+ perivascular macrophages in HIV- 
associated dementia (Boven et al., 2000). Similar observations have been 
recorded in an animal model study of simian immunodeficiency virus 
encephalitis (SIVE) (Luabeya etal., 2000). Cerebral vessels from macaques 
with SIVE displayed fragmentation and decreased immunoreactivity for ZO-1 
and occludin, in association with perivascular macrophage accumulation and 
extravasation of serum protein leakage (Luabeya et al., 2000). The authors 
report a further association between TJ disruption and the abnormal 
appearance of glucose transporter isoform-1 (GLUT-1), a metabolic BBB
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marker, suggesting an alteration in function with the presence of disrupted TJ 
(Luabeya et al., 2000). ZO-1 immunoreactivity is also reported to undertake a 
diffuse expression in the cerebral endothelium of dystrophic mdx mice (Nico 
et al., 2003).
Death-autopsy intervals were recorded for each case investigated to 
establish or eliminate autolysis as a cause of the abnormal TJ and serum 
protein leakage. Most of the DAI were less than 24 hours with the exception 
of one case which was 29 hours (range 1.5-29 hours). No correlation was 
observed between the extent of TJ disruption or serum protein leakage and 
length of DAI. This is in keeping with earlier studies that have shown that 
extended DAI had no effect on the quality of immunohistochemical 
characterization and the ability to extract mRNA (DeGroot et al., 1995; 
Cummings et al., 2001). This suggests that the quantified differences in 
extent of TJ disruption and BBB leakage between active MS lesions, chronic 
inactive lesions and NAWM are due to the pathological process. What 
processes are involved remains unclear, the complex cascade system 
involving MMPs, cytokines, chemokines and other signalling proteins within 
the inflammatory milieu that is present in MS lesions remains to be 
unravelled.
The results indicate that TJ disruption and abnormality is widespread 
throughout MS white matter, persisting in chronic inactive lesions but most 
common in active lesions. Further investigation would be required to 
investigate the functional aspects associated with this TJ disruption. The use 
of cell culture studies has been well documented and allows the investigator 
to manipulate the culture conditions to emulate those observed in CNS 
inflammation. However extrapolating information from culture studies and 
applying it to MS pathogenesis is fraught with problems. Endothelial cells 
from the microvasculature of the CNS differ from other vascular endothelial 
cells. CNS derived endothelial cells are phenotypically unstable in long-term 
culture (Romero et al., 2003). To overcome this problem well differentiated 
immortalised cultures can be used, however they lose their ability to maintain 
functional tight junctions (Romero et al., 2003).
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These results further underline the dramatic nature of the events at 
the BBB during lesion formation in the pathogenesis of MS (Claudio etal., 
1995). Although TJ disruption cannot be viewed in isolation from other of 
aspects of lesion formation, it does present a valid area for research as a 
therapeutic target. The effect of short-term or pulsed glucocorticosteroids, is 
transient, as indicated by changes in the number of Gd-DTPA-enhancing 
lesions on MRI imaging (Richert et al., 2001). In vitro and in vivo studies 
have demonstrated that TJ abnormality is responsive to IFN-p however the 
clinical benefits of this remain to be established (Richert etal., 2001; 
Kuruganti et al., 2002). A means of preventing the BBB damage associated 
with acute inflammation is offered by a new anti-leukocyte trafficking drug, 
the a4 integrin antagonist Natalizumab (Elan Pharmaceuticals, Biogen). This 
had recently entered phase III clinical trials in the UK and North America 
(O’Connor et al., 2004). Single dose treatment of Natalizumab has been 
shown to decrease the Gd-enhancing lesion volume in MS patients in acute 
relapse (O’Connor et al., 2004). Natalizumab binds to VLA-4 on T cells 
preventing the coupling of VLA-4 with VCAM-1 on the luminal surface of 
cerebral endothelium, an integral step in the transendothelial migratory 
process, thus preventing entry of T cells into the CNS. However following 
reports of progressive multifocal leukoencephalitis (PML) in two patients 
receiving dual therapy in the trial, Natalizumab (Tysabri) was withdrawn at 
the end of February 2005.
The widespread TJ disruption described here clearly has implications 
in MS prognosis and should be taken into account when planning therapies 
aimed at repairing established lesions and thereby possibly preventing 
disease progression. The extent of TJ disruption as shown here within all MS 
tissue, even in chronic inactive lesions, merits recognition as a third distinct 
form of tissue injury in MS, alongside demyelination and axonopathy.
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Chapter 3
Expression of ADAM-17 in the CNS in MS: a pathologic role
Chapter 3
3.1 Introduction
3.1.1 ADAM-17
ADAM-17 is regarded to be the major physiological TNF convertase 
(Black et al., 1997; Moss et al., 1997). ADAM-17 was first identified by its 
ability to cleave membrane bound TNF into a soluble form and was therefore 
termed JNFa converting enzyme (TACE) (Moss et al., 1997; Black et al., 
1997). ADAM-17 was purified from membrane fractions of the TNF producing 
human macrophage-like cell line, Mono-Mac 6 cells and extracts from pig 
spleen (Moss et al., 1997; Black et al., 1997). As with other members of the 
ADAM family, ADAM-17 is a multi-domain type I transmembrane protein, 
composed of 824 amino acids (Itai etal., 2001; Black, 2002;). A putative 
furin-cleavage motif lies between the pro-domain and the catalytic domain 
suggesting that ADAM-17 is produced as a zymogen that becomes active 
following the removal of the pro-domain (Moss etal., 1997; Schlondorff etal., 
2000; Itai et al., 2001). However arguments in favour of a role for furin in the 
maturation of ADAM-17 are speculative rather than direct (Peiretti et al., 
2003). X-ray crystal structure analysis of ADAM-17 catalytic domain shows 
that the zinc environment and the placement of the major structural elements 
are very similar to catalytic domains of the SVMP family members (Maskos 
etal., 1998).
TNF has been associated with numerous inflammatory diseases 
including, Crohn’s disease, rheumatoid arthritis, and MS, therefore research 
into the properties of ADAM-17 have been of interest in view of the search 
for therapeutic targets for these chronic diseases (Hyrich et al., 2004; Dalton 
et al., 2004; Baker, 2004). ADAM-17 has proved to be a protein with more 
diverse functions than its role in the cleavage of TNF. Knowledge of ADAM- 
17 substrates has been derived from studies using genetically modified 
animals that are devoid of catalytically active ADAM-17 (Peschon et al.,
1998; Killar etal., 1999). ADAM-17 knockout in these animals lead to 
perinatal lethality with the majority of embryos dying between embryonic day
17.5 and one day after birth (Peschon etal., 1998).
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ADAM-17 has been demonstrated to mediate the cleavage of other 
members of the TNF superfamily (Peschon etal., 1998; Lum et al., 1999; 
Black, 2002; Contin etal., 2003) as well as macrophage colony-stimulating 
factor receptor, transforming growth factor-a (TGF-a), epidermal growth 
factor receptor and IL-6 receptor (Moss et al., 1997; Black et al., 1997;
Rovida et al., 2001; Hinkle et al., 2004;). Both p55 and p75 TNFR have been 
shown to be substrates of ADAM-17 (Peschon etal., 1998; Dri etal., 2000), 
along with TNF-related activation-induced cytokine (TRANCE) (Lum et al., 
1999; Schlondorff et al., 2001) and CD40 (Contin etal., 2003). CD40 is 
expressed on the surface of antigen presenting cells and is essential for the 
induction of immune responses (Contin etal., 2003). Interaction between 
CD40 and CD40 ligand (CD40L) is required for co-stimulatory molecule 
expression and induction of cytokine synthesis (Shinde etal., 1996; Contin et 
al., 2003). The shedding of CD40 from APCs, into soluble CD40, is important 
as it is able to bind to membrane bound CD40L and inhibit CD40/CD40L- 
mediated antibody production by B cells (Contin et al., 2003). ADAM-17 has 
also been demonstrated as an effective mediator in the shedding of the 
adhesion molecules L-selectin and VCAM-1 (Borland etal., 1999; Garton et 
al., 2003) which are vital for cell adhesion and migration at the BBB.
Recently fractalkine, a new chemokine has been discovered to be a 
substrate of ADAM-17 activity that exists in both a membrane bound and a 
soluble form and has adhesive properties (Tsou et al., 2001; Garton et al., 
2001; Kastenbauer et al., 2003). Fractalkine (CX3CL1) is a novel member of 
the chemokine group CX3C that exists as a membrane form on endothelial 
cells, neurons, astrocytes and epithelial cells that has adhesive properties for 
cells expressing its receptor CX3CRI (Imai et al., 1997; Garton et al., 2001; 
Tsou etal., 2001; Hulshof etal., 2003; Ahn etal., 2004;). CX3CRI is 
expressed on monocytes, T-cells, natural killer cells, neurons and microglia 
(Nishiyori etal., 1998; Garton etal., 2001). Fractalkine can be cleaved from 
the cell membrane to produce a soluble form that creates a chemotatic 
gradient for inflammatory cells (Tsou et al., 2001; Garton et al., 2001; 
Kastenbauer et al., 2003). However soluble fractalkine reduces the potential 
of CX3CR+leukocytes to bind to endothelial membrane bound fractalkine, by
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blocking their receptor (Imai et al., 1997), thus reducing leukocyte 
transmigration. Reported in vitro studies have shown soluble fractalkine 
being unable to induce transendothelial migration in human umbilical vein 
endothelial and brain microvascular endothelial cells (Ancuta etal., 2004). 
Increased fractalkine expression has been observed in the CSF and serum 
of patients with inflammatory diseases, including MS and bacterial meningitis 
(Kastenbauer etal., 2003). In vitro studies have reported that constitutive 
shedding of fractalkine remained unaltered in unstimulated ADAM-17 null- 
fibroblast cells suggesting constitutive cleavage is mediated by a 
metalloproteinase other than ADAM-17 (Tsou etal., 2001; Garton etal.,
2001) which has recently been identified as ADAM-10 (Hundhausen et al., 
2003).
3.1.1.1 ADAM-17 in disease
ADAM-17 has the potential to participate in a broad range of immune 
functions and immune-mediated diseases through modulation of shedding of 
proteins vital to immune responses. The functional activity of ADAM-17, as 
measured by release of soluble TNF, is reported to be elevated in patients 
with ulcerative colitis in comparison to controls (Brynskov etal., 2002) 
suggesting a pathogenic role involving increased TNF release and inducible 
nitric oxide synthase (iNOS) (Colon et al., 2001). ADAM-17 expression and 
activity within the synovial tissue of people with rheumatoid arthritis is 
reported to be increased in comparison with the synovial tissue of people 
with osteoarthritis and controls (Patel et al., 1998; Ohta et al., 2001;). ADAM- 
17 has been shown to be up-regulated and associated with prostatic tumor 
cells and the metastatic capabilities of these cells, while TIMP3, an 
endogenous inhibitor of ADAM-17, has been reported to be down-regulated 
in prostate cancer biopsies (Karen et al., 2003).
ADAM-17 has recently been reported to be an a-secretase of APP 
and is localised in neurones where it is suggested that it competes with (B- 
secretases for APP cleavage (Skovronsky et al., 2001; Blacker et al., 2002; 
Asai et al., 2003; Kojro and Fahrenholz, 2005). The neuronal expression of 
ADAM-17 has been proposed as having neuroprotective properties in rodent 
models of ischemic stroke by increasing the level of glutamate transporters in
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neurons and glia (Cardenas etal., 2002; Romera et al., 2004;) therefore 
decreasing neurotoxic levels of glutamate within the extracellular space 
(Romera et al., 2004). Pre-treatment of rat cortical cultures with an ADAM-17 
inhibitor, BB3103, prevented oxygen-glucose deprived increase of glutamate 
transporters suggesting that neuroprotection by glutamate transporters is 
mediated by an ADAM-17-TNF dependent pathway (Romera et al., 2004). 
Another study however reports that the selective inhibition of ADAM-17 
protects rats from focal ischemic injury, suggesting ADAM-17 plays a 
deleterious role in stroke (Wang et al., 2004).
3.1.1.2 ADAM-17 and MS
The role of ADAM-17 in the pathogenesis of MS has not been 
extensively studied. Increased expression of ADAM-17 mRNA by peripheral 
blood mononuclear cells in serum samples from MS patients is reported to 
correlate with new Gd- DTPA MRI lesions, following a longitudinal study with 
11 patients with RRMS (Seifert et al., 2002). ADAM-17 protein has been 
detected in CSF samples from patients with MS and bacterial meningitis but 
not in other non-inflammatory neurological controls (Kieseier et al., 2003). 
ADAM-17 expression in MS autopsy brain has been demonstrated in small 
rounded CD3+ lymphocytes, primarily located in the perivascular cuffs 
associated with acute and chronic active plaques with no astrocytic or 
endothelial ADAM-17 expression in normal control or MS brain tissue 
(Keiseier et al., 2003). This contradicts an earlier study however where 
ADAM-17 immunoreactivity was been demonstrated to be expressed by the 
astrocytes and endothelial cells of normal control white matter (Goddard et 
al., 2001).
3.1.2 TIMP3
Like MMPs, ADAM-17 is regulated at a transcriptional level, pro­
enzyme activation, and inhibition by TIMP3 (Amour et al., 1998; Ozenci et 
al., 1999). TIMP3 is a 24 kDa protein composed of an amino-terminal domain 
and a carboxy-terminal domain that are held together by 6 disulphide bonds 
that hold the protein in a wedge shape resembling the Fab portion of 
immunoglobulins (Crocker et al., 2004). TIMP3 differs from the other 3
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members of the TIMP family in that it is the only one that is bound to the 
ECM via sulphated glycosaminoglycans (Borland et al., 1999; Yu et al.,
2000; Crocker etal., 2004; Visse and Nagase, 2003;).
TIMP3 mRNA has been reported to be expressed in the choroid 
plexus and dentate gyrus in normal mouse brain and within developing 
embryonic neural tissues and within astrocytes and neurons of the 
cerebellum, cerebral cortex, thalamus and the brain parenchyma of postnatal 
and adult rat brain (Pagenstecher etal., 1998; Vaillant etal., 1999; Jaworski 
and Fager, 2000).
TIMP3 is directly implicated in disease processes (Weber et al.,
1994). Mutations in the TIMP3 gene and not over expression of TIMP3 by 
retinal pigment epithelial cells leads to Sorby’s fundus dystrophy, a rare 
autosomal-dominant condition that causes blindness due to macular 
degeneration (Weber et al., 1994; Chong etal., 2003). Addition of 
recombinant human TIMP3, and notTIMPI and 2 has been shown to inhibit 
PMA-induced shedding of L-selectin from human lymphocytes in vitro 
suggesting that ADAM-17 is responsible for the induced proteolytic cleavage 
of L-selectin (Borland et al., 1999). TIMP3 is reported to have functions that 
are independent of its role as an MMP inhibitor (Visse and Nagase, 2003). 
TIMP3 has anti-angiogenic properties and actively inhibits VEGF-mediated 
angiogenesis by blocking the binding of VEGF to its receptor thus inhibiting a 
downstream signal for angiogenesis (Qi etal., 2003). TIMP3 is also believed 
to have pro-apoptotic activity through a Fas-associated apoptotic pathway, 
which leads to cell death in tumor cells and neurons (Bond et al., 2002; 
Wallace et al., 2002; Wetzel et al., 2003).
3.1.3. Aim of study
The key aim of this study was to establish whether ADAM-17 is involved 
in the pathogenesis of MS and if so to develop an understanding of its 
activity, which may then subsequently be exploited therapeutically through 
the design and application of ADAM-17 inhibitors.
This study set out to establish a reproducible protocol for the investigation 
of ADAM-17 expression together with phenotypic markers of specific CNS 
cells. Snap-frozen autopsy MS tissue was used and classified as described
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in Chapter 2. A semi-quantitative analysis of ADAM-17 expression by 
immunofluorescence was applied to establish if any differences in extent of 
ADAM-17 expression exists between MS and controls. The major objectives 
addressed were:
(i) To determine whether ADAM-17 and TIMP3 immunoreactivity is 
detectable in snap frozen autopsy material.
(ii) If so, to determine which cells are responsible for ADAM-17 and 
TIMP3 expression.
(iii) To establish whether ADAM-17 expression predominates at a 
particular stage or stages of lesion development.
(iv) To determine whether there is an imbalance between the 
expression of the enzyme and its inhibitor at a particular stage of 
lesion development.
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3.2 Materials and Methods
42 blocks of snap frozen autopsy CNS tissue from 19 clinically and 
neuropathologically confirmed MS cases, together with 18 blocks from 5 
normal control cases and one case of transverse myelitis, received from the 
UK Multiple Sclerosis Tissue Bank, Charing Cross Hospital, London and the 
Netherlands Brain Bank for Multiple Sclerosis, Amsterdam, The Netherlands 
were used in this study. Informed consent for research for all brain tissues 
and local ethical approval for the conduct of this study was obtained. These 
MS cases included 7 females, mean age 58.1 years (range 45-76) and 12 
males with a mean age of 56.16 years (range 44-75). The tissue used had a 
mean time from death to freezing of 18.1 hours (range 8-58 hours). 18 snap- 
frozen control white matter blocks were obtained from 5 normal controls and 
1 other neurological disease (OND). Mean age of the control cases was 75 
years (range 45-92). Table 3.1 contains the clinical and demographic details 
of all cases used in this part of the study.
3.2.1 Tissue characterisation
All MS and control snap-frozen blocks underwent preliminary 
screening to determine the pathological status of individual blocks. Cryostat 
sections (12pm) were cut onto polysine glass slides (BDH) and routinely 
stained with H&E and ORO (see appendix) for presence and grading of 
lesion activity. ORO positive blocks were classified as described in section 
2.2.2.
3.2.1.1 Immunohistochemistry
All MS and control samples were routinely screened for presence and 
extent of expression of HLA-DR. Sections were fixed in ice-cold acetone for 
10 minutes and allowed to air dry for at least 15 minutes prior to use. 
Endogenous peroxidase was quenched by incubating sections in 0.5% H2O2 
in methanol for 10 minutes at room temperature (RT). Following washes in 
running tap water and PBS, sections were incubated in mouse monoclonal 
anti-HLA-DR antibody (1:50, Novocastra) overnight at 4°C. Sections were 
washed 3 x 5  minutes in PBS then incubated in biotinylated rabbit anti-
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Table 3.1 Case details of subjects, used in study of ADAM-17 expression 
within the CNS
' 'c i 77 M 27 Normal Lung Cancer
C2 64 F 18 Normal Cardiac Failure
03 82 M 21 Normal na
04 92 M 13 Normal Cardiac failure, old age
05 90 F 15 Normal Old age
OND1 45 M 8.5 Transverse Myelitis na
MS1 57 F 38 SPMS Pneumonia, MS
MS2 63 M 11 SPMS Pneumonia, MS
MS3 44 M 16 SPMS Bronchial Pneumonia
MS4 53 M 12 SPMS Advanced MS
MS5 60 F 22 SPMS Myocardial Infarct
MS6 58 F 9 SPMS na
MS7 58 M 16 SPMS na
MS8 75 M 8 RPMS Pneumonia
MS9 76 F 58 PPMS Pulmonary embolus
MS10 46 M 7 SPMS Pneumonia
MS11 51 M 21 SPMS MS/Bronchial Pneumonia
MS12 59 M 18 SPMS Bronchial Pneumonia
MS13 51 F 12 SPMS na
MS14 47 M 14 SPMS na
MS15 53 M 17 SPMS na
MS16 62 M 22 SPMS na
MS17 45 F 10 SPMS na
MS18 60 F 29 SPMS Bronchial Pneumonia
MS19 63 M 10 SPMS na
na = Not available
DAI (h) = Death autopsy interval (hours)
SPMS = Secondary progressive MS
PPMS = Primary progressive MS
RRMS = Relapsing Remitting MS
111
r:: if;
t . .
•O' i-j.-. 
'O ! ’ jO
• ;oi'-
V., -Vi
r i'i
« O 0  . V ' Oi i V . ; ; . : ' : :  
P'A ?0;‘V PJ-- : :
■ i ■; J i : : r v j
0-'/.y*V
- \ ?■ .>: *•*
v;; •
iu ^O
’ V 'Vi
:i ci iVi
c-€iV- 
' •; •
M
: V j f
io PIP
:.P:PP 
ppm 
Oidai 
j- i 'em
i ' i r o i
oKirv,- vo 
v v/ovr;'; ’ ;!;03 i:
oiA ovo.'. .o ro  -v; yvBrno'-’: :;
i i i i i  v o :  ' : u\ u i -  0 ; 0 o i o  -
mouse lgG1 (1:400, Dako) for 30 minutes at RT. Following a further 3 x 5  
minute washes in PBS, sections were incubated in a streptavidin-biotin HRP- 
conjugated complex (SABC-Px, Dako) for 30 minutes at RT. SABC-Px was 
made 30 minutes prior to use to allow formation of avidin-biotin complex, by 
adding 45pl each of streptavidin and biotin to 5ml of PBS. Antibody affinity 
was detected using a commercial diaminobenzidine chromatin substrate 
(DAB, Dako). Sections were washed in running water and then 
counterstained for 45 seconds in Harris’s haematoxylin, washed for 5 
minutes in running tap water then dehydrated through graded ethanol. 
Sections were then transferred through two changes of xylene and mounted 
in DPX (BDH).
3.2.2 Indirect Immunofluorescence staining
12pm cryostat sections were cut and mounted onto polysine coated 
glass slides (BDH), fixed for 10mins in either ice-cold acetone, 4% 
paraformaldehyde or 70% methanol. After fixation, samples were washed in 
PBS with the exception of the acetone fixed samples which were allowed to 
air-dry for 15 minutes prior to further steps. Table 3.2 provides a summary of 
all the primary antibodies used in this study. Sections were incubated in the 
primary antibody overnight at 4°C, washed in PBS, and incubated in the 
appropriate secondary antibody for 90mins at room temperature (RT). 
Monoclonal mouse 1° antibodies were detected using FITC-conjugated 
rabbit anti-mouse immunoglobulins (1:50, Dako) and polyclonal 1° rabbit 
antibodies were detected with Alexa 488 conjugated goat anti-rabbit 
immunoglobulins (1:500, Molecular Probes).
To determine the cellular origin of ADAM-17 expression, the following 
sequential dual label immunofluorescence protocol was carried out. Sections 
were incubated with rabbit polyclonal antibody overnight at 4°C and then 
detected by incubating in Alexa 568 conjugated goat anti-rabbit 
immunoglobulins (1:500, Molecular Probes) at RT for 90mins. Following 
three, 5min washes in PBS, sections were then incubated in the monoclonal 
antibody overnight at 4°C. Sections were washed in PBS and incubated in 
rabbit anti-mouse FITC (1:50, Dako) for 90 minutes at RT. Following three
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5min washes in PBS, sections were mounted in Vectorshield mount with 
DAPI (Vector labs).
As a control during dual staining, serial sections were single label 
immunostained for each primary antibody to ensure that no cross reaction 
was observed when using two secondary antibodies. Omission of either 
primary antibody from the protocol resulted in no signal detection in the 
channel used to detect that antigen.
3.2.2.1 Semi quantitative analysis of ADAM-17 immunoreactivty
All blocks investigated in this study were coded and evaluated for the 
extent of ADAM-17 immunoreactivity by two blinded investigators. The 
following scoring system was applied; + when ADAM-17 immunoreactivity 
was associated to cerebral blood vessels; ++ when blood vessel 
immunoreactivity was present in the presence of distinct astrocytic 
immunoreactivity; +++ when there was an abundance of ADAM-17 
immunoreactivity throughout the section.
3.2.2.2 Tyramide Signal Amplification
A tyramide signal amplification kit (Molecular Probes) was used to 
localise TIMP3 within normal control and MS white matter. Sections were 
fixed in 4% paraformaldehyde for 20 mins at RT then washed through 2 x 5  
minute washes in PBS. Endogenous peroxidase was then quenched by 
incubating sections in 0.5% H2O2 in methanol for 10 mins at RT. Following 5 
minute washes in running tap water and then PBS, sections were incubated 
in blocking reagent for 1 hour at RT. Sections were then incubated in primary 
antibodies to TIMP3, diluted in 1% blocking reagent, overnight at 4°C. 
Following 3 x 5  minute washes in PBS, sections were incubated in HRP 
conjugate for 45 mins at RT. Following 3 x 5  minute washes in PBS, sections 
were incubated in Alexa 488-conjugated tyramide working solution for 10 
mins at RT. Sections were washed, counterstained in propidium iodide and 
mounted in citfluor as described in section 2.2.2.1.
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3.2.3 Imaging
3.2.3.1 Con focal Scanning Laser Microscopy
Immunofluorescent images were acquired using a Zeiss 510 confocal 
scanning laser microscope equipped with a krypton/argon laser as the 
source of the ion beam. Acquiring the optimal amount of optical sections in 
the Z-plane (as gauged by Zeiss 510 CSLM software) and running the 
series-scanning mode from the deepest focus point to the highest focus 
point, allowed a projected image and data set to be generated from which 
composite projected images were exported as high quality JPEGs without 
further manipulation
Co-localisation
Analysis of all dual stained sections was carried out using the Zeiss 
510 CSLM software. This software examines each individual pixel for 
emission in each fluorescent channel, where co-localisation occurs that pixel 
is displayed as white on the composite image and in the upper right quadrant 
of the spectra graph (See results and appendix).
3.2.3.2 Digital photography
Light microscope images were obtained using a Coolsnap-ProCf digital 
image camera (Media Cybernetics) attached to an Olympus BX60 upright 
fluorescent microscope. Images were acquired using the labworks software 
and saved as high quality JPEGs. The Leica digital camera was utilized to 
enable capture of comparable fields of view between anti-HLA-DR, ORO and 
anti-ADAM-17 (fluorescence) stained sections.
3.2.4 Protein and RNA extraction
5 x 30pm cryosections from each of 12 MS and 7 control blocks were 
collected in pre-cooled Eppendorfs (-20°C). Protein and RNA was extracted 
using 1ml of Tri Reagent™ (Sigma) following the manufacturer’s protocol 
(See Appendix).
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3.2.4.1 Bicinchoninic acid (BCA) Assay
The BCA assay was used to determine the amount of protein present 
in the extracted samples (Smith et al., 1985). Protein samples were 
resuspended in 200pl of 1% SDS. 20pl duplicates of bovine serum albumin 
protein standards (ranging from 0.1-2mg/ml) were added to a 96 well plate 
along with 20pl of each protein sample in triplicate. 200pl of copper II 
sulphate BCA solution (Sigma, Poole, UK) was added to each well and the 
plate incubated at RT for 30 minutes. Absorbance spectrophotometry was 
carried out at 570nm (Wallac). Protein concentrations for each sample were 
calculated from the trend line of the standard curve using the equation:
Y=mx + c using Microsoft Excel (See appendix).
3.2.5 SDS PAGE and Western blotting
Principles of method
Sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis 
(PAGE) is a technique used to separate a mixture of proteins by their size 
using an electrical current. SDS is a detergent that denatures and applies a 
negative charge to individual proteins. SDS is important as proteins of similar 
size (molecular weight) but with different tertiary structure would migrate 
different distances through the gel. Denaturing the proteins allows protein 
separation based on protein length (number of amino acids). The gel in SDS- 
PAGE refers to the matrix used to separate the proteins. Gels can be made 
of different concentrations of acrylamide with a cross linker to form a solid 
but porous polyacrylamide mesh network. Electrophoresis refers to the 
electromotive force that pushes or pulls the molecules through the gel matrix. 
An electrical current is passed across the polyacrylamide gel and the 
negatively charged samples migrate through the gel towards the positive 
electrode. SDS binds to proteins in a consistent ratio of 1.4:1 SDS:protein, 
therefore the amount of bound SDS is relative to the size of the protein. The 
distance migrated through the gel is directly related to the size of the protein 
due to the constant mass to charge ratio. The smaller proteins migrate 
further through the gel with the larger proteins remaining towards the top of 
the gel. Marker proteins, of known molecular weights, are loaded into a lane
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adjacent to the samples to allow calculation of the molecular weights of the 
samples (See Appendix).
Western blotting is a method of detecting specific proteins in a 
complex mixture of proteins separated by SDS-PAGE based on the 
principles described in immunohistochemistry (section 2.2.2.1). Following 
SDS-PAGE, proteins are transferred or blotted onto a nitrocellulose 
membrane by applying an electrical current. The nitrocellulose membrane is 
“sticky” and binds all proteins equally. Blotted membranes must be blocked 
in 5% non-fat milk solution to saturate any free protein binding sites, in order 
to prevent any non-specific binding of primary antibody to the membrane. 
Primary and secondary antibodies are applied to the membrane following the 
principles described in section 2.2.2.1.
Method
Extracted protein samples were added to sample buffer consisting of 
50% 4x concentrate NuPAGE LDS sample buffer, 20% sample reducing 
agent (Invitrogen) and 30% distilled H2O (1:1 v/v) and then denatured by 
heating at 60°C for 30 minutes. 20pl of each sample were loaded into wells 
and separated by SDS-polyacrylamide gel electrophoresis on 10% pre-cast 
bis/tris gels (Invitrogen) at 150V for 1hour using a Novex Mini-cell gell tank 
(Invitrogen). SeeBlue Plus2 pre-stained standard (Invitrogen) molecular 
weight markers (range 191-14 kDa) were included in each run.
Proteins were transferred onto nitrocellulose membranes (Hybond-C, 
Amersham) at 150V for 1 hour. Membranes were blocked overnight in 5% 
non-fat milk TBS-tween (Tris-buffered saline containing 0.02% Tween-20) 
solution at 4°C. Membranes were incubated in primary antibody for 1 hour at 
RT (polyclonal TACE, 1:500, Abeam, or monoclonal TIMP3, 1:1000, 
Oncogene). Following 3 washes in TBS-tween, membranes were incubated 
in either peroxidase-conjugated rabbit anti-mouse (1:1000, Dako,) or goat 
anti-rabbit (1:80,000, Sigma) immunoglobulins for 90 minutes at RT. All 
antibodies were diluted in 5% blocking solution.
Immunoreactivity was detected by chemiluminescence by incubating 
membranes in ECL reagent kit (Amersham) for five minutes at RT. Excess
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ECL reagent was removed and membranes were placed in clear plastic 
envelopes and visualised using a UVP Bioimaging system attached to a 
computer with Labworks software (Bio-Rad). Membranes were exposed 10 
times each over 90 seconds and an image series was obtained.
3.2.6 mRNA analysis
3.2.6.1 Reverse transcriptase PCR
Principles of method
Reverse transcriptase-polymerase chain reaction (RT-PCR) refers to 
a technique that transcribes RNA into complementary DNA (cDNA) which 
can then be amplified by the polymerase chain reaction. The original PCR 
technique was designed by Kay Mullis and patented by the Cetus 
Corporation in 1986 as a result Kay Mullis was awarded the Nobel Prize for 
chemistry in 1993. The classical PCR technique can only be applied to DNA 
strands. Reverse transcriptase is an enzyme from retroviruses that 
transcribes the genetic information from RNA to DNA. The enzyme works on 
a single strand of RNA and generates a complementary DNA (cDNA) based 
on the pairing of RNA bases (A, U, G, C) to their DNA complements (T, A, C,
G)-
PCR is a method of producing multiple copies (amplifying) of DNA. 
Amplification of PCR products is exponential with the first cycle producing 2 
copies, the next 4, the next 8, then 16 copies and so on. The DNA fragment 
to be amplified is determined by the use of specific primers. Primers are 
artificial oligonucleotide strands that match the beginning and end of the 
DNA fragment to be amplified. Heating double stranded DNA to 96°C breaks 
the hydrogen bonds separating the two strands. Another enzyme is required 
to create new copies of DNA, due to the high temperature required to 
separate the DNA this enzyme must be thermostable. The first thermostable 
DNA-polymerase was obtained from Thermus aquaticus and was named 
Taq polymerase. Once the DNA strands are separated the temperature is 
reduced to allow the primers to adhere (anneal) to the beginning and end of 
the DNA fragment, the Taq polymerase then binds and begins to synthesise 
copies of the new DNA strand.
118
Primers
Paired forward and reverse primers are used in each reaction to 
amplify the double stranded DNA fragment. There are a number of 
considerations to be taken into account when using primers. The melting 
temperature (Tm) of primers is defined as the temperature below which the 
primer will anneal to the DNA template and above which the primer will 
dissociate from the DNA template. The Tm of individual primers used should 
not differ by more than 10°C. Primers are usually small ideally 18-25 base 
pairs (bp), the Tm increases with increasing primer size. The annealing 
temperature of the primers should be approximately 5°C below the Tm. The 
GC content of primers should be approximately 40-60%.
Agarose gel electrophoresis
The DNA PCR products can be identified by loading onto an agarose 
gel and subjecting them to electrophoresis. An electrical current is passed 
through the gel, separating DNA products based on size. Unlike proteins, 
DNA PCR products naturally migrate due to the negative charge carried on 
their sugar-phosphate backbone. PCR product size can be determined by 
running a DNA ladder of known size in the gel along side the samples. The 
agarose gels are normally stained with ethidium bromide, a dye that binds to 
double stranded DNA and fluoresces under ultraviolet radiation.
Method
RNA was reverse transcribed to cDNA using Superscript II RT 
(Invitrogen, Paisley, Scotland) with poly-dT primers. The PCR-amplification 
of the cDNA was achieved using commercially available primer pairs for 
ADAM-17, TIMP3 and GAPDH (R&D Systems) and the conditions used were 
according to the manufacturer’s protocol (see appendix), using Taq 
polymerase (Invitrogen) and an annealing temperature of 55°C using a 
Biometra trio-thermoblock (Biometra, UK). The amplified PCR products were 
analyzed on ethidium bromide stained 1% agarose gel. Product size was 
determined using a 100bp DNA ladder (Invitrogen). Gel images were 
obtained using a UVP Bioimaging system (Bio-Rad).
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3.3 Results
3.3.1 Tissue characterisation
To assess the extent of recent myelin breakdown and cellular 
activation within the active blocks, a 3 point grading system was applied to 
the ORO and HLA-DR staining (Table 3.3). Characterisation of the 42 MS 
blocks investigated revealed that 14 contained active lesions, 11 had chronic 
lesions and 17 were from NAWM. In the active lesion areas, 6 MS blocks 
displayed scattered isolated ORO-positive cells (Grade +) while 6 had in 
addition one or more foci or clusters of ORO-positive cells (Grade ++). In 2 
blocks however, ORO-positive cells were abundant throughout the entire 
section (Grade +++) as detailed and illustrated in section 2.3.2 and Figure 
2.5a-c.
HLA-DR immunoreactivity was graded as described and illustrated in 
section 2.3.2 and Figure 2.5d-f. 12 of the MS samples and one of the OND 
samples displayed a widespread level of HLA-DR immunoreactivity in the 
presence of foamy macrophages (Grade +++), 21 MS, 2 OND and 1 control 
samples displayed distinct foci of immunoreactivity (Grade ++), the 
remainder of the control samples and 8 of the MS samples, displayed a low 
level of activity associated with individual parenchymal microglia (Grade +). 
None of the samples used were classified as negative for HLA-DR 
immunoreactivity. 3 chronic lesion blocks, one of the active and 5 blocks 
from the NAWM displayed HLA-DR staining of scattered, isolated microglia 
(Grade +). Five of the active lesions, 6 of the chronic lesions and 10 of the 
NAWM blocks displayed HLA-DR immunostaining that was diffuse and 
widespread (Grade ++), which involved either parenchymal process-bearing 
cells or cells in small perivascular infiltrates. An abundance of large HLA-DR 
positive cells corresponding to foamy macrophages observed on H&E 
staining, were detected in both parenchymal and perivascular distributions in 
14 of the active lesion, 2 of the chronic lesion and 2 of the NAWM blocks 
(Grade +++) (Table 3.3).
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Table 3.3 Individual block characterisation for lesion activity and ADAM- 
17 expression
Block ID ORO HLA-DR ADAM-17 Characterisation
MS 122 A4E5 lesion - +++ ++ Chronic
MS18 lesion - + +++ Chronic
MS 18 P2C2 - + ++ Chronic
MS100 4/B6 - +++ +++ Chronic
MS 21 NAWM - ++ ++ Chronic
MS 21 Lesion - ++ + Chronic
MS 22 Lesion - ++ + Chronic
MS 22 A1B3 - ++ + Chronic
MS3 (104/97 79 94) - ++ ++ Chronic
MS3 (104/97 75 94-009) - ++ ++ Chronic
MS3 (104/97 75 94) - +++ ++ Chronic
MS104 P2A3 + ++ +++ Active
MS 104 12/D7 ++ +++ +++ Active
MS 56 P4D3 ++ ++ +++ Active
MS 22 NAWM +++ +++ +++ Active
MS 109 1a3c2 + + ++ Active
MS 122 A1D7 lesion + +++ ++ Active
MS127 L12C8 ++ +++ +++ Active
MS2 (103/97 91-307) ++ ++ ++ Active
MS2 (103/97 93-308) + +++ +++ Active
MS3 (104/97 75 92-56) ++ ++ ++ Active
MS4 (105/97 94-110) ++ ++ +++ Active
MS4 (105/97 80 92-187) + +++ + Active
MS 5 (106/97 84B 91.172) + +++ +++ Active
MS 6 (107/97 944 cBrBr) +++ +++ +++ Active
MS 104 P2C1 - + + NAWM
MS 45 P2C3 - + +++ NAWM
MS 49 P2C2 - + + NAWM
MS 49 P2C4 - + +++ NAWM
MS1 (25/01a) - ++ + NAWM
MS1 (25/01 b) - ++ + NAWM
MS1 (25/01c) - + + NAWM
MS2 (103/97 78 94-256) - ++ ++ NAWM
MS2 (103/97 78 91-230) - ++ ++ NAWM
MS3 (104/97 75 93-288) - ++ ++ NAWM
MS3 (104/97 75 92-187) - +++ ++ NAWM
MS4 (105/97 80 91-182) - ++ +++ NAWM
MS7 (10/99a) - ++ ++ NAWM
MS8 (102/97 186 95-339) - ++ ++ NAWM
MS8 (102/97 186 95-549) - ++ + NAWM
MS8 (102/97 186A 96-102) - +++ ++ NAWM
MS8 (102/97 186 96-37) - ++ ++ NAWM
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Table 3.4 Description and distribution of scoring for cellular activation within
the MS tissue samples studied.
■ S
OHO + Sparse +ve cells 6 0 0
++ Diffuse small foci +ve cells 6 0 0
+++ Abundance of +ve cells throughout 2 0 0
HLA-DR + Sparse single +ve microglia 1 3 5
++ Foci of +ve micoglia and foamy 
macrophages
5 6 10
+++ Abundance of +ve cells throughout 8 2 2
& H i i s i
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3.3.2. ADAM-17 immunoreactivity within control and MS white matter
ADAM-17 immunoreactivity was detected following ice-cold acetone, 
4% paraformaldehyde or 70% methanol fixation to assess optimal technique. 
Fixation of sections with 70% methanol provided a restricted ADAM-17 
expression in glial cell processes within the parenchyma. To allow efficient 
dual label immunofluorescence, acetone fixation was chosen as the optimal 
fixative for the study of ADAM-17 in snap frozen human autopsy material.
No immunoreactivity was observed for the polyclonal TACE (C15) 
antibody (Santa Cruz) using indirect immunofluorescence following any of 
the fixation methods used (Figure 3.1). ADAM-17 immunoreactivity was 
consistently demonstrated using both monoclonal anti-ADAM-17 (M222, 
Amgen) and polyclonal anti-TACE (Abeam) antibodies. Dual label 
immunofluorescence for the polyclonal anti-TACE and the monoclonal anti- 
ADAM-17 confirmed that these antibodies co-localised (Figure 3.2). ADAM- 
17 immunoreactivity was detected in all 60 samples of MS, OND and normal 
control brain tissue studied. ADAM-17 immunostaining appears 
heterogeneous in its distribution both between samples and within the same 
sections. ADAM-17 immunoreactivity was detected within normal control and 
MS white matter associated with the blood vessels and parenchymal glial 
cells (Figure 3.3). ADAM-17 immunoreactivity was also detected within the 
grey matter of both MS and controls, which was only associated with 
vasculature and did not vary between sections (Figure 3.3). ADAM-17 was 
observed within a few cells in occasional perivascular cuffs within 
inflammatory MS areas (Figure 3.3). Due to the varying extent of ADAM-17 
immunoreactivity within MS and control white matter, blinded scoring of the 
level of ADAM-17 immunoreactivity (Grade +, ++, +++) was carried out on 
each sample by two independent observers (Figure 3.4). 60% of the normal 
control samples displayed ADAM-17 expression only associated with the 
blood vessels (Grade +) whilst the remaining 40% showed a low level of 
astrocytic immunoreactivity along with the blood vessel staining (Grade ++). 
Samples displaying an abundance of parenchymal ADAM-17 staining (Grade 
+++) were only found in MS samples. Abundant grade +++ ADAM-17 
staining was predominantly observed within active lesions (Figure 3.5) where
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Figure 3.1 Comparison of immunostaining for ADAM-17 using different
fixatives and antibodies
M222 TACEC15
Acetone
CSLM images comparing immunoreactivity for two ADAM-17 (Green) 
antibodies M222 (a, c, e) and TACE (C15) (b, d, e) after fixation in acetone 
(a, b), 4% paraformaldehyde (c, d) and 70% methanol (e, f). Note the reduced 
expression of M222 after methanol fixation. Nuclei are counter stained with 
propidium iodide (Red). Scale bar = 50pm.
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Figure 3.2 Co-localisation of the monoclonal (Amgen) and polyclonal (Abeam)
antibodies to ADAM-17
Intensity Ch1-T2 
250 - M M
50 100 150 200 250
Intensity Ch2T1
100 150 200 250
Absolute Frequency
Dual label immunofluorescence for M222 (Green) and TACE (Red) demonstrating an 
overlap in fluorescent signal in blood vessels (a) and astrocytic processes (c). Co- 
localisation is demonstrated as white pixels on the composite images (a, c) and 
represented by the pixels in quadrant 3 (b, d) following Zeiss 510 CSLM software 
reading of individual pixels for each fiuorophore. Mag x400
Intensity Ch1-T2 
250
150
Intensity Ch2-T1
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Figure 3.3 ADAM-17 expression within control and MS CNS tissue
ADAM-17 immunoreactivity (Green), using the M222 anti-ADAM-17 monoclonal 
antibody, was observed within both control and MS white matter (a, c) to various 
extents but was only observed consistently in blood vessels within the grey 
matter (b). ADAM-17 expression was observed within MS lesions (c) and was 
observed to be expressed by a small number of cells within perivascular cuffs in 
MS white matter (d). Cell nuclei are counterstained with propidium iodide (Red) 
Scale bar = 100pm
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64.3% of the active lesions in the study were graded +++ for ADAM-17 
staining. High levels of ADAM-17 expression were observed in lesional 
areas that were high in lipid laden activated macrophages (Figure 3.6).
Cellular localisation of ADAM-17 within control white matter and MS tissue
Upon morphological examination, ADAM-17 expression appeared to 
be associated with the cell body and the elongated processes of 
parenchymal astrocytes. There was also a high level of blood vessel 
associated ADAM-17 expression, which appeared to be both endothelial and 
astrocytic-end-feet in origin. To determine the exact cellular distribution of 
ADAM-17, dual label immunofluorescence was carried out with monoclonal 
mouse anti-ADAM-17 (M222) and rabbit anti-GFAP or rabbit anti-VWF, for 
identification of astrocytes and endothelial cells respectively. Dual labelling 
was also carried out with polyclonal anti-TACE antibody and monoclonal 
anti-HLA-DR to identify activated macrophage/microglia cells. Utilisation of 
the Zeiss 510 software enabled individual pixels to be scanned and 
designated a white colour if true co-localisation existed between the two 
channels of interest. Co-localisation was observed with ADAM-17 and the 
cerebral vascular endothelium (Figure 3.7) and the surrounding parenchymal 
astrocytes and end-feet processes (Figure 3.8). Co-localisation was also 
observed in the foamy macrophages and activated microglia in MS lesions 
(Figure 3.9). Co-localisation of the endothelial and astrocytic phenotypic 
markers with M222 and the macrophage/micoglia marker with TACE, 
provides definitive evidence of ADAM-17 expression being produced by 
astrocytes, endothelial cells and activated macrophage/microglia within MS 
tissue.
3.3.3 TIMP3 immunoreactivity in control and MS white matter
Immunofluorescence was carried out following the application of three 
different commercially available antibodies to determine the cellular location 
of TIMP3 protein expression. However TIMP3 immunoreactivity appeared to 
be at a level that is below the detection threshold of the three techniques
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Figure 3.5 Extent of ADAM-17 immunoreactivity in active and chronic MS 
lesions, MS NAWM and control and OND white matter
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The extent of ADAM-17 immunoreactivity across the 5 categories of tissue 
investigated within the study. Note highest level of ADAM-17 expression 
(grade 3) is predominantly observed in the active lesions (9/14 blocks).
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Figure 3.7a ADAM-17 co-localisation with the endothelial marker, von Willebrand factor
VWF
Co-localistftion
C  Intensity Chi-T2
50 100 150 200 250
Intensity Ch2-T1
0 50 100 150 200 250
Absolute Frequency
Dual label immunofluorescence for (a) ADAM-17(Green) and (b) von Willebrand 
factor (Red) in MS white matter with a high level of parenchymal ADAM-17 
immunoreactivity. (c) Co-localisation is represented by the pixels in quadrant 3 
on graph and is demonstrated as white pixels in the composite image (d) 
following Zeiss 510 CSLM software reading of individual pixels for each 
fluorophore. Bar = 20pm
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Figure 3.7b ADAM-17 co-localisation with the endothelial marker, von Willebrand factor
VWF
Co-localisation
C Intensity Ch1-T2
50 100 150 200 250
Intensity Ch2-T1
50 100 150 200 250
Absolute Frequency
Dual label immunofluorescence for (a) ADAM-17(Green) and (b) von Willebrand 
factor (Red) in MS white matter with a low level of parechymal ADAM-17 
immunoreactivity. (c) Co-localisation is represented by the pixels in quadrant 3 
on graph and is demonstrated as white pixels in the composite image (d) 
following Zeiss 510 CSLM software reading of individual pixels for each 
fluorophore. Cell nuclei are counter stained with DAPI (Blue a&b). Bar = 20pm.
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Figure 3.8 ADAM-17 co-localisation with the astrocytic marker GFAP
Q Intensity Chi-T 2 
250
0 50 100 150 200 250
Intensity Ch2-T1
50 100 150 200 250
Absolute Frequency
Dual label immunofluorescence for (a) ADAM-17(Green) and (b) GFAP (Red) in MS 
white matter, (c) Co-localisation is represented by the pixels in quadrant 3 (c) and 
demonstrated as white pixels on the composite image (d) following Zeiss 510 
CSLM software reading of individual pixels for each fluorophore. Note blood vessel 
associated ADAM-17+ and GFAP+ astrocytic end feet (arrow).
Bar = 20pm
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aFigure 3.9 ADAM-17 co-iocalisation with MHC class II expressing microglia
and macrophages
b
HLA-Dr I ADAM-17
Intensity Ch1-T 2 
250 mmmm
50 100 150 200 250
Intensity Ch2-T1
50 100 150 200 250
Absolute Frequency
Dual label immunofluorescence for (a) HLA-Dr (Green) and (b) ADAM-17 (Red) in 
MS white matter, (c) Co-localisation is represented by pixels in quadrant 3 and 
demonstrated as white pixels in the composite image (d) following Zeiss 510 
CSLM software reading of individual pixels for each fluorophore. Bar = 20pm.
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used, indirect immunofluorescent, SABC immunoperoxidase and tyramide 
fluorescent amplification techniques as no TIMP3 was detected.
3.3.4 Western blot analysis of ADAM-17 and TIMP3 in CNS tissue from MS 
and control
Western blotting of protein samples obtained from CNS tissue 
homogenates provides evidence that ADAM-17 and its natural inhibitor 
TIMP-3 are constitutively expressed within MS and normal control CNS 
tissue (Figure 3.10). M222 antibody stains bands at 80kDa and 100kDa 
representing the active and pro forms of ADAM-17 respectively (Hurtado et 
a/., 2001, Peiretti etal., 2003), with the proform predominating in both control 
and MS tissue. Anti-TIMP3 antibody revealed a single band at approximately 
48kDa corresponding to either a dimer of the mature form of the protein 
(Langton et a/., 1998) or a stable complex formed between TIMP3 and ECM 
ligands (Jaworski and Fager 2000). As variations in the extent of ADAM-17 
immunoreactivity were detected within the white matter and not the grey 
matter no quantitation of protein samples were carried out due to the varying 
amount of grey and white matter in the tissue blocks used.
3.3.5 Identification of ADAM-17 and TIMP3 mRNA in MS and normal control
CNS tissue
RT-PCR revealed mRNA for ADAM-17 (Figure 3.11) and TIMP3 
(Figure 3.12) were present in all MS and control samples tested. ADAM-17 
and TIMP3 PCR products were observed at 527bp and 442bp with the 
positive controls at 380bp and 340bp respectively, as indicated by the 
manufacturer, in all MS and normal control samples investigated.
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Figure 3.10 Western blot analysis of ADAM-17 and TIMP3 protein 
expression in MS and control white matter
a .  A D A M -1 7
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The constitutive expression of both (a) ADAM-17 and (b) TIMP3 protein 
in tissue homogenates of MS and control white matter.
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Figure 3.11 ADAM-17 mRNA expression in MS and normal control white
matter using RT-PCR
1 2 3 4 5 6 7 8  9 10
ADAM-17 PCR product expression within samples of normal control 
white matter (lanes 3, 4), MS NAWM (lane 5), active MS (lanes 6, 7), 
chronic inactive MS (lanes 8, 9) tissue. No RT negative control is in 
lane 10. 100bp DNA ladder is shown in lane 1 and an R&D systems 
positive control in lane 2.
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Figure 3.12 TIMP3 mRNA expression in MS and normal control
white matter using RT-PCR
500bp400bp300bp
TIMP3 PCR product expression within samples of normal control 
white matter (lanes 3, 4), MS NAWM (lane 5), active MS (lanes 6, 7), 
chronic inactive MS (lanes 8, 9) tissue. No RT negative control is in 
lane 10 .100bp DNA ladder is shown in lane 1 and an R&D systems 
positive control in lane 2.
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Figure 3.13 GAPDH mRNA expression in MS and normal control
white matter using RT-PCR
1 2 3 4 5 6 7 8  9 10
bp
576—► 
340—►
GAPDH PCR product expression within samples of normal control 
white matter (lanes 3,4), MS NAWM (lane 5), active MS (lanes 6, 7), 
chronic inactive MS (lanes 8, 9) tissue. No RT negative control is in 
lane 10 .100bp DNA ladder is shown in lane 1 and an R&D systems 
positive control in lane 2. GAPDH results of these samples illustrates 
the lack of effect postmortem delay has on mRNA for these blocks 
used.
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3.4 Discussion
The results presented here demonstrate the spectrum of ADAM-17 
distribution in MS CNS tissue, along with a semi-quantitative analysis of the 
extent of ADAM-17 expression in active and chronic inactive lesions as well 
as the NAWM of MS and the white matter of normal control and OND cases. 
Utilising archival, SF autopsy material, tissue was classified based on 
evidence of recent myelin breakdown and extent of cellular activation as 
determined by ORO staining and HLA-DR immunoreactivity, classification 
parameters as described by other authors (Sanders etal., 1993; van der 
Valk and de Groot, 2000).
The first objective of this study was to determine whether ADAM-17 
and TIMP3 were expressed and then to establish a reproducible protocol for 
the identification of ADAM-17 and its natural inhibitor TIMP3 by 
immunofluorescence in snap frozen human autopsy brain material. Three 
antibodies for each protein were used, in conjunction with different fixation 
and detection methods. Protein expression of ADAM-17 and TIMP3 were 
further confirmed by western blotting following separation of protein extracts 
from tissue homogenates by SDS PAGE. Gene transcripts for these proteins 
were also demonstrated by reverse transcribing sample mRNA into cDNA 
followed by RT-PCR using commercially available primer pairs.
ADAM-17 and TIMP3 were demonstrated to be expressed in MS,
OND and normal control white matter. ADAM-17 expression was associated 
with the endothelium of the blood vessels and with the cell body and 
elongated processes of parenchymal astrocytes and the astrocytic endfeet 
that encompass the cerebral vasculature. Since both ADAM-17 and TIMP3 
were expressed in normal control brain this suggests that they play a 
constitutive role within the CNS. Co-localisation of ADAM-17 with the 
astrocyte phenotypic marker, GFAP, or the endothelial marker, von 
Willebrand factor, following dual labelled immunofluorescence, confirmed the 
morphological observations and clearly demonstrated that these two cell 
types are responsible for ADAM-17 expression in both MS and normal 
control white matter. These observations confirm those of ADAM-17
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expression within normal control white matter reported previously (Goddard 
et al., 2001). Furthering these observations here, ADAM-17 was also 
demonstrated to be expressed by activated macrophage/microglial cells in 
MS tissue and was upregulated in MS, particularly in active lesions where 
ADAM-17 immunoreactivity is evident on numerous large foamy 
macrophages, implicating a possible role in the disease process. Further 
evidence suggesting a disease association of ADAM-17 with MS was 
provided when gene transcripts for ADAM-17 in peripheral blood 
mononuclear cells (PBMCs) were shown to be positively correlated with MS 
disease progression in RRMS. Increases in ADAM-17 mRNA expression by 
PBMCs accompanied a higher mean number of new Gd-DTPA enhancing 
lesions on MRI following PBMC sampling (Seifert et al., 2002).
ADAM-17 may play a role in a number of ways in the development of 
MS; proteolytic cleavage of fractalkine into its soluble form may create a 
chemotatic gradient for inflammatory cells to enter the CNS; ADAM-17 is 
reported to cleave adhesion molecules from the luminal surface of blood 
vessels, however in MS increased expression of endothelial cell adhesion 
molecules has been reported suggesting an imbalance in enzyme/inhibitor 
activity which is investigated in vitro in Chapter 5; ADAM-17 expression has 
been demonstrated to be associated with astrocytes and activated 
macrophage/microglial cells and expressed at high levels in lesions with high 
levels of cellular activity as gauged by HLA-DR and ORO expression. ADAM- 
17 cleaves TNF into its soluble form thereby possibly subjecting 
oligodendrocytes to its cytotoxic effects; TNF has been reported to alter TJ 
expression in endothelial cultures possibly resulting in the disrupted TJ 
expression reported in chapter 2.
In the current study ADAM-17+ cells have been observed in a few 
perivascular cuffs within MS lesions in agreement to a previous study, which 
reported that ADAM-17 immunoreactivity in MS tissue was limited to a small 
number of CD3+ lymphocytes primarily located within perivascular cuffs 
associated with acute and chronic active plaques (Kieseier et al., 2003). In 
contrast to the present study however no astrocytic or endothelial cell ADAM- 
17 expression was reported by Kieseier et al., 2003. This difference in
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reported expression with the present study may be explained by the use of 
formalin fixed paraffin embedded tissue by Kieseier et al (2003) which may 
have reduced antigenicity, even following microwave antigen retrieval, 
whereas in this study snap frozen tissue was used. The differences in 
staining pattern may also be due to differences in primary antibodies used. 
Incorporating TACE (C15) with both the monoclonal M222 and another 
polyclonal TACE (Abeam) antibody to ADAM-17 within the various protocols 
used in this study on serial sections enabled comparisons to be drawn. Both 
the monoclonal M222 and polyclonal TACE, anti-ADAM-17 antibodies gave 
comparable results on the snap frozen tissue and were shown to be co­
localised following dual label immunofluorescence. However serial sections 
stained with the polyclonal anti-TACE antibody from Santa Cruz as used by 
Kieseier et al (2003) were devoid of any ADAM-17 immunoreactivity.
The identification of the cells responsible for the synthesis of ADAM- 
17 is important when analysing the functional aspects of ADAM-17. It has 
been shown to be the sheddase responsible not only for cleaving TNF, but 
also cytokine receptors p75 and p55 TNFR, IL-6R, the growth factor TGFa, 
growth factor receptor for macrophage colony stimulating factor (M-CSF), 
and the adhesion molecule L-selectin and the chemokine fractalkine (Black 
etal., 1997; Moss etal., 1997; Borland etal., 1999; Dri etal., 2000; Rovida 
etal., 2001; Garton etal., 2001 & 2003). Astrocytes along with microglia and 
macrophages have been shown to be responsible for synthesising TNF 
within MS tissue (Hofman et al., 1989). However, it has also been suggested 
that astrocytes may not actively synthesise TNF but merely take it up from 
the extracellular space as a consequence of receptor-mediated 
internalisation of TNF (Aranguez etal., 1995; Bitsch etal., 2000). It is 
important to note that immunoreactivity does not necessarily indicate 
synthesis (Selmaj etal., 1991a). Regardless of synthesis, ADAM-17 
expression by astrocytes and activated macrophage/microglia would allow 
cleavage of TNF releasing proinflammatory soluble TNF (see Chapter 5). 
ADAM-17 has also been reported to be constitutively expressed by neurons 
under basal conditions and has been associated with neuroprotective roles in 
the CNS by modulating the amount of glutamate deposits in the ECM by
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regulating the number of glutamate transporters and also by competing with 
(3- and y-secretases to cleave APP via a non-amyloidogenic pathway 
(Allinson etal., 2003; Romera etal., 2004; Koj'ro and Fahenholz, 2005;). 
Inhibition of ADAM-17 activity by pre-treatment of rat cortical cultures with 
the ADAM-17 inhibitor BB3103 has been reported to prevent oxygen-glucose 
deprived increase in glutamate transporters (Romera et al., 2004). As a 
result it has been suggested that physiological neuroprotection by glutamate 
transporters is mediated by an ADAM-17-TNF dependent pathway (Romera 
et al., 2004).
TNF has a host of pro-inflammatory effects including increased 
leukocyte cell attachment via upregulated adhesion molecules, chemotaxis 
and migration. TNF has also been shown to disrupt the function of the BBB 
in in vitro models (Dobbie etal., 1999). Conversely TNF induces a beneficial 
response to immune situations by causing apoptosis of autoreactive T-cells 
through TNF/p55 TNFR interaction as seen in experiments on EAE (Probert 
and Akassoglou, 2001; Weishaupt et al., 2004). It has been reported that 
induction of EAE in TNFR p55 deficient mice resulted in increased and 
prolonged levels of inflammation during later stages of the disease, with a 
marked reduction in T cell apoptosis in inflammatory infiltrates, suggesting 
that TNFR p55 plays a role in the removal of T cells from lesions and disease 
resolution (Probert and Akassoglou, 2001). It has been reported that 
membrane bound TNF is more effective than soluble TNF at binding with p75 
TNFR (Grell etal., 1995). Levels of TNF and TNFp75 have been positively 
correlated with relapses in MS (Martino etal., 1997). TNF/TNFR p75 
interaction on cerebral endothelial cells has been reported to lead to 
increased ICAM-1 expression (Akassoglou etal., 2003). ADAM-17 cleavage 
of TNF may therefore play a protective role by reducing the efficacy of 
TNF/p75 TNFR binding thus resulting in less T-cell infiltration and possibly 
facilitating in disease resolution.
Immunohistochemical studies of endothelial cell associated adhesion 
molecules have shown an increase in adhesion molecules on the cell surface 
of the vascular endothelial cells from MS lesions compared to NAWM and
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control sample white matter (Sobel et al., 1990; Washington et al., 1994; 
Dobbie etal., 1999; Etienne-Manneville etal., 2000). This increase in 
adhesion molecule expression is reported to be mediated by TNF (Wong and 
Dorovini-Zis, 1992 & 1995). Interaction of membrane bound TNF with p75 
TNFR on endothelial cells is reported to lead to an increase in expression of 
ICAM-1, which potentially allows increased infiltration across the BBB via 
interactions of endothelial ICAM-1 with LFA-1 on the surface of T-cells 
(Wong and Dorovini-Zis, 1992). ADAM-17 expression by the vascular 
endothelium in normal control brains, as shown here, may regulate adhesion 
molecule expression through their cleavage from the cell surface, thus 
ensuring a low level of entry of inflammatory cells under normal conditions 
(Hickey, 2001). However it is proposed that high levels of ICAM-1 substrate 
for ADAM-17 on endothelial cells in MS may saturate the enzyme, eventually 
leading to an increased number of membrane-bound adhesion molecules 
available for leukocyte infiltration.
People with MS treated with IFN-p have been reported to have higher 
serum and CSF levels of soluble VCAM-1 (Calabresi etal., 1997; Rieckmann 
et al., 1998). VCAM-1 has been shown to be proteolytically cleaved from the 
surface of murine endothelial and N1H3T3 cells in an MMP dependent 
mechanism under basal conditions and an ADAM-17-dependent mechanism 
following PMA stimulation (Garton et al., 2003) similar to those observed 
during L-selectin shedding from leukocytes (Faveeuw etal., 2001). PMA 
induced shedding of VCAM-1 was reported to be inhibited in ADAM-17 
deficient cells and following treatment with an ADAM-17 inhibitor (Garton et 
al., 2003). Cleavage of VCAM-1 may play a role in regulating cellular 
infiltration by limiting the amount of VCAM-1 available at the cell surface 
(Garton et al., 2003). Serum samples from patients with MS having IFN-p 
treatment are reported to contain CD4+ and CD8+ T cells with decreased 
levels of VLA-4 and increased amounts of soluble VCAM-1 (Jensen etal., 
2005). It may be possible that IFN-P stimulates ADAM-17 mediated cleavage 
of adhesion molecules resulting in the reported increased amounts of soluble 
adhesion molecules within the serum and CSF however this requires further 
investigations in vitro (Calabresi etal., 1997; Rieckmann etal., 1998; Jensen 
et al., 2005). Production of soluble VCAM-1 may represent a further
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protective role if it maintains adhesive function and binds to VLA-4 expressed 
on lymphocytes preventing them adhering to the vessel wall and subsequent 
transmigration.
The presence of ADAM-17 and TIMP3 protein and mRNA were 
analysed by western blotting and RT-PCR using protein and RNA extracted 
from 12 MS and 7 control tissue samples. TIMP3 protein was detected as a 
single band at approximately 48 kDa. ADAM-17 was detected in all samples 
by bands at 100kDa and 80kDa, probably corresponding to immature and 
mature forms of the protein (Skovronski etal., 2001; Hurtado etal., 2001; 
Peiretti et al., 2003). It is important to note that no quantitative analyses were 
carried out on whole tissue lysates due to the inter-sample variability in grey 
matter/white matter content. Western blot analysis has been used here to 
determine the presence of TIMP3 protein in both MS and control tissue, as 
commercial antibodies forTIMP3 have proved ineffective in detecting TIMP3 
protein by immunofluorescence. The RT-PCR results are in agreement with 
those of other workers, demonstrating ADAM-17 and TIMP3 mRNA is 
expressed in both MS and control samples (Lindberg etal., 2001).
TIMP3 is expressed in both normal control and MS brain at the 
transcriptional and protein level, but to date the attempts to elucidate the 
cellular origins of this protein have proved inconclusive. Difficulty in 
identifying the cellular localisation of TIMP3 may be due to the poor quality of 
commercial antibodies currently available. TIMPs interact with a 1:1 
stoichiometry with MMPs to inhibit their activity (Kossakowska et al., 1998; 
Crocker et al., 2004). It has been suggested that normally a balance is 
maintained between ADAM-17 and TIMP3. However, in inflammatory 
conditions, this balance may be disturbed allowing an overproduction of 
soluble TNF. Whether the imbalance is due to excess of the sheddase or a 
reduction in its inhibitor is unclear at present. TNF increases the adhesion 
molecule expression by endothelial cells and ADAM-17 cleaves TNF from 
the cell surface, whether TNF from parenchymal astrocytes and microglia 
cause this apparent increase in adhesion molecules remains to be clarified.
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In summary, the results indicate that ADAM-17 expression occurs 
throughout MS white matter, persisting in chronic inactive lesions but highest 
expression is seen in active lesions. Further investigation would be required 
to investigate the functional aspects associated with this increased ADAM-17 
expression in active lesions. To determine the role of ADAM-17 expression 
by the cerebral endothelium in both normal control white matter and MS 
lesion and the influence TIMP3 exerts during inflammatory conditions 
requires in vitro studies (See chapter 5).
TNF has long been associated with a pathological role in MS 
(Brosnan et al., 1988) and as such development of TNF inhibitors is an 
active area of drug discovery (Duan et al., 2003; Cherney et al., 2003). 
However recent trials using anti-TNF treatment were unsuccessful in MS as 
this treatment exacerbated disease rather than ameliorating the disease 
course (Lenercept study 1999; Sicotte and Voskuhl, 2001). ADAM-17 may be 
a potential alternative therapeutic target to TNF for the treatment of MS.
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Chapter 4
ADAM-17 expression within rat spinal cords of experimental 
autoimmune encephalitis, an experimental model of MS
4 .1 1ntroduction
A major problem in investigating the pathogenesis of 
neuroinflammatory disorders in humans is the inaccessibility of the affected 
tissue or organ. As a result human tissue for research can only be obtained 
from end stage autopsy material that may present results that do not have 
any bearing on the initiation processes of the disease (‘t Hart and Amor, 
2003; t’ Hart et al., 2004 ). To address these issues, experimental 
autoimmune (allergic) encephalomyelitis (EAE), a T-cell mediated 
autoimmune disease of the CNS is widely used in laboratories as an 
experimental model of MS (Genain and Hauser, 1997; ‘t Hart et al., 2004; 
Behi et al., 2005). EAE was first developed in an effort to gain an 
understanding of the initiation of the encephalomyelitis which develops after 
inoculation of subjects with Pasteur rabies vaccine (Behi et al., 2005). The 
Pasteur rabies vaccine was produced from virally infected neural tissue, so 
animals were either inoculated with the infected neural tissue or with 
uninfected neural tissue for control subjects. It was during these experiments 
when it was noticed that some of the controls subjects receiving uninfected 
neural tissue also developed encephalomyelitis (Behi et al., 2005). Although 
EAE was first described in macaque monkeys, most forms of EAE are 
produced in inbred laboratory rodents (Rivers etal., 1933; Rivers and 
Schwenkter, 1935; Genain and Hauser, 1997; Brok etal., 2001).
4.1.1 The use of EAE as a therapeutic model for MS treatment
EAE, as well as being readily inducible in susceptible animals is also 
readily treated. Many successful treatments in EAE have failed when 
transferred to treatment of humans. A prime example of this comes from the 
exciting findings in the treatment of EAE with soluble p55 TNFR which lead 
to a large clinical trial in people with MS, with disappointing results. Indeed 
the phase II randomised trial resulted in increased exacerbations in a dose 
dependent manner in comparison to placebo (Lenercept study 1999). 
Species differences appear to be an obvious reason for this. The majority of 
drugs or therapeutic tests are applied to and rely upon the rodent models as 
‘preclinical’ tests, these findings are then applied directly to humans in 
clinical trials. However rats and mice appear too distant from man to fulfil this
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(‘t Hart etal., 2004). In transplantation research a non-human primate model 
is required for preclinical tests to bridge the gap between human and 
rodents, however for autoimmune disease research this does not appear to 
be the case (t’Hart et al., 2004). Encouraging results taken from the anti- 
VLA-4 MAb treatment of EAE also came from the natalizumab clinical trial in 
relapsing remitting MS, where decreased numbers of enhancing MRI lesions 
and relapses have been reported with few side effects (Miller et al., 2003). 
However following reports of progressive multifocal leukoencephalitis (PML) 
in two patients receiving dual therapy in the trial, Tysabri (natalizumab) was 
withdrawn at the end of February 2005 (Kleinschmidt-DeMasters and Tyler, 
2005).
4.1.2 Aim of study
The aim of this study was to establish whether ADAM-17 is involved in 
the pathogenesis of EAE and if so to develop an understanding of its 
functional role so that the potential for therapeutic intervention targeting 
ADAM-17 could be exploited.
The known pathological role of TNF and adhesion molecules in EAE 
together with ADAM-17’s known involvement with their shedding, lead this 
study to establish the expression profile of ADAM-17 and its natural inhibitor 
TIMP3 at the protein and mRNA level during initiation, peak disease and 
recovery from rats with EAE. Snap-frozen spinal cord tissue from EAE rats 
was used. A semi-quantitative analysis of ADAM-17 protein and mRNA 
expression was applied to establish if any differences exist between study 
groups. ADAM-17 immunoreactivity was also investigated in relation to 
phenotypic markers for cells from the CNS, namely astrocytes, cerebral 
endothelium and activated macrophages and microglia. The major objectives 
addressed were:
(i) To determine whether ADAM-17 and TIMP3 immunoreactivity and 
mRNA was detectable in naive and EAE rat spinal cord and 
whether there were any differences in expression levels between 
the different disease stages
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(ii) To determine which cells are responsible for ADAM-17 and TIMP3 
expression within the spinal cord
4.2 Materials and methods
4.2.1 Experimental autoimmune encephalomyelitis tissue
EAE was induced in 15 Lewis rats by immunisation with spinal cord 
homogenate plus adjuvant, as previously described (Ohgoh etal., 2002, see 
appendix). The animal work was carried out at Eisai London Research 
Laboratories Ltd, University College London by Dr T Smith. Clinical disability 
was scored: 0, no detectable change in muscle tone and motor behaviour; 1, 
flaccid tail; 2, impairment of righting reflex and/or loss of muscle tone in 
hindlimbs; 3, complete hindlimb paralysis; 4, paraplegia; and 5, death 
(Ohgoh et al., 2002). At three time points during the disease course, 5 rats 
were sacrificed. Pre-disease rats were sacrificed 10 days post immunisation 
(dpi) with a clinical disability score of 0. Peak-disease rats were sacrificed 12 
dpi with a score of 3.25. Recovered rats were sacrificed 4 days after their 
score had returned to 0 (see appendix). Spinal cords from 5 naive rats were 
also obtained. Spinal cords were removed by insufflation with ice cold saline, 
placed onto foil and rapidly frozen on dry ice, serial 12//m cryostat sections 
were obtained for immunohistochemistry.
4.2.2 Immunohistochemistry
12pm cryostat sections were cut and mounted on to polylysine coated 
glass slides (BDH). Sections were fixed in ice cold acetone for 10 minutes 
then allowed to air dry for at least 15 minutes at RT prior to use or storage at 
-20°C. Endogenous peroxidase was quenched by incubating the sections in 
0.5% H2O2 in methanol for 10 minutes at RT. Following 5 minute washes in 
running water and PBS, non specific binding was eliminated by incubating 
the sections in 5% normal rabbit serum for 10 minutes at RT. Sections were 
incubated in mouse anti-rat monoclonal ED1 (1:50, Serotec) antibody 
overnight at 4°C. ED1 immunoreactivity was detected using the SABC 
immunoperoxidase method as described in section 3.2.1.1.
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4.2.3 Indirect Immunofluorescence staining
12pm cryostat sections were either fixed in 70% methanol, 4% 
paraformaldehyde (see appendix), or ice-cold acetone for 10 minutes. 
Following fixation all sections were washed in PBS with the exception of ice- 
cold acetone fixed sections, which were allowed to air dry for at least 15 
minutes prior to the next step.
4.2.3.1 Single label immunofluorescence
Following fixation, sections were incubated in polyclonal TACE 
antibody (1:100, Abeam) overnight at4°C, washed in PBS then incubated in 
goat anti-rabbit IgG Alexa 488 (1:500, Molecular Probes) for 90 minutes at 
RT. Cell nuclei were counterstained by incubating sections in propidium 
iodide (Sigma, 2pg/ml) for 30 seconds. Sections were mounted with 
coverslips in the non-fading mountant, citifluor (see appendix). All dilutions 
were performed in PBS except antibodies that were used on 
paraformaldehyde fixed sections, which were diluted in PBS with 0.5% Triton 
X-100. Table 3.2.2 provides the details of all the antibodies used in this 
study.
4.2.3.2 Dual label immunofluorescence
To determine the cellular origin of ADAM-17 expression, the 
sequential dual label immunofluorescence protocol, as described in section 
3.2.2, was carried out. Dual staining was performed with polyclonal 
antibodies to either the astrocytic marker, GFAP (1:100, Dako) or the 
endothelial marker von Willebrand Factor (1:100, Dako,) with the monoclonal 
antibody to ADAM-17, human anti-mouse M222 (1:100, Amgen). Rabbit 
polyclonal TACE was used in dual staining with the inflammatory 
macrophage marker, mouse anti-rat ED1 (1:50, Serotec) or a mouse 
monoclonal anti-GFAP (1:1000, Chemicon) antibody. All dilutions were 
carried out with PBS.
As a control during dual staining, serial sections were single label 
immunostained for each primary antibody to ensure that no cross reaction 
was observed when using two secondary antibodies. Sections with primary 
antibody omitted from the protocol showed no immunoreactivity.
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4.2.4 Imaging
All imaging was obtained using the Zeiss 510 confocal scanning laser 
microscope and Leica upright light microscope as described previously in 
section 3.2.3.
4.2.5 Quantification
Semi quantitative analysis was carried out to assess the extent of ED1 
and ADAM-17 immunoreactivity, following observation through the x20 
objective lens of the upright Leica microscope.
4.2.5.1 ADAM-17 and ED1 grading
All sections within this study were single label immunostained for ED1 
and ADAM-17 as described previously (Chapter 4.2.2 and 4.2.3.1 
respectively). Analyses of the staining was carried out by two independent 
observers, and a 4 point grading scale (-ve, +, ++, +++) was applied;
• 0 = no immunoreactivity observed;
• + = sections with only blood vessel associated immunoreactivity;
• ++ = sections where there is blood vessel immunoreactivity together 
with distinct white matter glial cell expression;
• +++ = sections which displayed an abundance of immunoreactivity 
throughout the spinal cord white matter.
Where observers scores differed a consensus score was obtained following 
joint re-examination.
4.2.5.2 Co-localisation
Analysis of all dual stained sections was carried out using the Zeiss 
510 CSLM software as described in section 3.2.3.1.
4.2.6 Protein and RNA extraction
From each of the 20 rat spinal cords, white matter was excised from 
the grey matter (at -20°C) and collected in pre-cooled Eppendorfs (-20°C). 
Protein and RNA were extracted by application of 1ml of Tri Reagent™ 
(Sigma) following the manufacturer’s protocol (See appendix). Sample
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protein concentrations were determined using the BCA assay as previously 
described in section 3.2.4.1.
4.2.7 Western blotting for ADAM-17 and TIMP3
Extracted protein samples (6jag) were loaded into wells and separated 
by SDS-polyacrylamide gel electrophoresis on 10% pre-cast bis/tris gels 
(Invitrogen) at 150V for 1hour and proteins transferred onto nitrocellulose 
membrane for western blotting as described (section 3.2.5). Omission of 
primary antibody during the first stage of western blotting was carried out as 
a control. Quantitative analysis was carried out by comparing the integrated 
optical density (IOD) using densitometric software of the UVP Bioimaging 
system. Group means of lODs were obtained and any significant differences 
determined using the two-tailed Mann-Whitney U-test (p<0.05).
4.2.8 RNA analysis for ADAM-17 and TIMP3
4.2.8.1 Reverse transcriptase PCR
RNA was reverse transcribed to cDNA using Superscript II RT 
(Invitrogen, Paisley, Scotland) with poly-dT primers. The PCR-amplification 
of the cDNA was achieved using rat specific ADAM-17 real time PCR primer 
pair (MWG Biotech, Ebbersberg, Germany, Table 4.1) and a rat specific 
TIMP3 primer pair (R&D Systems) using Taq polymerase (Invitrogen) and an 
annealing temperature of 60°C and 55°C respectively. The amplified PCR 
products were analyzed on ethidium bromide stained 4% and 1% agarose 
gels. Product size was determined using 10bp and 100bp DNA ladders 
(Invitrogen). Gel images were obtained using a UVP Bioimaging system (Bio- 
Rad).
4.2.8.2 Real time PCR 
Principle of method
RT-PCR is a semi-quantitative method for analysis of gene 
expression. Real-time quantitative PCR (qRT-PCR) provides a more 
sensitive analysis that enables quantification of gene expression (Wilheim
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Table 4.1 Rat specific primer sequences as used during qRT-PCR to assess
mRNA in EAE.
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and Pingould 2003; Arya et al., 2005). The principle of qRT-PCR was first put 
forward by Higuchi and colleagues in 1993 and relies upon the detection of a 
fluorescent signal that is proportional to the amount of PCR product 
generated during the reaction. Fluorescent dyes are used that bind 
specifically to double stranded DNA allowing the amount of PCR product 
being produced to be analysed after every cycle in real-time using a 
fluorimeter. One of the major fluorescent dyes used in qRT-PCR is SYBR 
Green 1. SYBR Green 1 binds to the minor groove of double stranded DNA 
and is reported to have a binding affinity that is over 100 times higher than 
that of ethidium bromide (Wilheim and Pingould, 2003; Ponchel etal., 2003). 
During the initial phase of qRT-PCR the fluorescent signal is below that 
detected as background, once the signal rises above this baseline (cycle 
threshold (CT)) the signal increases exponentially until it reaches a plateau 
phase (Ponchel et al., 2003). The CT value is proportional to the logarithm of 
the initial amount of target in the sample. The relative concentration of a 
target with respect to another is determined as the difference in cycle 
number to achieve the same level of fluorescence (ACT). Experimental 
comparisons usually involve comparing ACT values of the target against 
those of an internal reference or housekeeping gene that remains constant 
during experimental conditions. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) is a common housekeeping gene used in qRT-PCR.
Method
The real time PCR analysis was carried out by Dr A Cross, Sheffield 
Hallam University, Sheffield. cDNA was used as a template for qRT-PCR 
using the ABI PRISM 7900 sequence detection system and 2xSYBR Green 
mastermix (Applied Biosystems, Warrington, UK). PCR primers were 
designed using Primer Express software (Applied Biosystems) and obtained 
from MWG Biotech (Ebbersberg, Germany). In order to preclude the 
amplification of nuclear DNA, all primers crossed an exon-exon boundary. 
Primer sequences and accession numbers are shown in Table 4.1.
Expression of ADAM-17 and TIMP3 were analysed, as well as the 
housekeeping gene GAPDH to normalise expression between different
154
samples. Sequences were confirmed as unique by a BLAST search 
(www.ncbi.nlm.nih.gov/BLAST).
Each primer pair generated a single product of the appropriate size when 
visualised by agarose gel electrophoresis, and by melt curve analysis 
following qRT-PCR (not shown). Relative mRNA levels of ADAM-17 and 
TIMP3 were determined using the formula 2'ACT where ACT = CT (target 
gene) -  CT (GAPDH).
Differences in mRNA levels were determined using the two-tailed Mann 
Whitney U test (p>0.001).
4.3 Results
20 Lewis rats used in this study were designated into 4 categories 
dependant on EAE disease course and clinical disability score: non­
inoculated rats were naive; inoculated rats with a clinical score of 0 were pre­
disease; rats with a clinical score >3 were peak disease; whereas rats whose 
clinical course had been >3 but had returned to 0 were in the recovered 
group (Table 4.2).
4.3.1 Characterisation of rat spinal cord histopathology
The cervical spinal cord was cryo-sectioned from 20 rat spinal cords 
(5 naive, 5 pre-disease, 5 peak disease and 5 recovered) and screened by 
H&E and for ED1+ macrophages to characterise the pathological state of 
individual cords used. No histological difference was observed between the 
spinal cords from the naive and pre-disease rats. Examination of H&E 
sections demonstrated large areas of hypercellular perivascular infiltrates 
within the white matter of peak-disease and recovered spinal cords. ED1 
immunoreactivity, a marker for inflammatory macrophages and microglia, 
was graded (Table 4.2) and revealed the highest level of immunoreactivity on 
microglial and perivascular cells at peak disease (2/5 rats) (Grade +++). 
Grade ++ level of ED1 immunoreactivity, was observed in the remaining 
peak disease rats and 3/5 recovered rats. Cells within the perivascular 
infiltrates were ED1+ as were other cells of microglial and macrophage 
morphology, throughout the parenchymal white matter of the spinal cords
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Table 4.2 ADAM-17 and ED1 immunoreactivity grades EAE rats.
m r n m m w m m E S D INMVi 0 + 0
Naive 0 + 0
Naive 0 + 0
Naive 0 + 0
Naive 0 + 0
Pre 0 + +
Pre 0 + 0
Pre 0 + 0
Pre 0 + +
Pre 0 + 0
Peak 3 +++ ++
Peak 3.25 +++ +++
Peak 3.25 +++ +++
Peak 3.25 +++ ++
Peak 3.25 +++ ++
Rec 0 ++ ++
Rec 0 ++ ++
Rec 0 +++ +
Rec 0 +++ +
Rec 0 ++ ++
H H H H h e
Clinical disability scores were assigned by Dr T Smith (Eisai). The extent of 
ED1 and ADAM-17 immunoreactivity were graded as:
0 = no immunoreactivity observed;
+ = sections with only blood vessel associated immunoreactivity;
++ = sections where there is blood vessel immunreactivity together with 
distinct white matter glial cell expression;
+++ = sections which displayed an abundance of immunoreactivity 
throughout the spinal cord white matter.
The animal’s clinical disability score was assigned at Eisai laboratories 
where a score of 3 represented complete hindlimb paralysis and 4 
paraplegia.
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(Figure 4.1). A low level of ED1 immunoreactivity (Grade +) was observed in 
two pre-disease spinal cords and two spinal cords from rats in recovery and 
was only associated with the vasculature. The remaining pre-disease naTve 
spinal cords (3/5) were devoid of any ED1 immunoreactivity (Figure 4.1).
4.3.2 Indirect immunofluorescence
Sections of rat spinal cord were fixed either in ice-cold acetone, 4% 
paraformaldehyde or 70% methanol to determine the optimal protocol for 
ADAM-17 and TIMP3 staining by indirect immunofluorescence. All fixatives 
permitted ADAM-17 immunoreactivity, however where parenchymal staining 
was evident, 70% methanol fixed sections provided a truncated expression 
upon glial cell processes within the parenchyma, as seen in human tissue 
(Figure 3.1e). Also under consideration was the efficacy of each fixative to 
permit optimal dual labelled immunofluorescence. 4% paraformaldehyde did 
not allow sufficient staining of ED1 and as such ice-cold acetone fixation was 
adopted as the fixative of choice for this study, since it enabled optimal 
staining for ED1, GFAP and VWF.
4.3.2.1 ADAM-17 expression in EAE and control rat spinal
All samples were stained with polyclonal anti-TACE to detect 
presence and extent of ADAM-17 within rat spinal cords (Figure 4.2). ADAM- 
17 immunoreactivity was constitutively expressed in all spinal cords 
assessed. All naive (5/5) and pre-disease (5/5) rat spinal cords were graded 
as ADAM-17+, with ADAM-17 expression associated with the vasculature. All 
peak disease animals (5/5) displayed abundant ADAM-17 immunoreactivity 
(graded +++) with an abundance of ADAM-17 staining throughout the spinal 
cord white matter, perivascular infiltrate and vasculature. Rats in the 
recovery phase maintained a high level of ADAM-17 (scores o f++/+++ for 
3/5 and 2/5 animals respectively).
Upon morphological examination, ADAM-17 immunoreactivity within both the 
naive and pre-disease spinal cords was only associated with the vascular 
endothelium, which was intensely stained (Figure 4.2a & b). Upon examination 
of the peak-disease spinal cords and those from rats in recovery, ADAM-17 
expression associated with blood vessels appears to be both endothelial and
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Figure 4.1 ED1 expression within naive and EAE spinal cords
!||$ggg£H  
• : •* ■'» " •?
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ED1 expression within spinal cord of naive (a) and Lewis rats with EAE (b- 
f). Naive spinal cords were devoid of any inflammatory cells and ED1 
immunoreactivity (a). Numerous inflammatory cuffs were detectably within 
the white matter of the spinal cords from peak disease (c, arrows) and 
animals in recovery (f). ED1+ cells are evident within these perivascular 
inflammatory infiltrate (d-f). Cell nuclei are counter stained with 
haematoxylin. Mag x200.
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astrocyte end-feet in origin. Within peak disease and rats in recovery phase, 
ADAM-17 immunoreactivity was also associated with the cell body and the 
elongated processes of parenchymal astrocytes and the perivascular infiltrate 
(Figure 4.2c & d). Upon examination of the spinal cord, grey matter displayed 
ADAM-17 immunoreactivity associated with the vasculature that was consistent 
between sample groups. Sections where the primary antibody was omitted 
from the protocol displayed no immunoreactivity.
4.3.2.2 TIMP3 expression in EAE and control rat spinal
TIMP3 immunoreactivity detection was assessed by both the indirect 
immunofluorescence and streptavidin/biotin methods using three 
commercially available primary antibodies to TIMP3. TIMP3 immunoreactivity 
however was not detectable due to the expression being below that of the 
detection thresholds of the techniques carried out.
4.3.2.3 Cellular localisation of ADAM-17
To determine the specific cellular localisation of ADAM-17, dual 
labelled immunofluorescence was carried out with monoclonal mouse anti- 
ADAM-17 (M222) and rabbit anti-GFAP or rabbit anti-VWF, for identification 
of astrocytes and endothelial cells respectively. Dual labelling with polyclonal 
rabbit anti-TACE antibody and anti- ED1 was used to identify the 
inflammatory macrophage expression of ADAM-17.
In EAE samples where parenchymal ADAM-17 expression was 
prevalent, GFAP and ADAM-17 immunoreactivity were co-expressed in 
astrocyte cell bodies and along their processes (Figure 4.3). ADAM-17 
expression was also in cells of the perivascular infiltrate. ED1 and ADAM-17 
immunoreactivity were co-expressed on the inflammatory cells in spinal 
cords of peak EAE and rats in recovery (Figure 4.4). VWF and ADAM-17 
immunoreactivity were observed at the vascular endothelium of all blood 
vessels from all four study groups (Figure 4.5).
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Figure 4.2 ADAM-17 expression within naive and EAE spinal cord
Naive
Single label immunofluorescent images of ADAM-17 expression (Green) within 
naTve (a) and EAE spinal cord white matter (b-d). ADAM-17 expression is 
associated with blood vessels in all naive and EAE samples (a-d arrows). At 
peak-EAE and in animals in recovery there is an abundance of ADAM-17 cells 
throughout the white matter and in the perivascular infiltrate indicated by * (e, f). 
All cell nuclei are counter stained with DAPI (Blue). Bar = 100pm.
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Figure 4.3 ADAM-17 co-localisation with the astrocytic marker GFAP in EAE
spinal cords
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Dual label immunofluorescence for (a) ADAM-17(Green) and (b) GFAP (Red) in 
EAE spinal cord white matter, (c) Co-localisation is represented by the pixels in 
quadrant 3 on graph and is demonstrated as white pixels in the composite image 
(d) following Zeiss 510 CSLM software reading of individual pixels for each 
fluorophore. Bar = 50pm.
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Figure 4.4 ADAM-17 co-localises with the macrophage marker ED1 in EAE
Intensity Ch1*T2 
250 - ■ ■ ■
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Intensity Ch2-T1
Absolute Frequency
Dual label immunofluorescence for (a) ADAM-17(Red) and (b) ED1 (Green) in 
EAE spinal cord white matter. Co-localisation is represented by the pixels in 
quadrant 3 on graph (c) and is demonstrated as white pixels in the composite 
image (d) following Zeiss 510 CSLM software reading of individual pixels for 
each fiuorophore. Nuclei in a&b are counterstained with DAPI (Blue).
Bar = 50pm.
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Figure 4.5 ADAM-17 co-locafises with the endothelial marker von
Willebrand factor in EAE
C Intensity Ch1-T2 
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Dual label immunofluorescence for (a) ADAM-17(Green) and (b) von Willebrand 
factor (Red) in EAE spinal cord white matter. Co-localisation is represented by the 
pixels in quadrant 3 on graph (c) and is demonstrated as white pixels in the 
composite image (d) following Zeiss 510 CSLM software reading of individual 
pixels for each fluorophore. Bar = 50pm.
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4.3.3 ADAM-17 and TIMP3 protein levels in EAE and control rat spinal cord
white matter
To confirm the indirect immunofluorescence findings for ADAM-17 and 
to assess TIMP3 expression in EAE CNS white matter SDS PAGE and 
western blot analysis was carried out upon extracted protein (6pg). ADAM-17 
and its natural inhibitor TIMP3 are co-expressed constitutively within both 
naive and EAE rat spinal cord white matter. Polyclonal TACE antibody 
produced a band at a molecular weight of 110 kDa whilst anti-TIMP3 was 
revealed a band at 46 kDa (Figure 4.6). Densitometric analysis of the 
western blots for ADAM-17 and TIMP3 expression in each group of 5 rats, 
shows a significant increase in integrated optical density (IOD) at peak- 
disease (p=0.016, p=0.028 respectively) compared with pre-disease. A 
significant increase was also observed in ADAM-17 (p=0.028) in recovery. 
However the increase in TIMP3 at this time point was not significant 
(p=0.27). The ratio of ADAM-17:TIMP3 was calculated from the mean lODs 
from each group and are given in table 4.3.
Table 4.3 Ratio of ADAM-17 and TIMP3 protein levels at four stages of EAE, 
as determined by western blotting.
EAE Disease 
Stage
Ratio of 
ADAM-17:TIMP3
Naive 1.58:1
Pre-disease 1.48:1
Peak-diseasse 2.10:1
Recovered 2.05:1
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Figure 4.6 Western blot analyses of ADAM-17and TIMP3 expression 
during the disease course of EAE
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Western Blot analysis of proteins extracted from rat spinal cord white matter 
homogenate for (a) ADAM-17 and (b) TIMP3 in naive (N) pre-disease (Pre), 
peak-disease (Peak) and rats in recovery (Rec) Two representative samples from 
each group are shown Graph shows the mean integrated optical density (IOD) +/- 
SEM for each group of 5 animals * Indicates statistical significant differences 
(p<0.G5) Western blotting for Actm (c) were performed as controls for sample 
loading
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4.3.4 Detection of ADAM-17 and TIMP3 mRNA at various stages of EAE 
disease course
4.3.4.1 RT-PCR
cDNA was reverse transcribed from RNA extracted from white matter 
from all of the 20 rat samples. PCR products were obtained from real-time 
PCR primers designed for ADAM-17 and commercially available primer pairs 
for TIMP3. The size of the PCR products was determined by agarose gel 
electrophoresis and found to correspond to predicted sizes. An 80bp 
fragment was produced by the ADAM-17 real-time PCR primer pair and a 
442bp fragment was produced by the TIMP3 primer pair (Figure 4.7 and 4.8).
4.3.4.2 qRT-PCR
Initially primer pair efficiency was determined by plotting log (cDNA 
dilution) against cycle threshold (CT), the slope of which was -3.3 +/- 0.1 for 
each primer pair, indicating maximal efficiency. qRT-PCR amplification of 
RNA from homogenates of EAE and normal control rat spinal cord white 
matter revealed that ADAM-17 and its natural inhibitor TIMP3 are 
constitutively and concurrently expressed at the mRNA level (Figure 4.9). 
ADAM-17 mRNA levels were shown to be significantly increased at peak- 
disease, compared with control samples, while TIMP3 mRNA levels were 
shown to be significantly decreased at peak-disease. ADAM-17 mRNA 
remained elevated in samples from rats in recovery and TIMP3 mRNA levels 
were also increased.
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Figure 4.7 RT-PCR products for ADAM-17 mRNA in naive and EAE spinal cords
at different stages of disease
RT-PCR products of 80bp for rat specific ADAM-17 real-time primer pairs 
on an ethidium bromide stained 1% agarose gel. 100bp DNA ladder was 
run in lane 1. Naive (lanes 2, 3) pre-disease (lane 4, 5), peak-disease 
(lanes 6, 7) and rats in recovery (lanes 8, 9). A negative control and a 
sample with no RT are in lanes 10 and 11 respectively.
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Figure 4.8 RT-PCR products for TIMP3 mRNA in naive and EAE spinal
cords at different stages of disease
1 2 3 4 5 6 7 8 9 10 11 12
442bp
340bp
TIMP3
RT-PCR products of 442bp for rat specific TIMP3 primer pairs on an 
ethidium bromide stained 1% agarose gel. 100bp DNA ladder was run in 
lane 1 and a positive control in lane 2. Naive (lanes 3, 4) pre-disease (lane 
5, 6), peak-disease (lanes 7, 8) and rats in recovery (lanes 9,10). A 
negative control and a sample with no RT are in lanes 11 and 12 
respectively.
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Figure 4.9 qRT-PCR analysis of ADAM-17 and TIMP3 mRNA expression in
naive and EAE rat spinal cords at different stages
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4.4 Discussion
The results presented here are the first to demonstrate the spectrum 
of distribution of ADAM-17 expression in EAE, along with a semi-quantitative 
analysis of the extent of ADAM-17 and TIMP3 protein and mRNA expression 
within the spinal cord white matter from pre-disease, peak disease and 
animals in recovery, compared with naive animals. The utilisation of a well 
documented experimental model for MS has allowed the comparison of 
ADAM-17 and TIMP3 expression at various time points throughout the 
disease course. The model used in this study was an acute EAE model in 
Lewis rats. Though it does not exhibit extensive demyelination, it does 
produce an inflammatory disorder of the CNS that leads to a decline in motor 
functions, not dissimilar to MS, allowing the mechanisms of which to be 
studied. Stages of disease progression were determined by the extent of 
clinical disability and weight loss as described previously (Ohgoh et a l,
2002) as well as using the extent of expression of the inflammatory 
macrophage marker ED1. The first objective of this study was to establish a 
reproducible protocol for the identification of ADAM-17 and its natural 
inhibitor TIMP3 by immunofluorescence in snap frozen rat spinal cord 
material. The spinal cord was analysed instead of the brain as it is the most 
susceptible region of the CNS to inflammation in EAE (Villarroya etal.,
1997). Five antibodies (4 commercial and 1 a gift) were used in conjunction 
with different fixation and detection methods. Protein expression levels of 
ADAM-17 and TIMP3 were analysed by western blotting following separation 
of protein extracts from tissue homogenates by SDS PAGE. Increased 
expression of ADAM-17 protein was observed at peak stage of disease.
Gene transcripts for these proteins were also demonstrated by reverse 
transcribing sample cDNA with commercially available rat specific primer 
pairs with semi-quantitative analysis achieved by qRT-PCR. Increased 
ADAM-17 mRNA was observed to coincide with a decrease in TIMP3 mRNA 
at peak disease suggesting an imbalance, between the enzyme and its 
inhibitor, in favour of ADAM-17 enzymatic activity.
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ADAM-17 is involved in the proteolytic cleavage of various cytokines, 
cytokine receptors, chemokines and adhesion molecules suggesting possible 
immunological and pathological roles in inflammatory CNS diseases like 
EAE. ADAM-17 is considered to be the major proteinase responsible for the 
proteolytic processing of TNF into its soluble form (Black et a/., 1997). TNF 
has been shown to be involved in the pathological events in EAE (Kassiotis 
et a/., 1999) and has been reported to be present at sites of inflammatory 
reactions in EAE and MS (Selmaj et a/., 1991; Villarroya et a/., 1997). 
However due to the pleiotropic nature of TNF it has also been reported to 
have a protective effect in EAE (Liu etal., 1998). In this present study, 
ADAM-17 immunoreactivity and mRNA levels were detected and reached a 
maximum at the peak-disease phase of EAE, which coincides with reported 
peak levels of CSF and serum TNF (Villarroya et a/., 1996).
ADAM-17 immunoreactivity is constitutively expressed during the 
disease course of EAE as demonstrated by indirect immunofluorescence. 
Morphologically, ADAM-17 immunoreactivity appeared associated with the 
microvasculature, within the spinal cord white matter of naive and disease 
animals. Additionally, ADAM-17 immunoreactivity in the spinal cords of rats 
at peak disease and in recovery was associated with white matter cells with 
astrocyte and macrophage morphology. Co-localisation of ADAM-17 
immunoreactivity with the astrocyte phenotypic marker, GFAP, the 
endothelial marker, von Willebrand factor and the inflammatory macrophage 
marker, ED1, following dual labelled immunofluorescence, clearly 
demonstrates that these cell types are responsible for ADAM-17 expression 
in EAE spinal cord white matter. These findings are in agreement with earlier 
studies on normal human CNS white matter (Goddard et al., 2001) and the 
results on MS white matter presented here (Chapter 3). The presence of 
ADAM-1 T  inflammatory cells within the perivascular cuffs is also in 
agreement with an earlier study on MS lesions (Kieseier et al., 2003) and the 
results on MS white matter presented here (Chapter 3). Astrocytes along 
with macrophage/microglial cells have been shown to be responsible for 
producing TNF in EAE and MS by immunocytochemistry (Hofman et al.,
1989; Probert and Akassoglou, 2001). ADAM-17 expression by astrocytes
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and inflammatory macrophages would allow cleavage of TNF, releasing pro- 
inflammatory soluble TNF. TNF is reported to be toxic to myelin and 
oligodendrocytes therefore the release of membrane bound TNF could 
diffuse within the CNS parenchyma and mediate demyelination (Hohlfeld, 
1997; Bitsch etal., 2000a; Probert and Akassoglou, 2001). Over-expression 
of TNF in transgenic mice has been shown to trigger CNS inflammation and 
demyelination (Akassoglou etal., 1998; Probert and Akassoglou, 2001). 
Further transgenic studies have demonstrated that TNFR p55 plays an 
exclusive role in mediating TNF-mediated oligodendrocyte apoptosis and 
primary demyelination in mice (Akassoglou etal., 2003). TNF has also been 
shown to disrupt the function of the blood brain barrier (BBB) in EAE and in 
in vitro models, as measured by an increase in surface expression of ICAM-1 
and a decrease in TER (Mayhan 2002; Dobbie et al., 1999). Thus it is 
proposed that increased ADAM-17 expression may lead to an increase in 
soluble TNF leading to subsequent BBB disruption, cellular infiltration and 
disease progression.
Cerebral endothelial cells are reported to express TNF mRNA in vitro 
and upon bacterial infection release soluble TNF into the culture media as 
measured by ELISA (Freyer et al., 1999). It is proposed that ADAM-17 
expression by glial cells in EAE and MS leads to an increase in soluble TNF 
which in turn increases the amount of membrane-bound vascular adhesion 
molecules. The increase in adhesion molecules may provide an increase in 
substrate availability for endothelial cell ADAM-17. ADAM-17 
immunoreactivity is evident at the cerebral endothelia in naive rats and 
during all the stages of EAE investigated. As it has been reported that 
adhesion molecules are increased on cerebral endothelial cells during EAE 
(Selmaj, 2000) it is suggested that either ADAM-17 is no longer functionally 
cleaving these molecules, as would occur in basal conditions, possibly due to 
an increase in TIMP3, as seen at peak disease or that the TNF induced 
increase in adhesion molecules causes saturation in the ability of ADAM-17 
to cleave these molecules.
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ADAM-17 activity is dependant on the presence of its natural inhibitor 
TIMP3, with TIMPs reported to interact with a 1:1 stoichiometry with MMPs to 
inhibit their activity (Kossakowska et al., 1998, Crocker et al., 2004). The 
levels of ADAM-17 and TIMP3 were assessed at the protein and mRNA level 
by western blotting and qRT-PCR, which demonstrated ADAM-17 and 
TIMP3 protein expression at all stages of disease. Highest levels of ADAM- 
17 protein and mRNA were observed at peak disease when inflammatory 
activity, as gauged by ED1 immunoreactivity, was also at its highest. This 
increase in ADAM-17 is in agreement with immunocytochemistry results 
which showed an abundance of ADAM-17 immunoreactive cells throughout 
the white matter and inflammatory cuffs. ADAM-17 was significantly 
increased at peak disease suggesting a role in the disease process. TIMP3 
protein expression was also increased at peak disease and in recovery 
however the extent of this increase was less than the increase recorded in 
ADAM-17. The amount of TIMP3: ADAM-17 shows a higher ratio of ADAM- 
17 at peak disease (2.01:1) compared with naive rats (1.5:1), suggesting a 
balance in favour of an inflammatory response when clinical scores are at 
the highest (Table 4.3). This appears to be the case as mRNA levels of 
ADAM-17 are increased by almost 50% at peak-disease coupled with a 50% 
decrease in TIMP3 mRNA levels. However why decreased TIMP3 mRNA 
levels coexist with increased protein TIMP3 levels at peak disease is unclear. 
If the reduction of mRNA was due to a negative feed back loop to reduce the 
production of TIMP3 you would expect there to be an increase in TIMP3 
protein prior to the reduction in mRNA, however this doesn’t appear to be the 
case. Examining TIMP3 protein and mRNA at shorter time differences 
between pre and peak disease may however reveal otherwise.
Increased ADAM-17 activity, release of TNF and lymphocytic 
infiltration has been observed in TIMPS'7'mice (Mohammed et al., 2004). 
TIMP3'7' mice spontaneously develop inflammation of the liver, similar to that 
observed in chronic hepatitis in humans, which corresponded with increased 
ADAM-17 activity in liver homogenates compared to wild-type. Soluble TNF 
is readily detected within the TIMP3'7' homogenates but not in wild-type 
(Mohammed et al., 2004). TIMP3'7' mice that were also devoid of TNFR p55 
showed no signs of inflammation while treatment of TIMP3'7' mice with
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TIMP3 prevented inflammation, suggesting that the inflammatory damage 
was due to ADAM-17/TNF activity (Mohammad et al., 2004). TIMP3 is 
suggested to be an important innate negative modulator of TNF in both 
tissue homeostasis and tissue response to injury (Black, 2004; Mohammed 
et al., 2004). However, how TIMP3 reaches its target remains unclear, as 
TIMP3 binds to the ECM components (Yu et al., 2000; Woessner, 2001; 
Black, 2004).
TIMP3 has been reported to be present in the choroid plexus and 
expressed by neurons and astrocytes in the parenchyma of normal mouse 
and rat brain (Pagenstecher et al., 1998; Vaillant et al., 1999; Jaworski and 
Fager, 2000; Crocker et al., 2004). We have shown that TIMP3 is expressed 
within both na'ive and EAE spinal cord white matter at the protein and mRNA 
level, but to date our attempts to elucidate the cellular origins of this protein 
in EAE have proved inconclusive. However In vitro studies using cerebral 
brain endothelial cell lines and primary human astrocytes (Chapter 5) have 
demonstrated TIMP3 to be expressed by these cell types.
Numerous TNF blockade studies, achieved via administration of anti- 
TNF monoclonal antibodies (MAb) or by soluble TNFRs, have been reported 
to efficiently inhibit EAE development, by neutralizing the pro-inflammatory 
properties of TNF (Baker etal., 1994; Selmaj etal., 1995; Selmaj and Raine, 
1995; Selmaj, 2000; Glabinski, etal., 2004). Subcutaneous administration of 
soluble TNFR p55 has been shown to prevent onset of EAE or a shorter and 
less severe disease course if administered upon clinical presentation of 
disease (Selmaj etal., 1995; Selmaj, 2000). Intraperitoneal injection of TNFR 
p75 has been reported to reduce the number of relapses and clinical score in 
a CREAE model (Glabinski etal., 2004). Treatment with soluble TNFR p55 is 
reported to be more potent inhibitor of TNF than TNFR p75 (Selmaj, 2000). 
TNF inhibition has proved highly successful in treating EAE however clinical 
trials of anti-TNF treatment in relapsing remitting MS proved ineffective and 
indeed exacerbated the disease (Van Oosten et al., 1996; Lenercept Study, 
1999; Sicotte and Voskuhl 2001).
Blockade of cell adhesion and transendothelial migration using anti­
adhesion molecule MAbs and glucocorticoids have been investigated with 
promising results (Cannella etal., 1995; Kent etal., 1995; Engelhardt, 2000;
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Theien et al., 2001; van der Laan et al., 2002; Pitzalis et al., 2002; Myers et 
al., 2005). Glucocorticoids are routinely administered as a treatment in MS 
and have been shown to modulate EAE disease course by regulating 
endothelial cellular adhesion molecule expression at the transcription level 
(Engelhardt, 2000; Pitzalis et al., 2002; Dietrich, 2004). MAbs to VLA-4 have 
been reported to reverse BBB changes, as gauged by MRI, in an acute EAE 
model in guinea pigs (Kent etal., 1995). Encouraging results taken from the 
anti-VLA-4 MAb treatment of EAE have been successfully applied to 
humans. The Natalizumab clinical trial in relapsing remitting MS was 
effective in reducing the relapse rate (Miller etal., 2003). However following 
reports of progressive multifocal leukoencephalitis (PML) in two patients 
receiving dual therapy in the trial, Tysabri (Natalizumab) was withdrawn at 
the end of February 2005 (Kleinschmidt-DeMasters and Tyler, 2005; Berger 
and Koralnik, 2005). Care needs to be taken by researchers when 
extrapolating EAE data with respect to MS, as EAE is a well characterised 
disease that can be readily induced, monitored and controlled in inbred 
animals. MS however, has multiple disease courses and possibly multiple 
etiologies that occurs in out bred populations. Despite this, studies using 
EAE models may indicate mechanisms occurring in the pathogenesis of MS. 
The work here points to a possible role for ADAM-17 in the pathogenesis of 
EAE especially influencing the inflammatory reactions at the BBB. As such 
ADAM-17 may be a potential alternative therapeutic target for the treatment 
of MS.
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Chapter 5
Expression and regulation of ADAM-17 and TIMP3 in 
endothelial cells in vitro
5 .1 1ntroduction
5.1.1. In vitro cultures of cerebral endothelial cells
Ethical issues and constraints in access to tissue, means that in vitro 
models of primary cells are predominantly either bovine, porcine or rat 
(Rubin etal., 1991; Franke etal., 2000; Demeuse etal., 2002). Primary brain 
capillary endothelial cells can be cultured on collagen coated culture flasks 
and after approximately 9 days are ready for experimental use (Franke et al., 
2000; Gumbleton and Audus, 2001). Primary cultures contain many 
similarities with the in vivo BBB endothelial cells, with the presence of 
endothelial antigens, adhesion molecules, TJ associated proteins and drug 
transporter systems. Functionally however, in vitro primary cells have a far 
lower TEER (160-200Qcm2) in comparison to in vivo (1000-5000Qcm2) and 
show an approximately 100 fold increase in sucrose permeability (Gumbleton 
and Audus, 2001). The use of co-cultures and conditioned media systems 
using primary porcine and rat astrocytes, astroglioma cells (C6) and brain 
pericyte cells and cell lines have been investigated as a means of 
establishing a more appropriate BBB model (Rubin etal., 1991; Rauh etal., 
1992; Wolburg e ta l 1994; Cecchelli etal., 1999; Gumbleton and Audus, 
2001; Jeliazkova-Mecheva and Bobilya, 2003; Terasaki etal., 2003; Kraus et 
al., 2004). These systems show an increase in TEER with a decrease in the 
paracellular permeability of sucrose. Removal of astrocytes from bovine 
brain capillary endothelial cell co-cultures returns the paracellular 
permeability to the high level recorded prior to co-culture (Kraus et al., 2004). 
However treatment with IFN-p enables the endothelial cells to maintain the 
low permeability even after removal of the astrocytes (Kraus et al., 2004). It 
is reported however that the intra- and inter- batch reproducibility of results, 
poor life span of the cells plus the genetic differences across species, does 
not make these ideal BBB models (Gumbleton and Audus, 2001).
GP8 cells are a cerebral endothelial cell line that has been derived from 
Lewis rats (Greenwood etal., 1996). GP8 cells have been shown to retain 
their phenotypic and immunological characteristics in vitro (Greenwood, et 
al., 1996; Harkness etal., 2000; 2003). GP8 cells are reported to express 
von Willebrand factor, P-glycoprotein and platelet endothelial cell adhesion
176
molecule. ICAM-1 expression can be up-regulated as can VCAM-1 and 
MCP1 expression following cytokine stimulation (Greenwood etal., 1996; 
Etienne-Manneville et al., 2000; Harkness et al., 2003).
ADAM-17 is constitutively expressed by the cerebral endothelium and 
astrocytes in normal control and MS white matter and also in the spinal cord 
white matter of Lewis rats with EAE, as described in chapters 3 and 4. As 
described in chapter 1, cytokines are critical components of the immune 
inflammatory process and have been implicated in the disease onset and 
progression in MS and models of EAE (Brosnan, etal., 1995; Imitola, etal., 
2005). To confirm the type of cells expressing ADAM-17 and to determine 
whether pro-inflammatory cytokines regulate expression levels of ADAM-17, 
and T IM P 3 ,  GP8 cells were stimulated with IF N y , T N F ,  T N F / IF N y  combined 
and LPS in vitro.
5.1.2 Aim of study
Endothelial cells and astrocytes have been shown to express ADAM- 
17 in normal control white matter and in the spinal cord white matter of Lewis 
rats. During the disease processes of MS and EAE, ADAM-17 is upregulated 
(Chapters 3 and 4) therefore it is important to elucidate the significance of 
ADAM-17 modulation with respect to inflammatory conditions. The aim of this 
study was to confirm that both astrocytes and GP8 cells express ADAM-17 in 
vitro and to determine the sub-cellular localisation of the protein and to 
assess whether pro-inflammatory cytokines can increase the expression of 
ADAM-17. Any functional consequences of increased ADAM-17 expression 
on TNF shedding were also examined. ADAM-17 activity may also be 
affected by changes in TIMP3 thus the expression of this natural inhibitor 
was also examined.
The major objectives addressed were:
(i.) To confirm the in vivo observation that astrocytes and endothelial cells 
express ADAM-17 in vitro.
(ii.) To determine whether these cells express TIMP3 in vitro.
(iii.) To examine the effect of pro-inflammatory conditions on ADAM-17, 
and TIMP3 protein expression in GP8 cells.
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(iv.) To determine whether GP8 cells release TNF under pro-inflammatory 
conditions.
5.2 Materials and methods
All cell culture reagents were obtained from Invitrogen unless stated 
otherwise. GP8 cells were a kind gift from Prof J Greenwood (University 
College London, London, UK). Primary human astrocytes were isolated from 
adult temporal lobe resections carried out at King's College Hospital, London 
(Flynn et al., 2003) and were obtained with ethical approval from Dr I 
Romero (Open University, Milton Keynes, UK).
5.2.1 Cell cultures
Rat cerebral endothelial cell line (GP8) and primary human astrocyte 
cultures were grown at 37°C in a 5% C02/95% air, humidified atmosphere. 
GP8 cells were maintained in MEM/Ham’s F10 medium (1:1 v/v) 
supplemented with 10% heat inactivated fetal calf serum, penicillin (100U/ml) 
and streptomycin (100pg/ml) (PenStrep) and geneticin (200pg/ml). GP8 cells 
were grown on collagen coated cell cultureware (see below). Primary human 
astrocytes were maintained in MEM/Ham’s F10 medium supplemented with 
10% fetal calf serum, L-glutamine (2mM), fungizone (2.5/yg/ml) and 
PenStrep. Culture media were changed every three days until cells became 
confluent, at which time they were then subcultured for experimental use or 
to maintain growth and stock levels. All cultures were grown with plasmocin 
(5pg/ml) to prevent mycoplasma contamination.
5.2.1.1 Collagen coating
It was essential to grow GP8 cells on collagen coated cellculture ware. 
Cultureware (flasks, coverslips or well plates) were incubated in 0.1% 
collagen solution from calf skin (Sigma), diluted 1:20 in Hank’s balanced salt 
solution (HBSS), for 2 hours at room temperature (RT). Excess collagen was 
removed by sterile aspiration and the culture ware was washed three times 
in sterile HBSS. Once coated the culture ware was maintained in HBSS at 
4°C until ready for use, for up to 7 days.
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5.2.1.2 Subculture
Upon reaching confluence, cultures were subcultured using trypsin 
EDTA solution (1mM EDTA and 2.5g/L of trypsin). 5mls of trypsin-EDTA 
solution was added to culture flasks where the cells were incubated at 37°C 
for five minutes until cells detached from the flasks. Cells were centrifuged 
for 10 minutes at 1000rpm (Sorvall RT7 plus) at RT. The resulting cell pellets 
were resuspended in the appropriate growth media and plated at a 1:10 split 
ratio. Growth media was changed the day after subculture and every three 
days thereafter.
5.2.1.3 Culture on coverslips
To enable immunocytochemical analyses, cells were grown on 13mm 
diameter glass coverslips (BDH) in the wells of sterile 6 well plates (3 
coverslips per well). Coverslips were stored in 70% ethanol until required. 
Coverslips were removed from the ethanol and allowed to air dry for 20 
minutes prior to collagen coating and introduction of the cells.
5.2.2 Indirect immunofluorescence staining
Cells on coverslips were removed from the media and washed 
through two changes of PBS and were then fixed in either ice-cold acetone 
or 4% paraformaldhyde at RT for 5 minutes. Acetone fixed cells were 
allowed to air dry for at least 15 minutes prior to use or storage at -20°C. 
Following paraformaldehyde fixation, cells were washed and stored in PBS. 
To enable permeablisation of the cells for intracellular staining following 
paraformaldehyde fixation, all antibodies were diluted in 0.5% Triton X-100 
(Sigma) in PBS.
The GP8 endothelial cells and primary human astrocytes were 
labelled for specific phenotypic markers by indirect immunofluorescence.
GP8 cells were labelled for VWF and primary human astrocytes for GFAP 
using polyclonal rabbit anti-human VWF (1:50) and rabbit anti-cow GFAP 
(1:100) respectively. Cells were incubated in primary antibody for 1 hour at 
37°C and then washed three times, 5 mins each, in PBS. Cells were then 
incubated in Alexa 488 conjugated goat anti-rabbit IgG (1:500, Molecular 
Probes) for 1 hour at 37°C. Following a further 3 x 5  minutes washes in PBS,
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cell nuclei were counterstained by mounting in a Vectashield mounting 
medium containing DAPI (Vector Labs). Alternatively cell nuclei were 
counterstained by incubating in propidium iodide in PBS (1:30,000, Sigma) 
for 15 seconds. Cells were then washed in PBS and mounted in the non­
fading mountant, citifiuor (See appendix).
Ice cold acetone and 4% paraformaldehyde fixed cells were labelled 
for ADAM-17 using monoclonal human anti-mouse M222 (1:100, Amgen, 
USA), and the polyclonal antibodies goat anti-rabbit TACE (1:50, Abeam) 
and goat anti-rabbit TACE C15 (1:20, Santa Cruz) using the indirect 
detection method described above. Monoclonal M222 was detected by 
incubating the cells in FITC-conjugated rabbit anti-mouse IgG (1:50, Dako) 
for 1 hour at 37°C. Cells were labelled for the cytoskeletal markers (3-tubulin, 
vimentin, and actin as well as the Golgi apparatus, Table 5.1 provides the 
details of the primary antibodies used in this study and the secondary 
antibodies used were the same as above for either monoclonal or polyclonal 
antibodies.
5.2.2.1 Dual label immunofluorescence to determine the sub-cellular 
localisation of ADAM-17 in GP8 endothelial cells
Dual label immunofluorescence was performed on cells to determine 
the sub-cellular localisation of ADAM-17 following the protocol described 
previously in section 3.2.2. GP8 endothelial cells were dual labelled with 
monoclonal anti-ADAM-17 antibody (M222) together with polyclonal anti- 
anti-tubulin and anti-vimentin antibodies and Alexa 568 conjugated 
phalloidin. Furthermore the polyclonal goat anti-rabbit TACE (Abeam) 
antibody was dual labelled with a monoclonal anti-Golgi antibody.
5.2.2.2 Imaging
All images were obtained using the Zeiss 510 confocal scanning laser 
microscope as described previously in section 3.2.3.
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Table 5.1 Primary antibodies used for immunocytochemistry in the
cell culture study
IB H H M H IttH l u n
Tubulin M (3-Tubulin cytoskeleton, 
human/rat/mouse
1 in 50 Pharmingen
Phalloidin
568*
Conjugated Actin cytoskeleton 1 in 40 Molecular Probes
Vimentin M Vimentin cytoskeleton, 
human/rat
1 in 50 Dako
Golgi M Golgi apparatus, 
human/rat/mouse
1 in 50 Abeam
TACE P ADAM-17,
human
1 in 50 Abeam
M222 M ADAM-17,
human
1 in 100 Amgen
TIMP3 M TIMP3,
human
1 in 100 Calbiochem
TIMP3 M TIMP3,
human
1 in 50 Oncogene
TIMP3 P TIMP3,
human
1 in 50 Abeam
VWF P Endothelial cells 
human/rat
1 in 50 Dako
GFAP P Astrocyte,
human/rat/mouse
1 in 100 Dako
’ -  v -■ . r
GFAP = glial fibrillary acidic protein 
VWF = Von Willebrand Factor 
M = mouse monoclonal antibody 
P = rabbit polyclonal antibody
* = Phalloidin is a phallotoxin isolated from the deadly Amanita phalloides 
mushroom that efficiently labels F-actin (Small e ta !., 1999).
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5.2.3 Cytokine stimulation of GP8 endothelial cells
GP8 cells were grown in collagen coated T-25 culture flasks. Upon 
reaching approximately 90% confluence, the cells were incubated in serum 
free media for 24 hours containing TNF, IFNy and combined TNF/IFNy rat 
specific recombinant cytokines (Peprotech, London, UK) at concentrations of 
1ng/ml, 10ng/ml and 100ng/ml. After 24 hours, the supernatant was removed 
and stored at -20°C and the protein and RNA were extracted from the cell 
lysates as described below in section 5.2.4. As a control, cells were also 
grown in serum free media without any stimulation from cytokines. All 
stimulation experiments were performed in triplicate.
5.2.4 Protein extraction
Following the removal of the cell culture supernatant, 500pl of an 
extraction buffer (5mM Tris-base, 26mM Tris-HCL, 1.25mM EDTA, pH 7.5) 
containing a cocktail of protease inhibitors (Roche) was applied to a T-25 
flask of cells and a cell suspension was obtained using a cell scraper. The 
cell suspension was homogenised by repeat pipetting and incubated on ice 
for 1 hour. Cell homogenates were vortexed every 10 minutes. After the 1 
hour incubation on ice, cell homogenates were centrifuged at 12000rpm 
(Sorvall RT7 plus) for 10 minutes at 4°C and the supernatant containing cell 
lysate was removed from the pellet and protein estimation was carried out 
using the BCA assay as described previously in section 3.2.6.1.
5.2.4.1 Western Blot
Extracted protein was added to sample buffer 1:1 (v/v) and the 
protein was denatured at 60°C for 30 minutes. 6pg of each protein sample 
was loaded onto pre-cast 10% BisTris gels (Invitrogen) and subjected to 
SDS PAGE and western blotting as described previously in section 3.2.7. 
Quantitative analysis was carried out by comparing the IOD using 
densitometric software of the UVP Bioimaging system. Group means of lODs 
were obtained, with control samples being the baseline of 100% and any 
significant differences determined using the two-tailed t test (p<0.05). The 
statistical analysis was carried out using Microsoft Excel.
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5.2.5 TNF enzyme linked-immuno-sorbent assay
Principle of method
The enzyme linked-immuno-sorbent assay (ELISA) used in this study 
is a solid phase sandwich ELISA. A rat specific TNF antibody is pre-coated 
onto the wells of the microtiter strips. Any rat specific TNF antigen within the 
test sample binds to the bound TNF antibody and is then labelled with a 
biotinylated antibody against TNF. A streptavidin-peroxidase solution binds 
to the biotinylated antibody completing a four-member sandwich. A substrate 
solution is added, which is acted upon by the bound enzyme to produce a 
colour that is directly proportional to the concentration of rat TNF present 
within the test sample, detected at 450nm in a plate reader. TNF standards 
of known concentrations are run on the same plate to produce a standard 
curve from which levels of TNF in cell culture supernatants can be 
determined.
Method
Supernatants, removed prior to protein and RNA extractions, were 
concentrated using a 10MW centricon centrifugal filtering device (Millipore). 
The original 7ml of supernatant was reduced 14 fold to 500pl prior to 
measurement of TNF by ELISA (Biosource), by centrifuging samples at 
2000g (Sorvall Legend RT) for 5 hours at 4°C. All samples were run in 
duplicate. All solutions used in the ELISA protocol were supplied within the 
kit unless otherwise stated.
Briefly, 50pl of incubation buffer was added to each well. 100pl of TNF 
standards were added to designated wells in duplicate, while 50pl of sample 
and 50//I standard diluent buffer were added into test wells. 50pl of a 
biotinylated anti-TNF antibody solution was added to each well and 
incubated for 90 minutes at RT. Solutions were removed from all wells which 
were then washed for 4 x 30sec in 400pl wash buffer. Excess wash buffer 
was removed by firm tapping of the wells onto paper towel. Wells were then 
incubated in 100pl of Streptavidin-HRP for 45mins followed by a further 4 x 
30sec washes with 400pl wash buffer. Wells were incubated in 100pl of
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stabilized chromogen (Tetramethylbenzidine) for 30mins at RT in the dark, 
which resulted in the formation of a blue product. To stop the reaction, 100pl 
of stop solution was added to each well resulting in a yellow colour. 
Absorbance of each well at 450nm was recorded using a Wallac Victor2 1420 
multilabel counter plate reader.
To distinguish between added and synthesised TNF, media containing TNF 
was examined along with supernatants from cells treated with TNF.
5.3 Results
5.3.1 Characterisation of cell cultures
GP8 cells were morphologically homogeneous and appeared as long 
thin spindle like cells (Figure 5.1a). The primary human astrocytes displayed 
a more heterogeneous morphology from bipolar to process bearing cells. 
Upon reaching confluence the primary human astrocytes formed a tightly 
packed population with few processes (Figure 5.1.c). GP8 cells expressed 
immunoreactivity for von Willebrand factor, a phenotypic marker for 
endothelial cells (Figure 5.1 b). The primary human astrocytes were 
immunoreactive for the intermediate filament protein, GFAP, which is a 
phenotypic marker for astrocytes (Figure 5.1d).
5.3.2 ADAM-17 and TIMP3 expression within cell cultures
The presence of ADAM-17 and TIMP3 within both cell types was 
investigated using immunocytochemistry and western blotting.
5.3.2.1 ADAM-17 expression in cell cultures
ADAM-17 immunoreactivity was expressed by both the cerebral 
endothelial cells and primary astrocytes following both acetone or 
paraformaldehyde fixation and detection by indirect immunofluorescence.
The distribution of ADAM-17 immunoreactivity was consistent when 
comparing staining with the monoclonal anti-ADAM-17 and the polyclonal 
antibody (TACE from Abeam) for both cell types (Figure 5.2 a & b).
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Figure 5.1 Characterisation of GP8 endothelial and primary human
astrocyte cell cultures
Phase contrast (a, c) and single label immunofluorescent images (b, d) 
showing the morphology and phenotypic makers of GP8 (a, b) and primary 
human astrocyte cells (c, d). Note the vesicular staining pattern of VWF 
(arrows b insert). Cell nuclei are counter stained with DAPI (b, d).
Bar = 100pm (a) and 50pm (b-d).
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Figure 5.2 Single label immunofluorescence for ADAM-17 and cytoskeletal 
markers in GP8 endothelial cells and 1° human astrocytes
Single label immunofluorescence on GP8 cells (a, c, e, f) and primary 
human astrocytes (b, d) for ADAM-17 (a, b), and the cytoskeletal markers 
phalloidin (c), vimentin (d) and tubulin (e) and the Golgi apparatus (e).
Cell nuclei are counterstained with propidium iodide (a, Red) and DAPI 
(b, c, e, f, Blue). Bar = 50pm (a-e) 25pm (f).
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Examination of CSLM z-stacks by the deconvolution software, Velocity 3.0, 
displayed cell surface ADAM-17 expression (Figure 5.3b) along with 
intracellular ADAM-17 expression throughout the thickness of the z-stack 
(Figure 5.3.c). ADAM-17 immunoreactivity appeared fibrillary with a 
cytoskeletal morphology thus dual label immunofluorescence was performed 
with Alexa 568 conjugated phalloidin and antibodies to tubulin and vimentin, 
to determine the specific cytoskeletal localisation of the ADAM-17 expression 
(Figure 5.4 and 5.5). Using the co-localisation software of the Zeiss 510 
CSLM revealed ADAM-17 expression was associated with the actin filaments 
(Figure 5.4). Dual label immunofluorescence was also carried out with 
ADAM-17 and antibodies to detect beta tubulin and the Golgi apparatus 
however no co-localisation was detected by this method (Figure 5.5).
Further evidence for the presence of ADAM-17 protein in both 
cerebral endothelial cell and primary human astrocytes was obtained using 
SDS PAGE and western blotting of cell lysates. Western blotting using the 
monoclonal ADAM-17 antibody consistently gave bands at 80 kDa (Figure
5.6).
5.3.2.2 TIMP3 expression in cell cultures
Attempts to identify the cellular localisation of TIMP3 by 
immunocytochemistry have proved inconclusive as no immunoreactivity was 
identified using three commercially available antibodies and detection by the 
indirect and biotin-avidin methods. TIMP3 protein expression as observed 
following SDS PAGE and western blotting suggests thatTIMP3 
immunoreactivity may be at a level below the detection threshold of these 
methods or that the epitope is not accessible or is destroyed following 
acetone and 4% paraformaldehyde fixation.TlMP3 protein expression 
however is constitutive in both cell cultures investigated by western blotting. 
TIMP3 was represented by a band at 46 kDa using the monoclonal antibody 
from Oncogene (Figure 5.6).
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ADAM-17 immunoreactivity (Green) in 4% paraformaldehyde fixed GP8 
endothelial cells a-c. CSLM z-stacks were deconvoluted using Velocity software to 
enable 3D manipulation of the z-stacks in the x, y and z planes (green, red and 
blue arrows b & c). ADAM-17 immunoreactivity is detected along the cell surface 
over the nuclei of the cells (white arrow b). Cross-section of cells demonstrates 
ADAM-17 immunoreactivity throughout the thickness of the cell (white arrow c). 
Cell nuclei are counterstained with propidium iodide (Red). Scale bar » 50pm 
One white grid unit = 23.1pm.
Figure 5.3 Cellular localisation of ADAM-17 in GP8 endothelial cell cultures
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Figure 5.4 ADAM-17 co-localises with actin filaments in GP8 endothelial cells
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CSLM image of GP8 cells dual labelled for ADAM-17 (a) and actin (b) with the cell 
nuclei counterstained with DAPI (Blue). Co-localisation analysis shows co-localised 
pixels in quadrant 3 (c) and ADAM-17 expression co-localising with the actin filaments 
as white pixels in the composite image (d). Bar = 50pm
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Figure 5.5 Dual label immunofluorescence for ADAM-17 and markers for Golgi apparatus and tubulin in GP8 endothelial cells
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Figure 5.6 ADAM-17 and TIMP3 protein expression in GP8 endothelial 
and primary human astrocyte cell cultures
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a. ADAM-17
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b. TIMP3 '*** ' OM U 48kDa
’
Western blots showing constitutive expression of (a) ADAM-17 and (b) 
TIMP3 in GP8 endothelial cell cultures and primary human astrocytes.
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5.3.3 Cytokine regulation of ADAM-17 and TIMP3 expression in GP8 
endothelial cells
GP8 cells were stimulated for 24hrs in serum free culture media that 
contained the pro-inflammatory cytokines IFNy and TNF. TNF and IFNy 
stimulation of GP8 cells resulted in a small significant increase in ADAM-17 
protein expression (p < 0.05) when assessed by western blotting (Figure
5.7). When GP8 cells were incubated simultaneously in both IFNy and TNF, 
a marked increase was observed following 1ng/ml and 10ng/ml (p < 0.0001), 
however a reduction in ADAM-17 expression was observed following 
concentrations of 100ng/ml compared with control (p < 0.01) (Figure 5.7). 
Immunoreactivity for ADAM-17 in GP8 cells no longer appeared associated 
with the actin cytoskeleton following 24 hour stimulation in pro-inflammatory 
conditions and showed a diffuse cytoplasmic distribution (Figure 5.8).
Following stimulation by pro-inflammatory cytokines TIMP3 protein 
expression levels were reduced compared to unstimulated controls when 
assessed by western blotting (Figure 5.9). Reduction ofTIMP3 protein levels 
were only significant following treatment with TNF at 1ng/ml and IFNy at 
10ng/ml (p < 0.05).
5.3.4 Cytokine regulation of TNF release by GP8 cells
The release of soluble TNF by GP8 endothelial cells was analysed by 
ELISA to determine ADAM-17 activity by GP8 cells following cytokine and 
LPS stimulation. Supernatant from GP8 cells incubated in serum free media 
for 24 hours was devoid of any soluble TNF. TNF was also not detected 
within the supernatant from cells stimulated with IFNy for 24 hours. 
Stimulation of GP8 cells with LPS produced soluble TNF within the 
supernatant in a dose dependent manner, up to a maximum of 250pg/ml. 
Stimulation of GP8 endothelial cells with TNF induced TNF shedding that 
was not influenced by simultaneous stimulation with TNF and IFNy (Figure 
5.10). To differentiate between added TNF and GP8 synthesized TNF, media 
with TNF that was incubated in T-25 flasks devoid of cells for 24 hours, were 
also analysed by ELISA. The amount of TNF within these control samples 
were more than 50% less than those recorded for the GP8 TNF stimulated 
samples (Figure 5.10).
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Figure 5.7 ADAM-17 expression in GP8 cells following pro-inflammatory
stimulation
a
b
c
Bar graphs illustrating the extent of ADAM-17 expression in GP8 cells 
following incubation for 24hrs in a. TNF, b. IFNy and c. TNF/IFNy. Amount of 
ADAM-17 protein is expressed as a percentage of the unstimulated control 
IOD +SD. * indicates significant difference between the means using student 
t-test p £ 0.05.
Control 1 10 100
TNF jng/m I)
Control 1 10 100
IFNy (ng/ml)
Control
TNF/IFNy (ng/ml)
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Figure 5.8 ADAM-17 expression by 6P8 endothelial cells under control and
inflammatory conditions
Control
ADAM-17 expression (Green) in GP8 endothelial cultures under basal 
control conditions and after 24hr stimulation with b. LPS, c. IFNy and d. 
TNF. Note that ADAM-17 expression relocates from the cytoskeleton under 
control conditions to a more perinuclear location under inflammatory 
conditions. Cell nuclei are counter stained with DAPI (Blue).
Bar « 50pm
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Figure 5.9 TIMP3 expression in GP8 cells following pro-inflammatory
stimulation
a  _
120
Control 1 10 100
TNF (ng/m I)
Control 1 10 100
IFNy (ng/ml)
Control 1 10 100
TNF/IFNy (ng/ml)
Bar graphs illustrating the extent of TIMP3 expression in GP8 cells following 
incubation for 24hrs in a. TNF, b. IFNy and c. TNF/IFNy. Amount of TIMP3 protein is 
expressed as a percentage of the unstimulated control IOD +SD.
* indicates significant difference between the means using student t-test p £ 0.05.
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Figure 5.10 Release of soluble TNF from GP8 endothelial cells following 
pro-inflammatory stimulation
TNF EUSA
C 2.5
y = 0.0023x + 0.2018 
R2 *  0.9816
200 400 600 800
Cone of TNF(pg/ml)
1000 1200
~~—
|  200 
OJ
£ 150 z
* 100 
!  -
Sample
Stimulated release of soluble TNF from GP8 endothelial cells as detected 
using an ELISA. The absorbance of samples and TNF standards (15.6pg/ml to 
1000pg/ml) were read at 450nm and sample TNF concentrations were 
calculated from the standard curve (a). Samples of media containing TNF that 
was never introduced to GP8 cells(*) were also analysed to differentiated 
between synthesized TNF and added TNF.
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5.4 Discussion
In human control and MS autopsy material (Chapter 3) and within the 
spinal cords of Lewis rats with EAE (Chapter 4) ADAM-17 immunoreactivity 
was shown to be associated with the endothelium of the CNS vasculature as 
well as white matter astrocytes. In this chapter, in vitro studies were 
performed to assess constitutive ADAM-17 expression following pro- 
inflammatory cytokine treatment in an attempt to mimic the environment seen 
in the CNS during MS to support the in vivo findings. ADAM-17 was 
expressed by primary human astrocytes and rat cerebral endothelial cells 
(GP8) as determined by immunofluorescence and western blotting. The in 
vivo observation that TIMP3 was constitutively expressed within human 
control white matter and the spinal cord white matter of naive Lewis rats, was 
confirmed in vitro as TIMP3 was shown to be expressed by both primary 
human astrocytes and GP8 endothelial cells, suggesting the source of 
TIMP3 in the CNS is astrocytes and endothelial cells however other cell 
types may also produce TIMP3.
GP8 cells are an immortalised endothelial cell line derived from the 
brains of Lewis rats (Greenwood et al., 1996) and therefore provided a 
suitable resource for the investigation of possible cytokine regulation of 
ADAM-17 and TIMP3 that may have occurred in EAE and by inference in 
MS. Other in vitro studies have investigated ADAM-17 expression within a 
human monocyte cell line (THP-1), human acute T leukaemia cells (Jurkat) 
and a kidney cell line from the African green monkey (COS-7) (Schlondorff et 
al., 2000; Peiretti etal., 2003; Srour et al., 2003). Mature and immature 
ADAM-17 have been reported to coexist on the surface of THP-1 COS-7 and 
Jurkat cell cultures (Doedens and Black, 2000; Schlondorff et al., 2000; 
Endres et al., 2003; Doedens et al., 2003; Peiretti et al., 2003) following 
immunoprecipitation. Examination of ADAM-17 expression by 
immunofluorescence has reported diffuse staining, consistent with surface 
and endoplasmic reticulum staining, with the majority of ADAM-17 
immunoreactivity reported to be localised within an intracellular perinuclear 
compartment (Schlondorff et al., 2000). This is in contrast to what was 
observed following immunofluorescence detection of ADAM-17 in GP8 
endothelial cell cultures under basal conditions, as reported here. ADAM-17
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localisation within these cells appeared to be cytoskeletal as well as diffuse 
cytoplasmic and on the cell surface. Deconvolution of confocal z-stacks, 
indicated ADAM-17 immunoreactivity associated with the cell surface of GP8 
cells. Following stimulation with PMA and LPS, ADAM-17 expression is 
reported to disappear from the cell surface of THP-1 cells and become 
internalised, as evidenced by immunofluorescence (Doedens and Black, 
2000; Endres et al., 2003; Doedens et al., 2003; Robertshaw and Brennan, 
2005). This relocation of ADAM-17 to the cytoplasm was observed here after 
stimulation of GP8 cells with LPS, T N F  and IF N y  (all at 10ng/ml) with a loss 
of the cytoskeletal ADAM-17 staining. Whether or not there is some 
functional importance to this sub-cellular location of ADAM-17 remains 
unclear, however the transmembrane domains of the adhesion molecules, E- 
selectin and I CAM-1 are reported to be associated with actin filaments and 
may point towards a possible intracellular function for ADAM-17 (Amos et al., 
2001; Vandenberg et al., 2004).
Relocalizing of ADAM-17 to the trans-Golgi is of functional importance 
as it is here that it is needed to processes substrates such as TNF (Moss et 
al., 2001). ADAM-17 has been reported to mature within the late Golgi 
apparatus by furin orfurin-like cleavage of the prodomain (Endres etal., 
2003; Srour et al., 2003), however co-localisation of antibodies to ADAM-17 
and the Golgi apparatus was not observed in GP8 cells. ADAM-17 
membrane expression by monocytes is at its maximum in basal conditions, 
however it is rapidly lost from the surface when enzymatic activity is maximal 
(Robertshaw and Brennan, 2005). In contrast to these findings LPS is 
reported to have no effect on the ADAM-17 surface expression on THP-1 
cells in culture (Doedens and Black, 2000).
TIMP3 is an endogenous inhibitor of MMPs and is the only TIMP that 
is able to inhibit ADAM-17 (Black, 2004). TIMP3 has been demonstrated to 
inhibit the release of TNF in vitro (Lee et al., 2002b). TIMP3 has been 
previously reported to be expressed by cultured rat brain microvascular 
endothelial cells and astrocyte cultures in vitro (Bugno etal., 1999; Muir et 
al., 2002) which is in agreement with the observation of TIMP3 protein
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expression by GP8 endothelial cells and primary human astrocytes found in 
the present study.
Following incubation of GP8 endothelial cells in a pro-inflammatory 
environment for 24 hours in vitro, TIMP3 protein expression was shown here 
to be reduced by approximately 20% by both TNF and IFNy. This is in 
concordance with a previous in vitro study that demonstrated TIMP3 to be 
reduced following treatment of cultured microvasculature endothelial cells 
with TNF and IFNy stimulation (Bugno et al., 1999). A decrease in TIMP3 
expression by the cerebral endothelium may result in a balance in favour of 
ADAM-17 enzymatic activity, which may have a detrimental effect in MS 
disease progression. TIMP3 expression by endothelial cells may also play a 
role in BBB breakdown due to its role in ECM remodelling (Crocker etal.,
2004). TIMP3 regulates the activities of MMP9 and MMP2 which have been 
associated with BBB breakdown, therefore a reduction in cerebral 
endothelium TIMP3 expression could lead to BBB breakdown (Rosenberg et 
al., 1998).
Both TNF and IFNy have been shown to play a role in the 
pathogenesis of MS and EAE (Raine, 1995; Glabinski etal., 2003). In vitro 
studies have demonstrated that TNF potentiates the toxicity of IFNy 
(Andrews et al., 1998). Treatment of GP8 cells here with TNF and IFNy 
resulted in approximately a 40% increase in ADAM-17 protein expression 
compared to basal levels of unstimulated cells. This is in concordance with a 
recent in vitro study that reported TNF, IFNy and IL-ip being able to up- 
regulate the transcription of ADAM-17 and also the expression of ADAM-17 
protein in murine brain and human microvascular endothelial cell cultures 
(Bzowska et al., 2004). This TNF-induced increase in ADAM-17 was also 
reported to be accompanied by an increase in ADAM-17 enzymatic activity 
as measured by the shedding of TNFRp55 from the endothelial cell surface 
(Bzowska et al., 2004). The increase in ADAM-17 protein expression in vitro 
coupled with the decrease in TIMP3 further suggests a balance in favour of 
ADAM-17 enzymatic activity under inflammatory conditions that was 
observed during the peak phase of EAE (Chapter 4). However ADAM-17 
mRNA expression levels in HUVECs did not alter following treatment with
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LPS and IL-1a (Imaizumi etal., 2000). ADAM-17 is also reported to remain 
unchanged following TNF stimulation in human colonic epithelial cell lines 
(Kirkegaard et al., 2004).
TNF, produced mainly by macrophages but also by microglial cells 
and astrocytes, is a powerful activator of endothelial cells (Franzen et al., 
2003). Characteristics of endothelial cells as a target for the actions of TNF 
have been well described however endothelial cells as a source of TNF is 
less definitive (Freyer etal., 1999; Imaizumai etal., 2000). Cerebral 
endothelial cells have shown immunoreactivity for TNF in MS (Cannella and 
Raine, 1995; Brosnan etal., 1995). TNF has been shown to be released 
from primary cultures of BMEC from Wistar rats, while its expression, protein 
and mRNA, is induced in HUVEC by treatment with LPS and IL-1 a (Freyer et 
al., 1999, Imaizumi etal., 2000). ADAM-17 is responsible for the proteolytic 
release of TNF by endothelial cell cultures in vitro, following treatment of 
cultures with an ADAM-17 inhibitor decreased levels of TNF secreted by 
HUVEC was reported (Imaizuni et al., 2000). GP8 cells are shown here to 
release TNF following stimulation with TNF and LPS however treatment with 
IFNy did not induce TNF release by GP8 cells, as detected by ELISA. 
Following these initial experiments TNF release by GP8 cells however 
cannot be definitively attributed to the actions of ADAM-17. TNF is reported 
to be manufactured as a membrane bound protein that becomes soluble 
upon proteolytic cleavage from the cell membrane. Although ADAM-17 is 
reported to be the main proteolytic convertase of TNF, ADAM-10 is also 
biologically capable of cleaving TNF (Black etal., 1997, Moss etal., 1997). 
To determine whether the soluble TNF observed within the current ELISA 
experiments is due to ADAM-17, repeated experiments pretreating the GP8 
cells with anti-ADAM-17 MAb or with a specific ADAM-17 protease inhibitor, 
would allow comparisons to be drawn and to elucidate whether ADAM-17 is 
responsible for TNF release in GP8 endothelial cells.
The importance of ADAM-17 in the control of TNF is not only in the 
production of soluble TNF but also in the removal of membrane bound TNF 
which has its own biological activities (Robertshaw and Brennan, 2005). TNF
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is manufactured as a membrane bound form (mTNF) that is biologically 
active and has been reported as being capable of mediating cellular 
responses such as proliferation, apoptosis and some inflammatory 
responses (Grell et al., 1995; Gerspach et al., 2000). Also important is the 
ADAM-17-dependant cleavage of TNFR p55 which when released is able to 
neutralise the effects of soluble TNF (Robertshaw and Brennan, 2005). 
However, cells expressing mTNF co-express TNFR making experimental 
data hard to distinguish between mTNF and soluble TNF bound to TNFR 
(Gerspach et al., 2000).
ADAM-17 and TIMP3 are clearly produced and expressed by GP8 rat 
cerebral endothelial cells with a balance in favour of enzymatic activity under 
pro-inflammatory conditions, as observed in active MS plaques and at peak 
phase of EAE (Chapters 3 and 4). The importance of the relocation of 
ADAM-17 from the actin cytoskeleton to the cytoplasm following treatment 
with LPS, TNF and IFN requires further investigation.
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The cerebral endothelium of the BBB constitutes a physical and 
metabolic barrier between the CNS and the periphery (Wolka et al., 2003). 
The cerebral endothelium expresses an elaborate system of transport 
proteins on both their luminal and abluminal surfaces, which in conjunction 
with the TJs ensure nutrient delivery and active regulation of brain 
extracellular fluid, whilst preventing entrance of harmful exogenous 
substances (Vorbrodt and Dobrogowska, 2003; Engelhardt, 2003; Ge etal., 
2005; McQuaid and Kirk, 2005). The endothelial barrier is supplemented with 
vascular pericytes and the astrocytic end-feet that encompass approximately 
95% of the endothelial abluminal surface, and are in constant communication 
with the each other (Vorbrodt and Dobrogowski, 2003; Ballabh et al., 2004). 
As technology and methodologies have evolved it has become evident that 
the BBB is pathologically affected in numerous diseases including stroke, 
bacterial infection, HIV encephalitis and MS (McQuaid and Kirk, 2005) and is 
associated with infiltration of activated monocytes, lymphocytes or 
neutrophils into the CNS compartment (Kwon and Prineas, 1994; Bolton et 
al., 1998; Boven etal., 2000).
The TJ of the BBB is comprised of three major transmembrane 
proteins, claudin, occludin and JAM that are connected to the cytoskeleton 
via ZO-1 (Vorbrodt and Dobrogowska, 2003). Several groups have 
demonstrated abnormalities in expression in these TJ-associated proteins in 
MS (Gay and Esiri, 1991), HIV and SIV encephalitis (Dallasta etal., 1999; 
Luabeya et al., 2000) and also in human brain endothelial cultures subjected 
to inflammatory conditions (Blum etal., 1997; Kuruganti etal., 2002; Romero 
et al., 2003). TJ properties have been reported to be altered as a 
consequence of TNF and MMP activities in endothelial cultures and animal 
models of MS (Cossins etal., 1997; Harkness etal., 2000; Minagar etal., 
2003; Avolio etal., 2003; Lohmann etal., 2004). The purpose of this study 
was to investigate the extent of occludin and ZO-1 TJ expression in MS CNS 
autopsy material, to determine whether any TJ abnormalities were detectable 
via immunofluorescent techniques and to correlate any findings with specific 
stages of lesion development.
Histopathological studies of MS and EAE CNS tissues reveal large 
perivascular inflammatory foci o fT  cells, B cells, and macrophages.
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Formation of the inflammatory foci requires the transendothelial migration of 
inflammatory cells which involves the interaction of endothelial adhesion 
molecules and their corresponding integrins on the surface of circulating 
cells. ICAM-1 and VCAM-1 are reported to be upregulated on the luminal 
surface of endothelial cells in MS and EAE (Laschinger and Englehardt, 
2000; Scott et al., 2004). A member of the ADAM family of 
metalloproteinases, ADAM-17, has been implicated in the proteolytic 
cleavage of both membrane-bound VCAM-1 and ICAM-1 from their cell 
surface.
ADAM-17 was first distinguished as TNF-a converting enzyme, 
responsible for the shedding of membrane bound TNF into its soluble form 
(Moss et al., 1997; Black et al., 1997). Soluble TNF has been reported to be 
implicated in the pathogenesis of MS and EAE. A further purpose of this 
study was to determine ADAM-17 expression within normal control white 
matter and MS white matter to assess whether expression levels correspond 
to different stages of lesion development. The expression of ADAM-17 and 
TIMP3 was further investigated in the animal model of MS, EAE, to 
determine any association with the clinical and pathological course of the 
disease. Pro-inflammatory cytokine effects on ADAM-17, TIMP3 and TNF 
expression by rat endothelial cell line GP8 was also investigated to elucidate 
the in vivo mechanisms involved in controlling their expression.
In vivo occludin and ZO-1 TJ associated protein expression has been 
described as forming linear continuous lines that form the outline of the blood 
vessel (Bolton etal., 1998; Brown etal., 1999). These findings are confirmed 
in the present study which also demonstrates that both occludin and ZO-1 
form linear radial bands in transversely transected blood vessels.
Examination of ZO-1 and occludin TJ protein expression in MS autopsy 
material from RRMS and SPMS in the present study has revealed 
abnormalities in their expression. ZO-1 and occludin expression 
abnormalities included an interruption or discontinuity of the normally linear 
bands, redistribution of the fluorescent signal from the cell membrane to the 
cytoplasm and what appears to be an apparent separation or opening of the 
fluorescent bands into two adjacent bands. Similar TJ abnormalities have
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been reported in autopsy material from HIV encephalitis, SIV encephalitis 
and cerebral malaria and also in vascular endothelial cells under 
inflammatory conditions in culture (Bolton etal., 1998; Dallasta etal., 1999; 
Brown etal., 1999; Boven etal., 2000; Kuruganti etal., 2002).
Quantitatively, the present study indicates that TJ disruption remains a 
constant feature in MS white matter with significantly increased incidence of 
TJ disruption in active lesions (42%) and inactive lesions (23%). A recent 
study using Affymetrix gene microanalysis has indicated lower gene 
expression of ZO-1 and occludin in active MS lesions compared with normal 
controls (McQuaid and Kirk, 2005) which would agree with the present study. 
TJ disruption observed in the present study was also associated with 
perivascular lymphocytic infiltrates. Leukocyte migration has been shown to 
trigger signal transduction cascades that lead to increased phosphotyrosine 
expression and loss of ZO-1 and occludin, and BBB breakdown (Bolton et 
al., 1998, Ballabh etal., 2004, Song and Pachter2004) possibly suggesting 
a role for the TNF/ADAM-17 pathway in TJ disruption via a TNF dependent 
increase in vascular adhesion molecules. A close relationship between TNF 
serum and CSF levels and BBB damage has been reported in patients with 
active MS (Sharief and Thompson, 1992) while several studies have 
reported an increase in TJ permeability and TJ protein abnormality in vitro 
after exposure to TNF and IFNy (Blum et al., 1997; Kuruganti et al., 2002; 
Mayhan, 2002; Lohmann et al., 2004) possibly implicating ADAM-17 
indirectly in BBB breakdown, through the release of TNF. Thus the present 
study demonstrates that astrocytic and endothelial cell expression of ADAM- 
17 would indicate that the enzyme is well placed to release TNF at the BBB.
Abnormalities in TJ protein expression were accompanied by 
evidence of serum protein leakage. Immunostaining with a FITC-conjugated 
antibody to fibrinogen revealed serum protein within the perivascular 
parenchyma, with the serum leakage extending further into NAWM in tissue 
with active lesions with severely disrupted TJ. This description of serum 
protein leakage correlates well with previous pathological studies which 
described the extent, severity and persistence of serum leakage in acute and 
chronic lesions (Gay and Esiri, 1991; Kwon and Prineas, 1994; Claudio et al., 
1995). Fibrinogen leakage in chronic lesions as described in this study
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confirms other studies that report the BBB being permanently damaged in 
many old chronic plaques, at a level undetectable by Gd-DTPA-MRI (Kwon 
and Prineas, 1994; Claudio etal., 1995). Although TJ disruption and serum 
protein leakage are described here as pathological features of MS, these 
features alone do not appear to be capable of inducing the demyelination 
observed in MS. TJ disruption and BBB breakdown have been reported in 
other CNS diseases, such as ischemia, HIVE and cerebral malaria where 
demyelination is not a pathological feature (Perry etal., 1997; Dallasta et al., 
1999; Boven et al., 2000).
Chemokines have been associated with regulating leukocyte 
trafficking into the CNS during MS (Simpson etal., 2000; Mahad etal., 2002; 
2003 & 2004). CCL2 has been associated with hypertrophic astrocytes and 
inflammatory cells within acute and chronic MS lesions whereas its receptor 
CCR2 has been identified on endothelial cells (McManus etal., 1998; Van 
der Voorn et al., 1999). In vitro, CCL2 is reported to disrupt ZO-1 and 
occludin in BMEC (Song and Pachter, 2004) whereby it may establish its 
chemotactic properties from behind the BBB by altering the TJ integrity. 
However whether TJ disruption is a prerequisite for inflammatory cell 
transmigration into the CNS is unclear. A recent electron microscopic study 
of an animal model of MS has suggested that mononuclear cells can cross 
the BBB via diapedesis leaving the TJs intact (Wolburg et al., 2005).
The NAWM in MS has been reported to be far from normal when 
assessed by MRI (Goodkin etal., 1998; Fillipi etal., 1998) and 
histopathological studies (Allen and McKeown, 1979). The present study 
further demonstrates that there is increased cellular activity and evidence of 
disease processes occurring within the NAWM. TJ abnormalities were 
observed in 13% of the blood vessels examined in the NAWM with evidence 
of moderate serum protein leakage, compared with vessels from normal 
control matter that displayed no serum protein leakage and TJ disruption in 
only 4% of the blood vessels examined. This low incidence of TJ abnormality 
in normal control white matter is in keeping with the view that a small degree 
of barrier opening may occur as a well regulated process under normal 
physiological conditions (Abbott, 2002). High levels of HLA-DR 
immunoreactivity was also observed in six NAWM sections as well as
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moderate levels of ADAM-17 immunoreactivity, confirming that the MS 
NAWM is far from “normal” and may represent pre-lesion disease tissue.
ADAM-17 and its endogenous inhibitor TIMP3 have been 
demonstrated in the present study as being constitutively expressed in 
normal control white matter and naive rat spinal cord white matter, 
suggesting a possible regulatory role for ADAM-17. Constitutive ADAM-17 
expression by cerebral endothelial cells under basal conditions suggests that 
ADAM-17 may play a regulatory role at the BBB by the proteolytic cleavage 
of adhesion molecules, TNF and TNFR p75. ADAM-17 cleavage of TNF may 
play a protective role by reducing the efficacy of TNF/p75 TNFR binding as it 
has been reported that membrane bound TNF (mTNF) is more effective than 
soluble TNF at binding with p75 TNFR (Grell et al., 1995). However, serum 
levels of TNF and p75 TNF have been positively correlated with relapses in 
people with RRMS (Martino et al., 1997). TNF/ p75 TNFR interaction on 
cerebral endothelial cells has also been reported to lead to increased ICAM- 
1 expression and levels of cellular accumulation at the vasculature in 
experimental cerebral malaria (Akassoglou etal., 2003).
ADAM-17 is reported in the present study to be expressed by 
endothelial cells, astrocytes, activated microglia/macrophages and by cells of 
the perivascular infiltrate in both active MS lesions and spinal cords of rats in 
the peak phase of EAE, suggesting a possible deleterious role in both 
diseases. In vitro results from this study confirmed that ADAM-17 and TIMP3 
are expressed by cerebral endothelial cells and astrocytes. The identification 
of the cell types responsible for ADAM-17 expression within the CNS 
suggests that ADAM-17 is in a position to be involved in many of the 
pathogenic mechanisms in MS (Figure 6.1).
ADAM-17 is reported to play a pathological role in stroke however 
others have reported ADAM-17 as having a beneficial neuroprotective role 
(Romera et al., 2004; Wang et al., 2004). These contradictory observations 
are possibly due to the pleiotropic nature of TNF in ischemic stroke although 
different forms of ADAM-17, in neurons and astrocytes, have been reported 
(Romera et al., 2004) possibly suggesting different activities of ADAM-17 in 
different cells. Under hypoxic conditions, astrocytes release inflammatory
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mediators that are capable of up-regulating IL-8, ICAM-1, E-selectin, TNF, 
IL-1 and MCP-1 gene expression in human cerebrovascular cells (Zhang et 
al., 2000), key proteins in inflammatory cell recruitment and TJ disruption.
ADAM-17 is reported to be responsible for the release of soluble TNF 
in human colonic epithelial cell lines following TNF stimulation. However, 
ADAM-17 expression levels remained unchanged following TNF stimulation 
(Kirkegaard et al., 2004). TIMP3 has been shown to inhibit ADAM-17 activity 
in vitro (Lee etal., 2002). Treatment of cultured microvasculature endothelial 
cells and astrocytes with the pro-inflammatory cytokines, IL-1 (3, TNF and 
IFNy are reported to decrease TIMP3 expression (Bugno et al., 1999; Muir et 
al., 2002) suggesting a balance in favour of enzymatic activity under 
inflammatory conditions, in agreement with this study at peak disease in 
EAE. TIMP3 expression by endothelial cells may also influence BBB 
breakdown in vivo due to its role in regulating ECM remodelling (Crocker et 
al., 2004) suggesting that the pro-inflammatory environment within the CNS 
in MS could result in decreased TIMP3 expression with the associated BBB 
breakdown as reported at the mRNA level in the present study in EAE white 
matter (Chapter 4).
At the protein level their appears to be discrepancies between the 
level of TIMP3 at peak EAE, that is increased compared to naive rats and the 
pro-inflammatory in vitro studies of GP8 cells where TIMP3 is reduced 
following stimulation. The EAE analysis involved examining the homogenate 
from rat spinal cords composed of various cell types including large foci of 
inflammatory cells. TIMP3 has been demonstrated here to be expressed by 
the cerebral endothelia and astrocytes and in neurons by other investigators 
(Pagenstecher etal., 1998; Vaillant etal., 1999; Jaworski and Fager, 2000).
It is reasonable to presume that TIMP3 may mediate different functions by 
different cell types at different anatomical locations, indeed increased TIMP3 
has been associated with neuronal cell death in reperfusion injury (Wallace 
et al., 2002). Therefore analysing whole white matter spinal cord, TIMP3 
protein may be increased, but locally at the cerebral endothelium it may be 
reduced favouring a balance in favour of ADAM-17 activity.
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Successful treatment of EAE and inflammatory diseases such as 
rheumatoid arthritis, Crohn’s disease and psoriasis with monoclonal 
antibodies (MAbs) and soluble receptors to TNF, lead to a high level of 
anticipation for their successful application in the treatment of MS (Baker, 
2004; Glabinski etal., 2004; Roberts and McColl, 2004; Tobin and Kirby,
2005). Although inhibition of ADAM-17 might be useful in diseases where 
TNF antagonism has been validated, activation of ADAM-17 might also 
prove effective in the treatment for Alzheimer’s disease, as ADAM-17 
cleaves APP by a non-amyloidogenic mechanism, preventing the formation 
of amyloid plaques (Moss et al., 2001; Skovronsky et al., 2001; Kojro and 
Fahrenholz, 2005). Targeting of the TJ and ADAM-17 represent plausible 
therapeutic strategies, however administration of treatment to the CNS is 
problematic. Recent findings from claudin-5 (CI-5) knock out mice have 
demonstrated size selective diffusion into the brain may be manipulated to 
allow therapeutic access to the brain. Tracer experiments and MRI on these 
CI-5'7' mice revealed that the BBB permeability was increased for small 
molecules (< 800D) but not larger molecules (Nitta et al., 2003). These point 
towards the potential of targeting CI-5 to enable access of small molecule 
therapies across the BBB and into the parenchyma.
Future direction for MS treatments
The aetiology of MS involves the complex combination of genetics, 
environmental factors and immune responses that result in a disease that is 
heterogeneous in both disease course and lesion type. Many of the current 
treatments for MS, IFN-(3, Glatiramer acetate and Mitoxantrone, are only 
effective in some MS patients, suggesting further heterogeneity in MS.
The area of leukocyte cell adhesion presents an array of potential 
targets for treatment of MS and other inflammatory and autoimmune 
diseases (Simmons, 2005). MAbs have been applied to disrupt the integrin- 
ligand interaction that allows leukocytes to strongly adhere to the vascular 
endothelium that ultimately leads to transmigration across the BBB. MAbs 
act by binding to the integrin competitively, inhibiting binding to the ligand. 
Antibodies may also bind in a way that produces an inactive conformation
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preventing formation of the activation epitopes and therefore preventing 
binding to ICAM-1 (Simmons, 2005). MAbs to VLA-4 have been reported to 
reverse BBB changes, as gauged by MRI, in an acute EAE model in guinea 
pigs (Kent et al., 1995). Encouraging results from the anti-VLA-4 MAb 
treatment of EAE has been successfully applied in clinical trials in RRMS 
(Miller et al., 2003). Tysabri (Natalizamub), approved for treatment of RRMS 
in November 2004, however it was withdrawn from the market in February 
2005 following reports of two cases of PML, one fatal, in MS patients taking 
Tysabri in conjunction with IFN-p (Kleinschmidt-DeMasters and Tyler, 2005) 
and one fatality in a patient receiving Tysabri for treating Crohn’s disease 
(Van Assche et al., 2005). PML is a demyelinating disease of the CNS 
caused by the reactivation of latent JC polyomavirus, which usually manifest 
in people with profoundly impaired cell-mediated immunity for example in 
patients with AIDS, leukaemia or organ transplant patients (Berger and 
Koralnik, 2005) thus the impairment of cell recruitment into the CNS via 
blocking VLA-4 prevented immune cell entry and thus allowed the JC virus to 
be activated. Although a major setback in the treatment of MS, search for a 
safe and effective anti-VLA-4 treatment for MS remains ongoing. The 
companies responsible for Tysabri are actively carrying out comprehensive 
safety evaluation of patients treated with Tysabri and PML, while 
GlaxoSmithKline are reported to have a small molecule antagonist of VLA-4 
that has entered phase lib clinical trial (Simmons, 2005). The fact that there 
was a major improvement in MS patients treated with Tysabri indicates the 
value in therapeutic targeting of cell trafficking to the CNS and the need to 
develop antigen-specific inhibitors of migration.
Future work
To extend the current study the following experimental approach 
would provide further understanding of the complex activities that occur at 
the BBB in MS.
In vitro
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The use of a human cerebral endothelial BBB model would be more 
relevant due to species differences in the rodent and porcine cerebral 
endothelial cell culture most commonly used. Establishing a working human 
model of the BBB would enable the analyses of TJ integrity and ADAM-17 
activity in response to cytokines and MMPs. The suggestion of a viral 
infection being an environmental factor in the aetiology of MS is long 
standing. Various CNS cells have been shown to be susceptible to viral 
infection and discovering whether a human model of the BBB could further 
elucidate the mechanisms and effects of virus entry into the BBB should be 
assessed. A human model of the BBB would also allow the study of the 
effects of BBB/TJ strengthening compounds, such as flavanoids, that may 
provide a way of closing the BBB in pathological conditions, thus 
ameliorating oedema formation and the severe pathological effects of 
neuroinflammation.
Further investigation is required to determine whether, under basal 
conditions, ADAM-17 expression being associated with the actin filaments of 
the cytoskeleton is due to protein transport or whether or not there is some 
functional importance to its sub-cellular location. The transmembrane 
domains of the adhesion molecules, E-selectin and ICAM-1 are reported to 
be associated with actin filaments and may point towards a possible 
intracellular function for ADAM-17.
Fractalkine exists as a membrane bound form on endothelial cells, 
neurons, astrocytes and epithelial cells that has adhesive properties for cells 
expressing its receptor CX3CRI (Garton et al., 2001; Hulshof et al., 2003). 
CX3CRI is expressed on monocytes, T-cells, natural killer cells, neurons and 
microglia (Nishiyori etal., 1998; Garton etal., 2001). Fractalkine can be 
cleaved from the cell membrane, by ADAM-17, to produce a soluble form 
that creates a chemotatic gradient for inflammatory cells (Tsou et al., 2 0 0 1 ; 
Garton et al., 2001; Kastenbauer et al., 2003). Increased fractalkine 
expression has been observed in the CSF and serum of patients with 
inflammatory diseases, including MS and bacterial meningitis (Kastenbauer 
et al., 2003). Proteolytic release of fractalkine from activated cerebral 
endothelial cells might be the source of soluble fractalkine in the circulation. 
Using flow cytometry and ELISA techniques would help confirm the shedding
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of fractalkine by cerebral endothelial cells. Further in vitro studies involving 
the interaction of ADAM-17 and fractalkine may further elucidate whether this 
interaction is detrimental or beneficial. Small interfering RNAs (siRNAs) 
specifically knock-down a gene's message, and subsequently the protein 
level of the targeted gene. Using siRNAs for ADAM-17 would allow cellular- 
based assays to be conducted in the absence and presence ADAM-17 to 
clarify its shedding activity under pro-inflammatory conditions.
Animal model
Having demonstrated an increase in ADAM-17 at peak disease in 
EAE, further studies using EAE would enable the examination of TIMP3 or 
anti-ADAM-17 treatments on disease progression and pathology. Employing 
a chronic-relapsing EAE (CREAE) model would enable the investigation of 
ADAM-17 and TIMP3 expression in a model with a demyelinating pathology. 
CREAE would also allow the investigation of ADAM-17 and TIMP3 
expression during remission and relapses to distinguish whether the increase 
in ADAM-17 expression observed in the current study is involved during later 
relapses. The use of ADAM-17, TIMP3 and fractalkine knockout animals 
could also shed light on the functions of ADAM-17, TIMP3 and fractalkine in 
disease progression.
Summary
Breakdown of the BBB in MS has been well documented and 
evidenced by MRI. Here it has been shown that the BBB is disrupted in MS 
at the microscopic level of the inter-endothelial TJ. TJ disruption is not only 
prevalent in active MS lesions but is also seen in the NAWM and is 
persistent in chronic lesions. TNF is known to have immunomodulatory 
effects on the BBB that lead to increased permeability and adhesion 
molecule expression on the vascular endothelial surface. ADAM-17, the 
enzyme responsible for the proteolytic cleavage of TNF, has been shown to 
be expressed by the vascular endothelium and astrocytes of the CNS in MS 
and EAE. Increased ADAM-17 expression is also shown to be associated 
with active lesions in MS and at peak disease stage in EAE. In vitro, ADAM- 
17 expression by endothelial cell cultures is increased under pro-
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inflammatory conditions, whereas expression levels of its endogenous 
inhibitor TIMP3 are decreased. This suggests an imbalance in favour of the 
enzymatic activity of ADAM-17 under pro-inflammatory conditions, like those 
observed in EAE. The functional consequence of this activity requires further 
research, which may lead to greater understanding of the pathological 
process in MS and to new therapeutic targets for MS being identified.
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A1 Buffers and solutions
A1.1 Phosphate buffered saline (PBS 10mM)
Weigh out 80g NaCI, 2g KCL, 14.4g Na2HP0 4  and 2g KH2PO4 . 
Dissolve the above buffer constituents in 1000ml of distilled H2O and pH 7.2. 
This buffer is x10 concentrate and should be diluted 1:10 prior to use.
A1.2 Phosphate buffer 0.2M
Weigh out 11.36g Na2HPC>4 and dissolve in 400ml of distilled H2O 
(Solution A).
Weigh out 3.2g NaH2P0 4 .2 H20  and dissolve in 100ml of distilled H2O 
(Solution B).
Mix solutions A&B and pH to 7.2.
A 7.3 Paraformaldehyde 4%
Add 16g of paraformaldehyde to 100ml of distilled H2O and heat to 
60°C then add 2M NaOH to dissolve. Add distilled H2O to make a total 
volume of 200ml. Add 200ml of 0.2M phosphate buffer and pH to 7.2.
NB Carry out the above procedure in a fume cupboard.
A 1.4 Citifluor
Weigh out 2.5g 1,4-diazobicyclo-2,2,2-octane (Sigma) and add 50mls 
PBS and 50mls glycerol. Mix well and store in the dark at 4°C.
NB Carry out the above procedure in a fume cupboard.
A1.5 Citrate Buffer
10.5g of Trisodium citrate dissolved in 500mls distilled water.
Add 10mls of 1M HCL and pH to 6.3
A1.5.1 Microwave Buffer
50mls of citrate buffer added to 450mls of distilled water and pH 6.0.
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A1.6TBS
Weigh out 80g NaCI and 6.05g Tris (hydroxyl-methyl). Add to 44mls of 
1M HCL and 10L of distilled water and pH 7.4.
A1.7 Oil RedO
Oil Red O solution is prepared by adding 1g of Oil Red O to 60mls 
Triethyl Phosphate and 40mls of distilled water. The mixture is heated to 
100°C for 5 minutes and constantly stirred. The mixture is filtered when hot 
then again when it cools. This is a stock solution and must be filtered prior to 
use.
Tissue for ORO staining is post fixed in 10% formalin at 4°C for 1 hour.
• Sections are placed in 70% ethanol for 2 minutes
• Sections are incubated in ORO for 20 minutes at RT
• Sections are washed in 70% ethanol until all excess stain is removed
• Sections are washed in distilled water
• Cell nuclei are counter stained by immersion in Harris’s haematoxylin 
for 30 seconds
• Nuclei are “blue up” dipping sections in ammonia water
• Sections are then washed in distilled water
• Sections are mounted in glycerin jelly (Stored at 37°C).
A1.8 Protein Sample Buffer
25pl of sample buffer (Invitrogen), 10pl sample reducing buffer 
(Invitrogen) and 15pl distilled water. Added to extracted protein sample 1:1.
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B1 Extra experimental details
B1.1 Example of BCA and standard curve
BCA standards where made using bovine serum albumin as shown in 
table below and analysed in duplicate.
Standards
Cone
(mg/ml)
Absorbance 
@ 570nm 
Reading 1
Absobance 
@ 570nm 
Reading 2
Ave SD
0.1 0.122 0.120 0.121 0.001509
0.2 0.148 0.152 0.150 0.002697
0.4 0.199 0.214 0.206 0.010596
0.6 0.262 0.259 0.261 0.002237
0.8 0.312 0.305 0.308 0.004847
1 0.350 0.353 0.352 0.002419
1.2 0.372 0.383 0.378 0.007709
1.4 0.428 0.432 0.430 0.00307
1.6 0.467 0.466 0.467 0.000427
1.8 0.500 0.501 0.500 0.000874
2 0.537 0.546 0.542 0.005932
EAE WM only BCA
0.600
I  0.500 o
k  0.400
y = 0.2179x + 0.1178 
R2 = 0.9930.3000.200 |  0.100 
< 0.000
0.5 10 1.5 2.52
Protein Cone (mg/ml)
Following BCA assay described in 3.2.4.1 sample absorbance at 570nm 
were read and plotted as illustrated in the graph above. Equation of chart line 
and R squared value of the chart were displayed.
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EAE Reading Reading Reading Ave Cone
Sample_______1_________ 2_________3_________________ (mg/ml)
3 0.311 0.286 0.298 0.298 0.828360212
8 0.340 0.348 0.328 0.339 1.013863396
10 0.283 0.270 0.263 0.272 0.707038932
14 0.274 0.267 0.283 0.275 0.720139407
21 0.341 0.319 0.338 0.333 0.985644255
23 0.199 0.207 0.206 0.204 0.395641899
26 0.189 0.194 0.211 0.198 0.368107919
36 0.363 0.349 0.340 0.351 1.067937039
38 0.276 0.280 0.280 0.279 0.737950208
42 0.190 0.190 0.199 0.193 0.34499101
44 0.362 0.367 0.313 0.347 1.053017008
46 0.346 0.338 0.332 0.339 1.014493036
49 0.216 0.220 0.225 0.220 0.470940544
50 0.262 0.280 0.272 0.271 0.704778807
51 0.252 0.249 0.251 0.251 0.610394305
52 0.342 0.261 0.268 0.290 0.792526756
Test samples were analysed in triplicate and protein concentrations of 
samples were calculated using the equation y = mx + c where y is the 
absorbance at 570nm and x is the protein concentration in mg/ml.
X = (y-c)/m
B1.2 Co-localisation spectra graphs
Co-localisation software of the Zeiss 510 CSLM was utilised to 
determine whether or not individual pixels were truly co-localised for the 
proteins of interest. The software produces a spectra dot plot that displays 
channel 1+ pixels in quadrant 2, channel 2+ pixels in quadrant 1 and pixels 
that are both channel 1+ + 2 + in quadrant 3
Green
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B1.3 EAE induction and copy of clinical data from Eisai
Animal housing and all procedures were carried out according to the 
guideline laid down by the Animal Care and Use Committee of Eisai. Lewis 
rats (180-200 g in body weight, 7-9  weeks, Charles River Japan, Tokyo, 
Japan) were immunized subcutaneously in each hind foot pad with a 50-pl 
inoculum containing 50-pg guinea pig myelin basic protein, prepared 
according to a published method (Dunkley and Carnegie), and emulsified in 
Freund's complete adjuvant containing 5.5 mg/ml Mycobacterium 
tuberculosis H37Ra (Difco, Detroit, Ml).
Dunkley and Carnegie, 1974. P.R. Dunkley and P.R. Carnegie , Amino acid 
sequence of the smaller basic protein from rat brain myelin. Biochem. J. 141 
(1974), pp. 243-255.
Carnegie et al., 1974. P.R. Carnegie, P.R. Dunkley, B.E. Kemp and A.W. 
Murray , Phosphorylation of selected serine and threonine residues in myelin 
basic protein by endogenous and exogenous protein kinases. Nature 249 
(1974), pp. 147-150.
B1.4 Tri reagent method (Sigma protocol)
I. Sample Preparation
1A. Tissue:
Homogenize tissue samples in TRI REAGENT (1 ml per 50-100 mg of 
tissue) in a Polytron or other appropriate homogenizer. Note: If minimal 
shearing of the DNA is desired, use a loosely fitting homogenizer, not a 
Polytron (see also Note b. under Step 3 of the DNA Isolation procedure). The 
volume of the tissue should not exceed 10% of the volume of the TRI 
REAGENT.
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IB. Monolayer cells:
Lyse cells directly on the culture dish. Use 1 ml of the TRI REAGENT 
per 10 cm2 of glass culture plate surface area. After addition of the reagent, 
the cell lysate should be passed several times through a pipette to form a 
homogenous lysate.
IC . Suspension cells:
Isolate cells by centrifugation and then lyse in TRI REAGENT by 
repeated pipeting. One ml of the reagent is sufficient to lyse 5-10 x 106 
animal, plant or yeast cells or 107 bacterial cells.
Notes:
a. Some yeast and bacterial cells may require a homogenizer.
b. After the cells have been homogenized or lysed in TRI REAGENT, 
samples can be stored at -70 °C for up to 1 month.
c. If samples have a high content of fat, protein, polysaccharides or 
extracellular material such as muscle, fat tissue and tuberous parts of plants 
an additional step may be needed. After homogenization, centrifuge the 
homogenate at 12,000 x g for 10 minutes at 4 °C to remove the insoluble 
material (extracellular membranes, polysaccharides, and high molecular 
weight DNA). The supernatant contains RNA and protein. If the sample had 
a high fat content there will be a layer of fatty material on the surface of the 
aqueous phase that should be removed. Transfer the clear supernatant to a 
fresh tube and proceed with step 2. Recover the high molecular weight DNA 
from the pellet by following steps 2 and 3 under DNA Isolation.
2. To ensure complete dissociation of nucleoprotein complexes, allow 
samples to stand for 5 minutes at room temperature. Add 0.2 ml of 
chloroform (see note below) per ml of TRI REAGENTD used. Cover the 
sample tightly, shake vigorously for 15 seconds and allow to stand for 2-15 
minutes at room temperature. Centrifuge the resulting mixture at 12,000 x g 
for 15 minutes at 4 °C. Centrifugation separates the mixture into 3 phases: a 
red organic phase (containing protein), an interphase (containing DNA), and 
a colorless upper aqueous phase (containing RNA).
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Note: The chloroform used for phase separation should not contain isoamyl 
alcohol or other additives.
II. RNA Isolation
1. Transfer the aqueous phase to a fresh tube and add 0.5 ml of isopropanol 
per ml of TRI REAGENT used in Sample Preparation,
Step 1 and mix. Allow the sample to stand for 5-10 minutes at room 
temperature. Centrifuge at 12,000 g for 10 minutes at 4 °C. The RNA 
precipitate will form a pellet on the side and bottom of the tube.
Note: Store the interphase and organic phase at 4 °C for subsequent 
isolation of the DNA and proteins.
2. Remove the supernatant and wash the RNA pellet by adding 1 ml 
(minimum) of 75% ethanol per 1 ml of TRI REAGENT used in Sample 
Preparation,
Step 1. Vortex the sample and then centrifuge at 7,500 x g for 5 minutes at 
4°C.
Notes:
a. If the RNA pellets float, perform the wash in 75% ethanol at 12,000 x g.
b. Samples can be stored in ethanol at 4 °C for at least 1 week and up to 1 
year at -20  °C.
3. Briefly dry the RNA pellet for 5-10 minutes by airdrying or under a vacuum. 
Do not let the RNA pellet dry completely, as this will greatly decrease its 
solubility. Do not dry the RNA pellet by centrifugation under vacuum (Speed- 
Vac). Add an appropriate volume of formamide, water or a 0.5% SDS 
solution to the RNA pellet. To facilitate dissolution, mix by repeated pipetting 
with a micropipette at 55-60 °C for 10-15 minutes.
Notes:
a. Final preparation of RNA is free of DNA and proteins. It should have a 
260/280 ratio of >1.7.
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b. Typical yields from tissues (jjg RNA/mg tissue): liver, spleen, 6-10/yg; 
kidney, 3-4 /yg; skeletal muscle, brain, 1-1.5 //g; placenta, 1-4 jjg.
c. Typical yields from cultured cells (jjg RNA/106 cells): epithelial cells, 8-15 
/;g; fibroblasts, 5-7 //g.
III. DNA Isolation
1. Carefully remove the remaining aqueous phase overlaying the interphase 
and discard. To precipitate the DNA from the interphase and organic phase, 
add 0.3 ml of 100% ethanol per 1 ml of TRI REAGENT used in Sample 
Preparation, Step 1. Mix by inversion and allow to stand for 2-3 minutes at 
room temperature. Centrifuge at 2,000 x g for 5 minutes at 4 °C.
Note: Removal of the remaining aqueous phase before DNA precipitation is 
a critical step for the quality of the isolated DNA.
2. Remove the supernatant and save at 4 °C for protein isolation. Wash the 
DNA pellet twice in 0.1 M sodium citrate, 10% ethanol solution. Use 1 ml of 
wash solution for every 1 ml of TRI REAGENT used in Sample Preparation, 
Step 1. During each wash, allow the DNA pellet to stand (with occasional 
mixing) for at least 30 minutes. Centrifuge at 2,000 x g for 5 minutes at 4 °C. 
Resuspend the DNA pellet in 75% ethanol (1.5-2 ml for each ml TRI 
REAGENT) and allow to stand for 10-20 minutes at room temperature.
Notes:
a. Important: Do not to reduce the time samples remain in the washing 
solution. Thirty minutes is the absolute minimum time for efficient removal of 
phenol from the DNA.
b. If pellet contains >200 //g of DNA or large amounts of non-DNA material, 
an additional wash in 0.1 M sodium citrate, 10% ethanol solution is required.
c. Samples suspended in 75% ethanol can be stored at 4 °C for several 
months.
3. Dry the DNA pellet for 5-10 minutes under a vacuum and dissolve in 8 mM 
NaOH and dissolve by repeated slow pipetting with a micropipette. Add
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sufficient 8 mM NaOH for a final DNA concentration of 0.2-0.3 j jq !j j \ (typically
0.3-0.6 ml to the DNA isolated from 50-70 mg of tissue or 107 cells). This 
mild alkaline solution assures complete dissolution of the DNA pellet. 
Centrifuge at 12,000 x g for 10 minutes to remove anyinsoluble material and 
transfer the supernatant to a new tube.
Notes:
a. A viscous supernatant indicates the presence of high molecular weight 
DNA.
b. The size of the DNA will depend on the force exerted during 
homogenization. Avoid using a Polytron homogenizer.
c. Samples dissolved in 8 mM NaOH can be stored at 4 °C overnight. For 
long term storage, adjust the pH value to between 7 and 8 and supplement 
with EDTA (final concentration 1 mM).
d. To determine DNA concentration, remove an aliquot, dilute with water and 
measure the A260. For double stranded DNA, 1 A260 unit/ml = 50 /yg/ml.
e. To calculate cell number, assume the amount of DNA for 106 diploid cells 
of human, rat and mouse equals 7.1 /yg, 6.5 jjq  and 5.8 j j q , respectively.
f. Typical yields from tissues (/yg DNA/mg tissue): liver, kidney, 3-4 /yg; 
skeletal muscle, brain and placenta, 2-3 j j q .
g. Typical yields from cultured human, rat and mouse cells: 5-7 jjq  DNA/106 
cells.
To Amplify DNA by PCR: After dissolving in 8 mM NaOH, adjust to pH 8.4 
using HEPES (add 66 j j \ of 0.1 M HEPES, free acid/ml DNA solution). Add 
sample (generally 0.1-1 j j q )  to PCR mix and follow PCR protocol.
To Digest DNA with Restriction Enzymes:
Adjust the pH of the DNA solution to that needed for the restriction enzyme 
digestion using HEPES, or dialyze samples against 1 mM EDTA, pH 7-8. 
Allow the restriction enzyme digestion to continue for 3-24 hours under 
optimal conditions. It is recommended that 3-5 units of enzyme be used per 1 
j jq  of DNA. Typically, 80-90% of the DNA is digested.
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IV. Protein Isolation
1. Precipitate proteins (see note below) from the phenol-ethanol supernatant 
(DNA Isolation, Step 2) with 1.5 ml of isopropanol per 1 ml of TRI 
REAGENTD used in Sample Preparation, Step 1. Allow samples to stand for 
at least 10 minutes at room temperature. Centrifuge at 12,000 x g for 10 
minutes at 4 °C.
Note: For some samples, the protein pellet may be difficult to dissolve in 1% 
SDS (step 3 below).
Use this alternate procedure to correct the problem:
a. Dialyze the phenol-ethanol supernatant against 3 changes of 0.1% SDS at
4 °C.
b. Centrifuge the dialysate at 10,000 x g for 10 minutes at 4 °C.
c. The clear supernatant contains protein that is suitable for use in western 
blotting procedures.
2. Discard supernatant and wash pellet 3 times in 0.3 M guanidine 
hydrochloride/95% ethanol solution, using 2 ml per 1 ml of TRI REAGENTD 
used in Sample Preparation, Step 1. During each wash, store samples in 
wash solution for 20 minutes at room temperature. Centrifuge at 7,500 x g for
5 minutes at 4 °C. After the 3 washes, add 2 ml of 100% ethanol and vortex 
the protein pellet. Allow to stand for 20 minutes at room temperature. 
Centrifuge at 7,500 x g for 5 minutes at 4 °C.
Note: Protein samples suspended in 0.3 M guanidine hydrochloride/95% 
ethanol solution or 100% ethanol can be stored for 1 month at 4 °C or 1 year 
a t-2 0  °C.
3. Dry protein pellet under a vacuum for 5-10 minutes. Dissolve pellet in 1% 
SDS aided by working the plunger of micropipette with tip in the solution. 
Remove any insoluble material by centrifugation at 10,000 x g for 10 minutes
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at 4 °C. Transfer supernatant to a new tube. The protein solution should be 
used immediately for western blotting or stored at -20  °C.
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Abbott, N.J. 2002. Astrocyte-endothelial interactions and blood-brain barrier 
permeability. J Anat 200:629-638.
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